別添１

厚生労働科学研究費補助金

腎疾患政策研究事業

慢性腎臓病(CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究

令和６年度　総括･分担研究報告書

研究代表者　要　伸也

令和7（2025）年　5月

別添２

目　　次

Ⅰ．総括研究報告 ---------- 1
慢性腎臓病(CKD)患者に特有の健康課題に
適合した多職種連携による生活・食事
指導等の実証研究
要　伸也

II．研究成果の刊行に関する一覧表 ---------- 12

別添3

厚生労働科学研究費補助金（腎疾患政策研究事業）
総括研究報告書

慢性腎臓病(CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究

研究代表者
要　伸也　　杏林大学・客員教授

研究分担者:
柏原　直樹　川崎医科大学・学長付特任教授
岡田　浩一　埼玉医科大学・教授
猪阪　善隆　大阪大学・教授
阿部　雅紀　日本大学・教授
金﨑　啓造　島根大学・教授
内田　明子　さとうクリニック・統括部長
石川　祐一　茨城キリスト教大学・教授
竹内　裕紀　東京医科大学・教授

研究協力者：
櫻田 勉　　聖マリアンナ医科大学・教授
今村吉彦　　日産玉川病院・副院長
八田 告　　八田医院・院長

研究要旨：本研究の目的は、前班で得られた多職種連携の実証研究を踏まえ、追加解析や教育資材の収集・分析により、有効な教育プログラムを開発し、最終的に多職種連携の戦略案を策定することである。今後のエビデンス実証研究の追加解析および追加研究および教育資材の収集・とりまとめによって、効果的な介入方法が明らかになり、これらを基盤に標準的な教育プログラムを作成することができれば、我が国のチーム医療の診療水準向上につながり、治療目標の達成率の向上を通じて、最終的にはCKD重症化予防とCKD患者のQOL改善、医療費節減が図れると期待される。

A. 研究目的：

我が国の慢性腎臓病（CKD）患者は最近の報告では約2,000万人と推定され、ハイリスク群を形成している。CKD の重症化予防の基本は生活習慣の適正化と治療目標の遵守であるが、これらは腎臓専門医だけでは対処が難しく、かかりつけ医との医療連携、看護師・管理栄養士・薬剤師等との多職種連携が必須となる。これまでの取り組みにより、多職種連携に関する一定のエビデンスが得られたが、一般外来診療における多施設研究はなく、さらに、具体的にどのような患者に、どのように介入するのが効果的かは明らかになっていない。

本研究の目的は、前班で得られた多職種連携の実証研究を踏まえ（**資料1-3**）、追加解析や教育資材の収集・分析により、有効な教育プログラムを開発し、最終的に多職種連携の戦略案を策定することである。本研究班は、進行中の厚生労働省研究班（柏原・岡田班）や日本腎臓病協会、コメディカルの関連3団体、日本糖尿病学会とも連携し、CKD対策に係る職種横断的なオールジャパン体制を構築する。

B. 研究方法：

本研究では、以下の研究計画・方法にしたがって、多職種介入研究の追加解析を行いつつ、必要に応じて追加研究実施し、効果的な介入方法を探る。また、多職種研究に参加した施設を中心に得られた教育資材を分析することを通じて、効果的な多職種による教育方法が何かを検討し、最終的に、標準的な教育プログラムを開発する。同時にこれを普及する基盤作りも進め、マニュアルへの反映や課題解決への提言を行ってゆく。

1) **多職種連携のエビデンス構築の継続**（阿部、岡田、内田、石川、竹内）：

多職種連携による生活指導・食事指導等がCKDの予防・重症化予防に有効かどうかを検証するための実証研究の成果（R2～R4年度多職種研究班）を踏まえ、追加解析を行う。どのようなアプローチがどのアウトカムに有効か、どの職種あるいはどの患者群に有効かも検討する。医療経済的な有効性についても検討する。必要に応じて統計専門家にも加わっていただく。

2) **多職種による教育プログラムの開発と普及**（阿部、岡田、猪阪、金崎、内田、石川、竹内）：

多職種介入の方法・資材は施設により様々であるため、R2～R4年度の実証研究の実施施設を中心に、介入方法・資材の収集を進める。これらのうち、とくに有効な成果の得られた介入方法の分析により、効果的な教育プログラムを検討、作成し、標準化プログラムを開発する。完成後はこれらの普及を図るため、HPによる公表、マニュアルや戦略案等への反映を検討、実施する。

3) **マニュアル作成と有効活用の推進**（岡田、柏原、金崎、内田、石川、竹内）：

前研究班で作成したCKD多職種連携マニュアルの有効活用、普及に努める。また、「腎臓病療養指導士のためのCKD指導ガイドブック」の改訂に際して、本研究班のCKD多職種連携マニュアルや標準化教育プログラムを反映できるよう、連携して検討を進める。

4) **ホームページ等による成果の公表**（金崎、柏原、岡田、要）：

研究班のホームページを充実させる。本研究班の取り組みから得られた成果やコンテンツをHP等で公表することにより、全国的な周知と普及を目指す。

5) **課題解決のための戦略案策定**（要、柏原、岡田、猪阪、阿部、金崎、内田、石川、竹内）：

得られた成果をもとに課題解決へ向けた戦略案を策定し、具体的な成果目標を示す。これらを提言として公表する。

（倫理面への配慮）

各臨床研究は、実施施設の倫理委員会の承認のもとに進め、個人情報にも十分な配慮のもとに進めている。

C. 研究結果：

前研究班の実証研究の中心メンバーからなるWGに加えて、多職種による教育プログラム作成のためWGを組織した。WEB会議にて、前班で得られた多職種連携の実証研究を踏まえた実証研究の追加解析・二次調査案の策定を開始した（**資料4,5**）。

（ワーキンググループメンバー）

・**実証研究WG**：○阿部雅紀、櫻田 勉、今村吉彦、八田 告

・**教育プログラム作成WG**：○岡田浩一、阿部雅紀、櫻田 勉、今村吉彦、八田 告
内田明子 他看護師3名
石川祐一　他管理栄養士2名
竹内裕紀　他薬剤師2名
理学療法士 2名

1) **多職種連携のエビデンス構築の継続**

① 実証研究WGにて追加研究を行い、報告した。さらにWGにで、効果的な教育方法の作成に資する追加研究、および追加調査案を検討し、予備的な結果を得ている（**資料6**）。今後さらに解析を進め、追加調査を実施する。

✓ 介入効果は何によるか？　服薬アドヒアランスの改善、投与薬剤の違い、減塩効果(食事療法)、通院頻度、ドロップアウト率、などが候補となる。これらのうち、追加解析なものは検討を行い、新たなデータ収集が必要なものは追加研究を立案する。

✓ 施設ごとの介入効果の違いと関連する因子はないか？とくに効果の大きなモデル施設と小さな施設が何かを明らかにする。

✓ 効果はどこまで持続するかを明らかにするために追跡調査を行う。

✓ 介入前の状況（腎臓専門医単独の診療、非専門医で院内からの紹介、非専門医でかかりつけ医からの紹介、のどれか）

✓ 入院介入であれば外来でのチーム医療実施状況を調査する。

今後は、これらのうち、ワーキンググループで継続検討し、実際に測定可能かつ重要な項目案を選択後、24施設との合同会議を開催のうえ追加解析、追加研究案を確定する方針である。

② 同時に、最適な教育プログラムの作成に必要な介入方法や教育資材の収集を行った。

今後は、これらから推奨される教育プログラムの素案を作成しつつ、①の結果を踏まえてプログラムの改良を行ってゆく。

2) **多職種による教育プログラムの開発と普及**：実証研究の参加施設から介入方法と教育資材を収集する。その後、1）の分析結果も踏まえ、多職種による効果的な標準教育プログラムを開発する。
3) **マニュアル作成と有効活用の推進**：2）で作成した教育プログラムを普及させる。前研究班で作成した「CKDケアのための多職種連携マニュアル」などにもこれを反映させるようにする。
4) **ホームページ等による成果の公表**：得られた成果・コンテンツをHP等で公表することにより、全国的な周知と普及を目指す。
5) **課題解決のための戦略案策定**；以上1)～4)をもとに課題解決へ向けた戦略案を策定する。

D. 考察

本研究班の取り組みにより、CKD患者に特有の健康課題に適合した多職種連携による生活・食事指導等のエビデンスが強化され、多職種による療養指導方法の標準化を図ることができると期待される。すなわち、前研究班で実施した多職種連携実証研究の追加解析、および多職種による療養指導の実施プロトコールや教育資材の収集により、多職種連携の効果的な介入方法が具体的に明らかになり、教育プログラムの開発と標準化が可能になると考えられる。

さらに、これらの標準化教育プログラムを将来の多職種連携マニュアル改訂や、ホームページ・ガイドブック等に反映させ、さらに、連携する厚生労働省研究班（柏原・岡田班）や日本腎臓病協会/腎臓病療養指導士委員会とも共有、発信することによって、効果的な多職種チーム医療の全国的な普及とチーム力の向上が進み、ひいてはCKD患者の生活習慣改善やセルフマネジメント力向上に繋げることができると期待される。また、多職種連携の実態把握によって地域差が明らかになれば、地域ごとに重点的な支援を行うことによって、多職種教育プログラムの全国普及と均霑化が図られると期待される。

E. 結論

今後のエビデンス実証研究の追加解析および追加研究および教育資材の収集・とりまとめによって、効果的な介入方法が明らかになり、これらを基盤に標準的な教育プログラムを作成することができれば、我が国のチーム医療の診療水準向上につながり、治療目標の達成率の向上を通じて、最終的にはCKD重症化予防とCKD患者のQOL改善、医療費節減が図れると期待される。

F. 健康危険情報

なし

G. 研究発表

1. 論文発表

（主要論文）

1) Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S: Effectiveness and current status of multidisciplinary care for patients with chronic kidney disease in Japan: a nationwide multicenter cohort study. Clin Exp Nephrol 2023 27(6):528-541. **（資料1）**
2) Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S. Inpatient multidisciplinary care can prevent deterioration of renal function in patients with chronic kidney disease: a nationwide cohort study. Front Endocrinol (Lausanne). 2023 Jun 20; 14:1180477. **（資料2）**
3) Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S: Examine the optimal multidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study. Kidney Res Clin Pract. 2025 Mar;44(2):249-264. **（資料3）**

（研究者別）

研究代表者：要　伸也

1) Maruyama S, Ikeda Y, Kaname S, Kato N, Matsumoto M, Ishikawa Y, Shimono A, Miyakawa Y, Nangaku M, Shibagaki Y, Okada H. Eculizumab for adult patients with atypical haemolytic-uraemic syndrome: full dataset analysis of Japanese post-marketing surveillance. J Nephrol 37: 2181-2190, 2024.
2) Nagase M, Ando H, Beppu Y, Kurihara H, Oki S, Kubo F, Yamamoto K, Nagase T, Kaname S, Akimoto Y, Fukuhara H, Sakai T, Hirose S, Nakamura N: Glomerular endothelial cell receptor adhesion G-protein-coupled receptor F5 (ADGRF5) and the integrity of the glomerular filtration barrier. J Am Soc Nephrol 2024 Oct 1;35(10):1366-1380.
3) Kawazoe M, Nanki T, Saeki K, Ishikawa H, Nakamura Y, Kawashima S, Ito S, Kodera M, Konda N, Kaname S, Harigai M: Nationwide

epidemiological survey of polyarteritis nodosa in Japan in 2020. Mod Rheumatol 34: 1284-1287, 2024.
4) Sada KE, Nagasaka K, Kaname S, Nango E, Kishibe K, Dobashi H, Hiromura K, Kawakami T, Bando M, Wada T, Amano K, Murakawa Y, Harigai M: Clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of microscopic polyangiitis and granulomatosis with polyangiitis: The 2023 update-secondary publication. Mod Rheumatol 34: 559-567, 2024.
5) Sada KE, Nagasaka K, Kaname S, Higuchi T, Furuta S, Nanki T, Tsuboi N, Amano K, Dobashi H, Hiromura K, Bando M, Wada T, Arimura Y, Makino H, Harigai M. Evaluation of Ministry of Health, Labour and Welfare diagnostic criteria for antineutrophil cytoplasmic antibody-associated vasculitis compared to ACR/EULAR 2022 classification criteria. Mod Rheumatol 34: 551-558, 2024.
6) Katsumata Y, Sada KE, Kameda T, Dobashi H, Kaname S, Tsuboi N, Matsumoto Y, Amano K, Tamura N, Harigai M: Comparison of different ANCA detection methods in a predominantly MPO-ANCA-associated vasculitis cohort. Immunol Med 2025 Mar;48(1):47-57.
7) Kaname S, Ong M-L, Mathiasc J, Gattad F, Lawe L, Wang Y: Outcomes in patients with thrombotic microangiopathy associated with a trigger following plasma exchange: a systematic literature review. Transfus Apher Sci Transfus Apher Sci. 2025 Feb;64(1):104048.
8) Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S: Examine the optimal multidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study. Kidney Res Clin Pract 2025;44(2):249-264.
9) 要 伸也：CKD 対策における多職種ケアの重要性. 特集：病診連携と多職種で取り組む日本の CKD 対策. 日本医師会雑誌 153(4):407-411, 2024.
10) 要 伸也：慢性腎臓病に対するチーム医療と慢性腎臓病透析予防指導管理料の新設.日本透析医会雑誌 39(33):472-479, 2024.

研究分担者：柏原直樹

1) Kitai T, Maruyama S, Kuwahara K, Tamura K, Kinugawa K, Kashihara N. Establishing Cross-Specialty Expert Consensus on the Optimal Management of Hyperkalemia in Patients With Heart Failure and Chronic Kidney Disease. *Circ J.* 2025 Mar 25;89(4):470-478.
2) Kashihara N, Okada H, Suzuki Y, Iwamoto T, Yasutomi M, Matsui M, Takezawa R, Ishii T, Tomioka Y. Efficacy and safety of patiromer for hyperkalemia: a randomized, placebo-controlled phase 3 study. *Clin Exp Nephrol.* 2025 Feb 20. doi: 10.1007/s10157-025-02637-4. Online ahead of print.
3) Johannes CB, Ziemiecki R, Pladevall-Vila M, Ebert N, Kovesdy CP, Thomsen RW, Baak BN, García-Sempere A, Kanegae H, Coleman CI, Walsh M, Andersen IT, Rodríguez Bernal C, Robles Cabaniñas C, Christiansen CF, Farjat AE, Gay A, Gee P, Herings RMC, Hurtado I, Kashihara N, Kristensen FPB, Liu F, Okami S, Overbeek JA, Penning-van Beest FJA, Yamashita S, Yano Y, Layton JB, Vizcaya D, Oberprieler NG. Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study. *Diabetes Ther.* 2025 Feb;16(2):205-226.
4) Mondal R, Ritu RB, Kitaoka K, Azahar NM, Moniruzzaman M, Ogata S, Kiyoshige E, Tohara H, Kobayashi Y, Kashihara N, Naito T, Nakashima N, Tamura K, Nishimura K, Viera AJ, Yano Y. Oral microbiome alpha diversity and all-cause, cardiovascular, and non-cardiovascular mortality in US adults: Evidence from the NHANES 2009-2019. *Atherosclerosis.* 2025 Feb;401:119074.
5) Pollock C, Carrero JJ, Kanda E, Ofori-Asenso R, Chen H, Garcia Sanchez JJ, Pentakota S, Pecoits-Filho R, Fishbane S, Lam CSP, Kashihara N, Wheeler DC. Baseline Characteristics of the DISCOVER CKD Prospective Cohort. *Adv Ther.* 2025 Mar;42(3):1393-1418.
6) Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, Trimarchi H, Kollins D, Papachristofi O, Jacinto-Sanders S, Merkel T, Guerard N, Renfurm R, Hach T, Rizk DV; APPLAUSE-IgAN Investigators. Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. N Engl J Med.

2025 Feb 6;392(6):531-543.
7) Ohashi M, Ishikawa Y, Arai S, Nagao T, Kitaoka K, Nagasu H, Yano Y, Kashihara N. Comparative analysis of kidney function prediction: traditional statistical methods vs. deep learning techniques. *Clin Exp Nephrol.*. 2025 Jan 15. doi: 10.1007/s10157-024-02616-1. Online ahead of print.
8) Asahi K, Konta T, Tamura K, Tanaka F, Fukui A, Nakamura Y, Hirose J, Ohara K, Shijoh Y, Carter M, Meredith K, Harris J, Åkerborg Ö, Kashihara N, Yokoo T. The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes. *J Diabetes Investig.* 2025 Jan;16(1):108-119.
9) Konta T, Asahi K, Tamura K, Tanaka F, Fukui A, Nakamura Y, Hirose J, Ohara K, Shijoh Y, Carter M, Meredith K, Harris J, Åkerborg Ö, Kashihara N, Yokoo T. The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients. *Clin Exp Nephrol.*. 2024 Dec 16. doi: 10.1007/s10157-024-02600-9. Online ahead of print.
10) Heerspink HJL, Perkovic V, Tuttle KR, Pergola PE, Mahaffey KW, Patel UD, Ishida JH, Kuo A, Chen F, Kustra R, Petrovic V, Rossing P, Kashihara N, Chertow GM. Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial. J Am Soc Nephrol. 2024 Dec 1;35(12):1726-1736.
11) Shimamoto S, Nakahara T, Yamada S, Nagasu H, Kishi S, Nakashima N, Tsuruya K, Okada H, Tamura K, Narita I, Maruyama S, Yano Y, Yokoo T, Wada T, Wada J, Kanda E, Kataoka H, Nangaku M, Kashihara N, Nakano T. Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD-DB-Ex). *Sci Rep.* 2024 Nov 11;14(1):27481.
12) Kashihara N, Kumeda Y, Higashino Y, Maeda Y, Kaneko Y, Kanai H, Taniguchi Y, Ishii T, Tomioka Y. Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study. *Clin Exp Nephrol.* 2024 Nov 24. doi: 10.1007/s10157-024-02585-5. Online ahead of print.
13) Umebayashi R, Matsuoka-Uchiyama N, Sugiyama H, Shikata K, Kashihara N, Makino H, Wada J, Uchida HA. The Change in Public Perception and Knowledge Acquisition Methods of Chronic Kidney Disease Among General Population in Okayama Prefecture, Japan. *Diseases.* 2024 Oct 25;12(11):268.
14) Kishi S, Kadoya H, Kashihara N. Treatment of chronic kidney disease in older populations. Nat Rev Nephrol. 2024 Sep;20(9):586-602.
15) Aoki R, Nihei Y, Matsuzaki K, Suzuki H, Kihara M, Ogawa A, Nishino T, Sanada S, Yokote S, Okabe M, Shirai S, Fukuda A, Hoshino J, Kondo D, Yokoo T, Kashihara N, Narita I, Suzuki Y. Gross Hematuria after the COVID-19 mRNA Vaccination: Nationwide Multicenter Prospective Cohort Study in Japan. Kidney360. 2024 Sep 1;5(9):1322-1332.
16) Sugawara Y, Kanda E, Hamano T, Itano S, Okada H, Tomori K, Watanabe Y, Asakura W, Isaka Y, Iseki K, Usui T, Suzuki Y, Tanaka M, Nishimura R, Fukami K, Matsushita K, Wada J, Watada H, Ueki K, Kashihara N, Nangaku M; Research Working Group for Establishing Guidelines for Clinical Evaluation of Chronic Kidney Disease. Guidelines for clinical evaluation of chronic kidney disease in early stages : AMED research on regulatory science of pharmaceuticals and medical devices. *Clin Exp Nephrol.* 2024 Sep;28(9):847-865.
17) Kishi S, Nakashima T, Goto T, Nagasu H, Brooks CR, Okada H, Tamura K, Nakano T, Narita I, Maruyama S, Yano Y, Yokoo T, Wada T, Wada J, Nangaku M, Kashihara N. Association of serum magnesium levels with renal prognosis in patients with chronic kidney disease. *Clin Exp Nephrol.* 2024 Aug;28(8):784-792.
18) Pollock C, Carrero JJ, Kanda E, Ofori-Asenso R, Palmer E, Niklasson A, Linder A, Woodward H, Pentakota S, Garcia Sanchez JJ, Kashihara N, Fishbane S, Pecoits-Filho R, Wheeler DC. The Lived Experience of Patients with Chronic Kidney Disease: Insights From DISCOVER CKD. *Am J Nephrol.* 2024;55(6):618-628.
19) Fishbane S, Carrero JJ, Kumar S, Kanda E, Hedman K, Ofori-Asenso R, Kashihara N, Kosiborod MN, Lainscak M, Pollock C, Stenvinkel P, Wheeler DC, Pecoits-Filho R. Hyperkalemia Burden and Treatment

Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective Cohort. *Kidney360.* 2024 Jul 1;5(7):974-986.
20) Kanaoka T, Wakui H, Yano Y, Nagasu H, Kanegae H, Nangaku M, Hirakawa Y, Nakagawa N, Wada J, Tsuruya K, Nakano T, Maruyama S, Wada T, Konishi M, Nagahiro T, Yamagata K, Narita I, Yanagita M, Terada Y, Araki S, Emoto M, Okada H, Isaka Y, Suzuki Y, Yokoo T, Kataoka H, Kanda E, Kashihara N, Tamura K; J‐CKD‐DB investigators. Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database. *Diabetes Obes Metab.* 2024 Jul;26(7):2905-2914.
21) Nangaku M, Herrington WG, Goto S, Maruyama S, Kashihara N, Ueki K, Wada J, Watada H, Nakashima E, Lee R, Massey D, Mayne KJ, Tomita A, Haynes R, Hauske SJ, Kadowaki T. Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY. *Clin Exp Nephrol.* 2024 Jun;28(6):588-595.
22) Kitaoka K, Yano Y, Nagasu H, Kanegae H, Chishima N, Akiyama H, Tamura K, Kashihara N. Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex. *BMJ Open Diabetes Res Care.* 2024 May 30;12(3):e004115.
23) Nyma Z, Kitaoka K, Yano Y, Kanegae H, Bayaraa N, Kishi S, Nagasu H, Nakano T, Wada J, Maruyama S, Nakagawa N, Tamura K, Yokoo T, Yanagita M, Narita I, Yamagata K, Wada T, Tsuruya K, Nakashima N, Isaka Y, Nangaku M, Kashihara N, Okada H; J-CKD-DB study collaborative. Evaluating the associations between compliance with CKD guideline component metrics and renal outcomes. *Sci Rep.* 2024 May 20;14(1):11481.
24) Waki K, Nara M, Enomoto S, Mieno M, Kanda E, Sankoda A, Kawai Y, Miyake K, Wakui H, Tsurutani Y, Hirawa N, Yamakawa T, Komiya S, Isogawa A, Satoh S, Minami T, Iwamoto T, Takano T, Terauchi Y, Tamura K, Yamauchi T, Nangaku M, Kashihara N, Ohe K. Effectiveness of DialBetesPlus, a self-management support system for diabetic kidney disease: Randomized controlled trial. *NPJ Digit Med.* 2024 Apr 27;7(1):104.
25) Okada H, Ono A, Tomori K, Inoue T, Hanafusa N, Sakai K, Narita I, Moriyama T, Isaka Y, Fukami K, Itano S, Kanda E, Kashihara N. Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients. *PLoS One.* 2024 Apr 11;19(4):e0302101.
26) Yusei O, Nagasu H, Nakagawa N, Terawaki S, Moriwaki T, Itano S, Kishi S, Sasaki T, Kashihara N, Otomo T. A case series of Fabry diseases with CKD in Japan. *Clin Exp Nephrol.*. 2024 May;28(5):404-408.
27) 柏原 直樹. NPO 法人日本腎臓病協会の取り組み. 日本医師会雑誌 153(4):393-396. 2024 年 7 月
28) 岡田浩一, 柏原直樹, 桒原孝成, 小林一雄. 日本の CKD 対策に今,何が必要か. 日本医師会雑誌 153(4):369-382. 2024 年 7 月
29) 角谷裕之, 柏原直樹. 今,なぜ,透析医療と臨床倫理なのか? AMED CKM ガイド 2022 から日本透析医学会の提言 2020 を倫理的に読み解く. 臨床透析 40(10):1261-1265. 2024 年 9 月
30) 柏原直樹. 高齢化社会における腎臓病診療. Management of Kidney Disease in Aging Societies: Challenges and Innovations". 日本腎臓学会誌 66(2):351-356. 2024 年 4 月

研究分担者：岡田浩一

1) Shimamoto S, et al. Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database extension (J-CKD DB-Ex) Sci Rep 2024 Nov;14:27481.
2) Nyma Z, et al Evaluating the associations between compliance with CKD guideline component metrics and renal outcomes. Sci Rep. 2024 May 20;14(1):11481.
3) Okada H, et al. Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients. PLoS One. 2024 Apr 11;19(4):e0302101.
4) Kishi S, et al. Association of serum magnesium levels with renal prognosis in

patients with chronic kidney disease. Clin Exp Nephrol. 2024 Aug;28(8):784-792.
5) Kanaoka T, et al. Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: The Japan Chronic Kidney Disease Database. Diabetes Obes Metab. 2024 Jul;26(7):2905-2914.
6) Tomori K, et al. Long-term survival of patients receiving home hemodialysis with self-punctured arteriovenous access. PLoS One. 2024 May 31;19(5):e0303055

研究分担者：阿部　雅紀

1) Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S. Examine the optimal multidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study. Kidney Res Clin Pract. 2025;44(2):249-264.
2) 阿部雅紀. CKD 診療におけるチーム医療の効果. 日本腎臓リハビリテーション学会誌. 2025; 4(1):46-55.
3) 阿部雅紀.透析予防のための CKD チーム医療の効果.腎と透析.2025: 98(2): 167-171.

研究分担者：金﨑　啓造

1) Ferdaus SA, Ohara H, Matsuo H, Kawakami K, Takeuchi F, Fujikawa K, Kawakita E, Kato N, Nabika T, Kanasaki K. NAD(+) deficiency plays essential roles in the hyperuricemia of stroke-prone spontaneously hypertensive rat via xanthine dehydrogenase to xanthine oxidase conversion. Biochem Biophys Res Commun. 2025;744:151136.
2) group Rs, Tsukamoto S, Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, Tsuriya D, Machimura H, Shimura H, Wakui H, Takeda H, Yokomizo H, Takeshita K, Chin K, Kanasaki K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Muta Y, Takashi Y, Tamura K. Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2024;26(8):3248-60.
3) Kanasaki K. Risk of preeclampsia in pregnant individuals with chronic kidney disease: a framework from Chinese cohort. Hypertens Res. 2024;47(10):2948-51.
4) Kanasaki K, Nangaku M, Ueki K. 'DKD' as the kidney disease relevant to individuals with diabetes. Diabetol Int. 2024;15(4):673-6.
5) Kanasaki K, Ueki K, Nangaku M. Diabetic kidney disease: the kidney disease relevant to individuals with diabetes. Clin Exp Nephrol. 2024;28(12):1213-20.
6) Kawakita E,　Kanasaki K. Cancer biology in diabetes update: Focusing on antidiabetic drugs. J Diabetes Investig. 2024;15(5):525-40.
7) LeBleu VS,　Kanasaki K, Lovisa S, Alge JL, Kim J, Chen Y, Teng Y, Gerami-Naini B, Sugimoto H, Kato N, Revuelta I, Grau N, Sleeman JP, Taduri G, Kizu A, Rafii S, Hochedlinger K, Quaggin SE, Kalluri R. Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome. Life Sci Alliance. 2024;7(6).
8) Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, Machimura H, Shimura H, Takeda H, Yokomizo H, Takeshita K, Chin K,　Kanasaki K, Tamura K, Miyauchi M, Saburi M, Morita M, Yomota M, Kimura M, Hatori N, Nakajima S, Ito S, Tsukamoto S, Murata T, Matsushita T, Furuki T, Hashimoto T, Umezono T, Takashi Y, Kawanami D. Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study. Front Pharmacol. 2024;15:1358573.
9) Sato A, Rodriguez-Molina D, Yoshikawa-Ryan K, Yamashita S, Okami S, Liu F, Farjat A, Oberprieler NG, Kovesdy CP,　Kanasaki K, Vizcaya D. Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan-A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform. J Clin Med. 2024;13(17).
10) Srivastava SP, Zhou H, Shenoi R, Morris M, Lainez-Mas B, Goedeke L, Rajendran BK, Setia O, Aryal B,　Kanasaki K, Koya D, Inoki K, Dardik A, Bell T, 3rd, Fernandez-Hernando C, Shulman GI, Goodwin JE. Renal

Angptl4 is a key fibrogenic molecule in progressive diabetic kidney disease. Sci Adv. 2024;10(49):eadn6068.

研究分担者：内田明子

1) 内田明子・高齢透析患者の認知機能低下と看護・介護の問題点・日本透析医会雑誌 Vol.39 No.3・P442‐449

研究分担者：竹内裕紀

1) 辻本高志，安田知弘 大城匡史，藤山信弘，竹内裕紀移植医療に活用したい薬剤師パワー. 日本臨床腎移植学会雑誌 12（2）：180 ～ 187，2024
2) Ikegaya K, Muramatsu T, Sekiya R, Sekine Y, Harada Y, Miyashita R, Yamaguchi T, Ichiki A, Chikasawa Y, Bingo M, Yotsumoto M, Hagiwara T, Amano K, Takeuchi H, Kinai E. Effects of switching to dolutegravir/lamivudine from tenofovir alafenamide fumarate/emtricitabine/dolutegravir or abacavir/lamivudine/dolutegravir on body weight and lipid profile in Japanese people living with HIV. J Infect Chemother. 2024.S1341-321X(24)00291-5. doi: 10.1016/j.jiac.2024.10.012
3) Fujimiya T, Azuma K, Togashi Y, Kuwata K, Unezaki S, Takeuchi H. Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report. J Pharm Health Care Sci. 2024 Feb 16;10(1):10. doi: 10.1186/s40780-024-00332-2.
4) Furumi Y, Yusuke Sekine, Takata Y, Sato T, Hirao K, Kanetaka H, Takeuchi H, and Shimizu S. Polypharmacy and changes in prescribing with pharmacological intervention in geriatric inpatients in an acute care hospital: a single center study. 東京医科大学雑誌 82(1):77-84.
5) 竹内　裕紀.服薬アドヒアランスの向上をめざした心理面へのアプローチ. 日本腎臓リハビリテーション学会誌　3（2）：94-104,2024

2. 学会発表

（研究者別）

研究代表者：要　伸也

1) Anti-GBM disease: pathogenesis, diagnosis and treatment. APLAR SHORT COURSE. Vasculitis Foundation Course 2024, September 7, 2024,オンライン.
2) Importance of multidisciplinary team care in dietary education for CKD patients. International Workshop on Dietary Therapy for CKD 2025. Naha, Okinawa, March 29, 2025.
3) AAVの腎病変および血漿交換療法. 日本リウマチ学会・難治性血管炎の医療水準・患者QOL向上に資する研究班 合同シンポジウム：エビデンスをAAV診療に活かすために. 第68回日本リウマチ学会総会・学術集会. 神戸, 2024/4/20.
4) AvacopanとANCA関連血管炎.シンポジウム１：糸球体病変に対する新世代治療の可能性と実践方法. 第67回日本腎臓学会学術総会. 横浜, 2024/6/28
5) 腎臓病療養指導士制度の役割と今後の展望. 特別企画 腎臓病療養指導士制度を評価する. 第17回CKDチーム医療研究会. 東京, 2024/9/22
6) 腎臓病療養指導士育成の今後の展望. シンポジウム10：日本腎臓病協会のこれまでの成果と今後の目標. 第54回日本腎臓学会東部学術大会. 宇都宮, 2024/9/29
7) 膠原病に合併するTMAの診断と治療. ランチョンセミナー13. 第39回日本臨床リウマチ学会. 浜松, 2024/12/1

研究分担者：柏原　直樹

1) Naoki Kashihara. Healthy ageing and the kidney Prevention of kidney diseases in the aged population. Kidney Health In Aging and Aged Societies: JSN/ERA Symposium Collaboration with JSDT. 2024.9.14, Kyoto
2) Naoki Kashihara. Kidney and Hypertension - Optimizing Antihypertensive Therapy in Aging Societies. Kidney Health In Aging and Aged Societies: JSN/ERA Symposium Collaboration with JSDT. 2024.9.14, Kyoto
3) Kaori Kitaoka, Yuichiro Yano, Hajime Nagasu, Hiroshi Kanegae, Noriharu Chishima, Hiroki Akiyama, Kouichi Tamura, Naoki Kashihara Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chronic Kidney Disease Database Ex. Kidney Health In Aging and Aged Societies: JSN/ERA Symposium Collaboration with JSDT. 2024/9/14, Kyoto
4) Seiji Kishi, Takaya Nakashima, Tadahiro Goto, Hajime Nagasu, Naoki Kashihara . The relationship between serum magnesium levels and kidney prognosis in patients with chronic kidney disease - Analysis of Real-

World Data in the Treatment of Chronic Kidney Disease in Japan-. Kidney Health In Aging and Aged Societies: JSN/ERA Symposium Collaboration with JSDT. 2024/9/14, Kyoto

5) Hirokazu Okada, Atsushi Ono, Ken Sakai, Ichiei Narita, Toshiki Moriyama, Yoshitaka Isaka, Kei Fukami, Eiichiro Kanda, Naoki Kashihara. Development of a prognostic risk score to predict early mortality in inci- dent elderly Japanese hemodialysis patients. Kidney Health In Aging and Aged Societies: JSN/ERA Symposium Collaboration with JSDT. 2024/9/14, Kyoto
6) Hirokazu Okada,Ken Sakai, Ichiei Narita, Toshiki Moriyama, Yoshitaka Isaka, Kei Fukami, Eiichiro Kanda, Naoki Kashihara. Development of a Prognostic Risk Score to Predict Early Mortality in Incident Elderly Japanese Patients on Hemodialysis. American Society of Nephrology Kidney Week 2024. 2024/10/24, San Diego
7) Eiichiro Kanda, Bogdan I. Epureanu, Taiji Adachi, Tamaki Sasaki, Naoki Kashihara. Vector Field Model of CKD Stage and Its Directional Derivative Mathematically Enable Accurate Kidney Prognosis Prediction. American Society of Nephrology Kidney Week 2024. 2024/10/24, San Diego
8) Eiichiro Kanda, Bogdan I. Epureanu, Taiji Adachi, Tamaki Sasaki, Naoki Kashihara. Natural Language Processing Artificial Intelligence (AI) Predicts CKD Progression in Medical-Word Virtual Space. American Society of Nephrology Kidney Week 2024. 2024/10/25, San Diego
9) Naoki Kashihara. Our Journey to Overcome Chronic Kidney Disease. Taiwan Society of Nephrology. 2024/12/12, Tainan
10) 腎臓病の克服を目指して－Our Journey to Conquer Kidney Diseases－. 第 67 回日本腎臓学会学術総会. 2024/6/28、横浜市
11) 福井亮、徳永紳、豊泉夏紀、岡田浩一、柏原直樹　. 一般市民における慢性腎臓病(CKD)の認知度に関するアンケート調査 2023 年度. 第 67 回日本腎臓学会学術総会. 2024/6/29、横浜市
12) 大橋瑞紀、石川裕也、荒井敏、長尾智晴、北岡かおり、長洲一、矢野裕一朗、柏原直樹. リアルワールドデータにおける深層学習を用いた腎機能予測の精度比較. 第 67 回日本腎臓学会学術総会. 2024/6/29、横浜市
13) 糖尿関連腎臓病の克服をめざして. 第 11 回糖尿病年次学術集会. 2024/7/20
14) 「NPO 法人日本腎臓病協会のこれまでの成果と今後の目標」普及啓発・診療連携の現状と今後の課題～幹事長の視点～日本腎臓病協会の挑戦. 第 54 回日本腎臓学会東部学術大会. 2024/9/29、宇都宮市
15) 梅林亮子、内田治仁、杉山斉、柏原直樹、和田淳. 岡山県の健診受診者の慢性腎臓病（CKD）認知度～2023 年度～. 第 54 回日本腎臓学会西部学術大会. 2024/10/5、姫路市
16) 柏原直樹.腎臓病・腎不全の現状を未来予想図. 日本内科学会学術集会第 52 回内科学の展望. 2025/1/19、奈良市

研究分担者：岡田浩一

1) Okada H, et al. Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients. ASN Kidney Week 2024, 2024/10/24
2) Tomori K, et al. Home hemodialysis skills assessment predicts treatment survival in patients on home hemodialysis. ASN Kidney Week 2024, 2024/10/24

研究分担者：阿部雅紀

1) 腎臓病療養士とともに行う CKD チーム医療とその効果. 第 14 回日本腎臓リハビリテーション学会. 2024/3/16
2) 保存期と透析期から考える CKD 治療の課題と展望. 第 15 回日本腎臓リハビリテーション学会.2025/3/16

研究分担者：金﨑　啓造

1) シンポジウム 30：日本における糖尿病関連腎臓病の概念と定義（Diabetic Kidney Disease: concepts and anddefinition in Japan）第 67 回日本糖尿病学会年次学術集会 東京 2024/5/19
2) シンポジウム 40：CKD を合併した糖尿病患者に対する血圧管理について 第 67 回日本糖尿病学会年次学術集会東京 2024/5/19
3) キャリアデベロップメント報奨金の成果報告会：カテコール代謝不全に注目した研第 67 回日本糖尿病学会年次学術集会東京 2024/5/18
4) 教育講演 4：糖尿病関連腎臓病の概念と定義.第 67 回日本糖尿病学会年次学術集会東京　2024/5/17

5） シンポジウム 28：糖尿病性腎症のこれまでと DKD の未来 糖尿病関連腎臓病という考え方第 67 回日本腎臓学会学術総会　横浜 2024/6/30
6） Update:糖尿病・肥満「糖尿病関連腎臓病の概念と定義」
第 34 回臨床内分泌代謝 Update　名古屋 2024/11/29
7） シンポジウム 2：糖尿病関連腎臓病の概念と定義：潜在的残余リスクの解明に向けて
第 59 回糖尿病学の進歩　那覇　2025/1/24
8） Post-SGLT2 inhibitor Era における糖尿病関連腎臓病とファインレノン 37th Spring Congress of Korean Diabetic Association
昌原市 2024/5/3
9） ランチョンセミナー16：糖尿病合併症制御における血圧管理 Up date　第 67 回日本糖尿病学会年次学術集会
東京　2024/5/18
10）ランチョンセミナー2：糖尿病関連腎臓病の早期介入を考える～EMPA-KIDNEY 試験を中心に～第 11 回 JADEC 年次学術集会. 京都 2024/7/20
11）ランチョンセミナー1：糖尿病関連腎臓病に対する診療 2024～finerenone への期待～第 39 回日本糖尿病合併症学会, 筑波 2024/10/4
12）スウィーツセミナー1：糖尿病関連腎臓病に対する診療 2024～finerenone への期待～
第 98 回日本糖尿病学会中部地方会
金沢　2024/9/14
13）イブニングセミナー1：エビデンスを積極的に活用した糖尿病関連腎臓病に対する介入戦略 2024 第 35 回日本糖尿病性腎症研究会
東京　2024/11/30
14）ランチョンセミナー1：糖尿病関連腎臓病の早期介入を考える～EMPA-KIDNEY 試験を中心に～日本糖尿病学会中国四国地方会第 62 回総会　岡山 2024/12/6
15）イブニングセミナー1：糖尿病関連腎臓病の治療戦略 2025～ミトコンドリア恒常性維持と細胞老化抑制を標的として～
第 59 回糖尿病学の進歩　那覇 2025/1/24+
16）ランチョンセミナー3：糖尿病関連腎臓病に対する治療戦略 2025
第 62 回日本糖尿病学会関東甲信越地方会
宇都宮　2025/2/8
17）ランチョンセミナー：糖尿病をもつ人を「がん」で看取る時代の診療
第 13 回中四国糖尿病療養指導スキルアップセミナー　岡山 2025/3/2
18）ランチョンセミナー5：腎症進行抑制を見据えた 2 型糖尿病治療戦略
第 35 回日本糖尿病性腎症研究会 東京 2024/12/1

研究分担者：内田明子

1） 第 8 回日本臨床薬理学会九州・沖縄地方会・末期腎不全患者の人生の最終段階における薬剤マネジメントへの期待 2024/7/27
2） 第 15 回日本腎臓リハビリテーション学会学術集会・認知症を有する透析患者の看護
3） 第 69 回日本透析医学会学術集会・総会・腎代替療法専門指導士必修講習・腎代替療法選択支援と腎代替療法指導管理料

研究分担者：石川祐一

1） 腎リハ患者に対する栄養評価と実際.
第 15 回日本腎臓リハビリテーション学会学術集会　2025/3/15　横浜
2） CKD 患者に対する透析予防指導の取り組み.　第 11 回日本栄養改善学会関東甲信越支部学術集会　2025/2/8　日立

研究分担者：竹内裕紀

1） 竹内裕紀、岩崎藍、三澤翔、菅野義彦.ワークショップ 6「組織的に展開する腎臓領域の医療安全推進」医薬連携による CKD 患者の安全な薬物療法をめざして　第 67 回日本腎臓学会　2024/6/30
2） 竹内裕紀、増田智先、渡井 至彦、谷川原祐介. シンポジウム 9：TDM 標準化ガイドラインの果たしてきた役割と将来に向けて「免疫抑制薬ＴＤM標準化ガイドライン臓器移植編」の果たしてきた役割と将来に向けて　第 40 回日本 TDM 学会・学術大会 2024/7/15
3） MMF の体内動態の特徴を知った上で TDM を実践しよう.第 9 回 TDM-QC 研究会 2024/8/3
4） 東加奈子、竹内裕紀　岩本整. シンポジウムがんと腎臓 ～急性腎障害を中心に～.
第 54 回日本病院薬剤師会 関東ブロック学術大会　2024/8/10
5） 腎臓病薬物療法における薬剤師の課題と展望.　第 18 回日本腎臓病薬物療法学会学術集会　2024/9/7
6） 竹内 裕紀、松本有右. シンポジウム 53.地域医療で求められる保険薬局薬剤師の TDM 業務について.血清クレアチニン自己簡易測定による腎機能低下減量必要薬の薬学的管理の可能性.第 34 回日本医療薬学会年会.　2024/11/04

H．知的財産権の出願・登録状況

1. 特許取得
該当なし

2. 実用新案登録
該当なし

3. その他

＜政策提言＞

分担研究者：内田明子

1） 日本医療政策機構（HGPI）腎疾患対策推進プロジェクト2023「患者・市民・地域が参画し、協働する腎疾患対策に向けて」アドバイザリーボードメンバー

◎分担研究者：石川祐一

1） 日本医療政策機構腎疾患対策推進プロジェクト「腎疾患対策推進プロジェクト」アドバイザリーボードメンバー 「腎疾患対策推進プロジェクト 2023「患者・市民・地域が参画し、協働する腎疾患対策に向けて」政策提言・地方自治体における慢性腎臓病（CKD）対策好事例集

Clinical and Experimental Nephrology
https://doi.org/10.1007/s10157-023-02338-w

ORIGINAL ARTICLE

Effectiveness and current status of multidisciplinary care for patients with chronic kidney disease in Japan: a nationwide multicenter cohort study

Masanori Abe[1,2] · **Tsuguru Hatta**[1,3] · **Yoshihiko Imamura**[1,4] · **Tsutomu Sakurada**[1,5] · **Shinya Kaname**[1,6]

Received: 17 January 2023 / Accepted: 4 March 2023

Abstract

Background Multidisciplinary care is well established in clinical practice, but its effectiveness in patients with chronic kidney disease (CKD) remains unclear. The aim of this study was to determine whether multidisciplinary care could help to avoid worsening kidney function in patients with CKD.

Methods This nationwide study had a multicenter retrospective observational design and included 3015 Japanese patients with CKD stage 3–5 who received multidisciplinary care. We assessed the annual decrease in estimated glomerular filtration rate (ΔeGFR) and urinary protein in the 12 months before and 24 months after the start of multidisciplinary care. All-cause mortality and initiation of renal replacement therapy were investigated according to baseline characteristics.

Results Most of the patients had CKD stage 3b or higher and a median eGFR of 23.5 mL/min/1.73 m^2. The multidisciplinary care teams consisted of health care professionals from an average of four disciplines. ΔeGFR was significantly smaller at 6, 12, and 24 months after initiation of multidisciplinary care (all $P < 0.0001$), regardless of the primary cause of CKD and its stage when multidisciplinary intervention was started. Urinary protein level also decreased after initiation of multidisciplinary care. After a median follow-up of 2.9 years, 149 patients had died and 727 had started renal replacement therapy.

Conclusion Multidisciplinary care may significantly slow the decline in eGFR in patients with CKD and might be effective regardless of the primary disease, including in its earlier stages. Multidisciplinary care is recommended for patients with CKD stage 3–5.

Trial registration UMIN00004999.

Keywords Certified Kidney Disease Educator · Chronic kidney disease · Estimated glomerular filtration rate · Kidney function · Multidisciplinary care · Renal replacement therapy

✉ Masanori Abe
abe.masanori@nihon-u.ac.jp

1 The Committee of the Evaluation and Dissemination for Certified Kidney Disease Educator, Japan Kidney Association, Tokyo, Japan

2 Division of Nephrology, Hypertension and Endocrinology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan

3 Department of Medicine, Hatta Medical Clinic, Kyoto, Japan

4 Department of Nephrology, Nissan Tamagawa Hospital, Tokyo, Japan

5 Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan

6 Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan

Introduction

The number of patients with chronic kidney disease (CKD) is growing around the world. Approximately 13.3 million adults in Japan were estimated to have CKD in 2005 [1], and this number had increased to 14.8 million by 2015, potentially reflecting the aging population in Japan [2]. Accordingly, the number of patients with end-stage kidney disease starting renal replacement therapy (RRT) in Japan is increasing annually and the number of patients who are undergoing dialysis therapy now exceeds 340,000 [3]. The prevalence of dialysis in Japan is 2682 per million population, which is the second highest worldwide after Taiwan [4]. There are numerous risk factors for progressive CKD, including hypertension, diabetes, and advancing age, which result in worsening kidney function that can lead to end-stage kidney

Published online: 31 March 2023

disease and cardiovascular disease (CVD). CKD is an internationally recognized public health problem because of its epidemiological features, high mortality rate, and considerable medical costs [5]. Therefore, important treatment goals in patients with CKD are slowing of disease progression, minimizing complications, and improving quality of life.

The multidisciplinary care model encompasses a range of disciplines with different but complementary skills, knowledge, and experience and aims to improve health care and achieve optimal outcomes in terms of the physical and psychosocial needs of patients [6]. However, there is still a need to improve the standard care for patients with CKD in clinical practice. The Certified Kidney Disease Educator (CKDE) system was established in Japan by the Japan Kidney Association (JKA) in 2017 with the aims of preventing progression of CKD and improving and maintaining patients' quality of life. Nurses, registered dietitians, and pharmacists who meet certain requirements are eligible for qualification as a CKDE. All CKDEs have acquired the basic skills for management of patients with CKD, including guidance on lifestyle modification, dietary counseling, and medical therapy according to stage of CKD. Thus, CKDEs play an important role in multidisciplinary care. By 2022, there were 1935 CKDEs in Japan, and multidisciplinary care of patients with CKD by board-certified nephrologists and CKDEs has become widespread. However, only a limited number of studies in Japan have investigated the association between multidisciplinary care for patients with CKD and kidney function, and these studies involved small numbers of patients from single centers [7, 8]. In this multicenter cohort study, we investigated the current status of multidisciplinary care for patients with CKD and whether multidisciplinary care can help to avoid worsening of kidney function in patients with CKD.

Methods

Study design and participants

This nationwide study was designed as a multicenter retrospective observational cohort study involving approximately 3000 Japanese patients who were enrolled at 24 selected medical institutions in Japan. Patients with CKD who received continuous multidisciplinary care between January 2015 and December 2020 and had kidney function data available for the 12 months before and the 24 months after receiving multidisciplinary care were included.

The following exclusion criteria were applied: age younger than 20 years; estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m^2; active malignant disease; transplant recipient status; history of long-term dialysis; and missing data on age, sex, or kidney function. The primary efficacy endpoint was the annual decline in eGFR (ΔeGFR) between 12 months before and 24 months after the start of multidisciplinary intervention. Secondary endpoints were the annual change in the urinary protein level between 12 months before and 24 months after the start of multidisciplinary intervention and the composite outcome of all-cause mortality and initiation of RRT until the end of 2021.

The study was approved by the ethics committee of Nihon University Itabashi Hospital and conducted in accordance with the Declaration of Helsinki, Japanese privacy protection laws, and the Ethical Guidelines for Medical and Health Research Involving Human Subjects published by the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare in 2015. The need for informed consent was waived due to the use of de-identified data. Information in this study was disclosed to subjects in an opt-out format. The study is registered in the University Hospital Medical Information Network (UMIN000049995).

Multidisciplinary care

Multidisciplinary care was defined as follows: (1) a care team comprising nephrologists and professionals from other disciplines, including nurses, registered dietitians, pharmacists, physical therapists, social workers, clinical engineers, and clinical laboratory technicians; and (2) an operational model of multidisciplinary care, whereby patients with CKD were managed medically, received patient education, and were encouraged to make lifestyle modifications according to the stage of CKD. The quality of the educational content provided was maintained in accordance with the recommendations of the Japanese Society of Nephrology, Japanese Society for Dialysis Therapy, Japan Society for Transplant, and Japanese Society for Clinical Renal Transplantation or the CKD Teaching Guidebook for Certified Kidney Disease Educators by the JKA [9, 10].

Data collection

Data were collected on patient demographics and clinical characteristics, including age, sex, history of CVD, primary etiology of CKD, body mass index (BMI), hemoglobin, serum albumin, blood urea nitrogen, creatinine (Cr), eGFR, urinary protein, and glycated hemoglobin (for patients with diabetes) at the time when multidisciplinary care intervention was initiated (baseline). CVD was defined as coronary artery disease, ischemic stroke, hemorrhagic stroke, and limb amputation. The eGFR was calculated according to the following formula for Japanese patients: eGFR (mL/min/1.73 m^2) = $194 \times \text{serum Cr}^{-1.094} \times \text{age}^{-0.287}$ ($\times 0.739$ for women) [11]. Urinary protein was calculated as the urinary protein to creatinine ratio (UPCR). The eGFR and UPCR

values at 12 months before the intervention and at 6, 12, and 24 months after the start of the intervention were obtained. Information on the method and setting of intervention (outpatient or inpatient), duration of intervention (number of visits for intervention for outpatients or hospitalization days for inpatients), and type and number of staff was collected. The composite outcome of all-cause mortality and initiation of RRT was assessed using dates of death and initiation of RRT or the end of 2021 was reached, whichever came first. The type of RRT (i.e., hemodialysis, peritoneal dialysis, or kidney transplantation) was recorded.

Statistical analysis

Data are reported as the number and proportion, mean ± standard deviation, or median [interquartile range]. Categorical variables were examined using the chi-squared test, and continuous variables were compared using the *t* test. Three or more groups were compared using repeated-measures analysis of variance with Tukey's honestly significant difference test or the Kruskal–Wallis test, as appropriate. The associations between the number of multidisciplinary care team members and the number of interventions by the multidisciplinary care team, and the mean ΔeGFR and the % changes in UPCR were analyzed using Spearman's rank correlation coefficient. Incidence of all-cause death and incidence of initiation of RRT are presented as the number of events per 1000 person-years. For survival analysis of the composite outcome, the patients were divided into two groups according to diabetes mellitus (DM) status and four groups according to CKD stage (G3a, G3b, G4, or G5) at baseline. The composite outcome was estimated using the Kaplan–Meier method and compared between groups using the log-rank test. A univariate analysis was performed according to eGFR stage, and multivariate survival analyses were performed using Cox proportional hazards models adjusted for confounders to examine associations between baseline CKD stage and the composite outcome during 6 years of follow-up. Model 1 was used to calculate the hazard ratios adjusted for basic characteristics, including age, sex, history of CVD, and DM status. Model 2 was the same as model 1 but was further adjusted for BMI, hemoglobin, serum albumin, and UPCR levels. A univariate analysis was performed according to DM status, and multivariate survival analyses using Cox proportional hazards models adjusted for confounding factors were performed to examine DM status and the composite outcome. Model 1 was used to calculate the hazard ratios adjusted for basic factors, including age, sex, and history of CVD, and model 2 was adjusted for BMI, hemoglobin, serum albumin, eGFR, and UPCR levels in addition to the factors included in model 1. The results from the models are expressed as hazard ratios (HRs) with 95% confidence intervals (CIs) and P-values. Multivariate survival analyses were performed using Cox proportional hazards models adjusted for confounders to examine associations between the number of multidisciplinary care team members and the number of multidisciplinary care team interventions and composite outcomes. Moreover, to discover which factors and specialty compositions within the multidisciplinary care team are advantageous for the composite endpoint, we estimated the HRs and compared them between the group with each specialist member present and the group without as the reference group. For the regression analyses, imputation of missing data was performed by conventional methods, as appropriate. All analyses were performed using JMP® version 13.0 (SAS Institute Inc., Cary, NC, USA). A P value < 0.05 was considered statistically significant.

Results

Patient characteristics at time of initiation of multidisciplinary care

Of 3146 patients registered during the study period, 131 were excluded (CKD stage 1 or 2, $n = 118$; no baseline kidney function data, $n = 13$), leaving 3015 patients for inclusion in the analysis. The patients' background characteristics are shown in Table 1. Mean age was 70.5 ± 11.6 years and 74.2% were male. In terms of disease severity, median eGFR was 23.5 [15.1–34.4] mL/min/1.73 m^2 and median UPCR was 1.13 [0.24–3.1] g/gCr. CKD was stage 4 in 1248 patients (41.4%), stage 3b in 761 (25.2%), and stage 5 in 726 (24.1%). Diabetic nephropathy was the most common primary cause of CKD, followed by hypertension and glomerulonephritis.

Interventions implemented by the multidisciplinary care team

Details of the interventions implemented by the multidisciplinary care team are shown in Table 2. Intervention was provided in an inpatient setting for more than half of the patients and on an outpatient basis for the remainder. The majority of the multidisciplinary team members were registered dieticians (90.4%), followed by nurses (86.2%), pharmacists (62.3%), and physical therapists (25.9%). The mean number of multidisciplinary care team members was four; 33.7% of the patients received intervention by five team members and 29.2% by four team members.

ΔeGFR before and after multidisciplinary care

The mean annual decline in eGFR (ΔeGFR) was − 6.0 ± 9.0 before multidisciplinary intervention and − 0.34 ± 5.78 at

Table 1 Baseline characteristics of the patients

Variable	
Patients, *n* (% male)	3015 (74.2)
Age, years	70.5 ± 11.6
Body mass index	24.2 ± 4.3
Serum creatinine, mg/dL	2.08 [1.48–3.14]
eGFR, mL/min/1.73 m^2	23.5 [15.1–34.4]
Blood urea nitrogen, mg/dL	32 [23–45]
Hemoglobin, g/dL	11.7 ± 1.9
Serum albumin, g/dL	3.7 ± 0.5
Urinary protein, g/gCr	1.13 [0.24–3.1]
Comorbid CVD, *n* (%)	885 (29.4)
HbA_{1c} (in DM patients), %	6.4 ± 1.0
CKD stage, *n* (%)	
3 (3a + 3b)	1041 (34.5)
3a	280 (9.3)
3b	761 (25.2)
4	1248 (41.4)
5	726 (24.1)
Primary cause of CKD, *n* (%)	
Diabetes	1321 (43.8)
Hypertension	894 (29.7)
Glomerulonephritis	384 (12.7)
PCKD	88 (2.9)
Other	328 (10.9)

Data are shown as the number (percentage), mean ± standard deviation, or median [interquartile range]

Cr creatinine, *CKD* chronic kidney disease, *CVD* cardiovascular disease, *DM* diabetes mellitus, *eGFR* estimated glomerular filtration rate, HbA_{1c} glycated hemoglobin, *PCKD* polycystic kidney disease

Table 2 Characteristics of the multidisciplinary care team and interventions

Variable	
Place of intervention, *n* (%)	
Outpatient	1246 (41.3)
Inpatient	1769 (58.7)
Number of interventions	
Outpatient setting, *n*	4 [1–11]
Inpatient setting, *n*	7 [6–12]
Professional makeup of MDC team, *n* (%)	
Nurses	2600 (86.2)
Registered dieticians	2726 (90.4)
Pharmacists	1878 (62.3)
Physical therapists	781 (25.9)
Clinical laboratory technicians	178 (5.9)
Social workers	72 (2.3)
Other professionals	31 (1.0)
Number of MDC team members, *n* (%)	4 [3–5]
2	700 (23.2)
3	416 (13.8)
4	882 (29.2)
5	994 (33.0)
6	23 (0.8)

Data are shown as the number (percentage), mean ± standard deviation, or median [interquartile range]

MDC multidisciplinary care

6 months, − 1.40 ± 6.82 at 12 months, and − 1.45 ± 4.04 at 24 months after intervention (all $P < 0.0001$; Fig. 1). Furthermore, in the DM group, mean ΔeGFR was − 6.60 ± 9.5 before intervention and − 1.04 ± 5.92 at 6 months, − 2.28 ± 7.39 at 12 months, and − 2.06 ± 4.50 at 24 months after intervention (all $P < 0.0001$; Fig. 2a); the respective values in the non-DM group were − 5.55 ± 8.56, 0.20 ± 5.61, − 0.76 ± 6.29, and − 1.06 ± 3.66 (all $P < 0.0001$; Fig. 2b).

In patients with CKD stage 3, mean ΔeGFR was − 4.05 ± 9.19 before intervention and − 0.53 ± 6.84 at 6 months, − 1.82 ± 7.43 at 12 months, and − 1.83 ± 4.21 at 24 months after intervention; the difference was significant at all assessment points after intervention (Fig. 3a). When the patients with CKD stage 3 were divided into G3a and G3b subgroups, the difference in mean ΔeGFR was significant only for stage G3b (Supplementary Fig. 1). For patients with CKD stage 4, mean ΔeGFR was − 6.20 ± 8.35 before intervention and − 0.19 ± 5.01 at 6 months, − 1.33 ± 6.14 at 12 months, and − 1.54 ± 3.66 at 24 months after intervention (all $P < 0.0001$; Fig. 3b); the respective values in patients with CKD stage 5 were − 8.43 ± 9.13, − 0.33 ± 5.42, − 0.72 ± 6.98, and − 0.20 ± 4.36 (all $P < 0.0001$; Fig. 3c).

There was no significant correlation between the mean ΔeGFR and the number of multidisciplinary care team members, but there was a significant correlation between the mean ΔeGFR and number of interventions by the multidisciplinary care team at all time points (all $P < 0.05$; Supplementary Table 1).

Changes in proteinuria after multidisciplinary intervention

Median UPCR decreased significantly from 1.13 [0.24–3.10] g/gCr at baseline to 0.96 [0.23–2.63] g/gCr at 6 months ($P < 0.0001$), 0.82 [0.21–2.30] g/gCr at 12 months ($P < 0.0001$), and 0.78 [0.19–2.07] g/gCr at 24 months ($P = 0.019$) after intervention in all patients. There was a significant decrease in UPCR at all measurement times after intervention in the DM group but only at 6 months in the non-DM group ($P = 0.0003$) (Fig. 4).

There was a significant correlation between the % changes in UPCR and the number of multidisciplinary care team members at 12 and 24 months after intervention, but no significant correlation between the % changes in UPCR and the



Fig. 1 Annual changes in eGFR decline (ΔeGFR) in the 12 months before and 24 months after initiation of multidisciplinary care in all patients. Data are shown as the mean. Bars indicate the 95% confidence interval. *$P < 0.0001$ vs. before start of MDC. eGFR estimated glomerular filtration rate, MDC multidisciplinary care



Fig. 2 Annual changes in eGFR decline (ΔeGFR) in the 12 months before and 24 months after initiation of multidisciplinary care according to DM status. **a** DM group, **b** non-DM group. *$P < 0.0001$ vs. before start of MDC. Data are shown as the mean. Bars indicate the 95% confidence interval. DM diabetes mellitus, eGFR estimated glomerular filtration rate, MDC multidisciplinary care



Fig. 3 Annual changes in decline of eGFR (ΔeGFR) in the 12 months before and 24 months after initiation of multidisciplinary care according to CKD stage at the time of initiation of MDC. **a** CKD stage G3, **b** CKD stage G4, **c** CKD stage G5. ***$P < 0.0001$, **$P < 0.001$, *$P < 0.01$ vs. before start of MDC. Data are shown as the mean. Bars indicates the 95% confidence interval. CKD chronic kidney disease, eGFR estimated glomerular filtration rate, MDC multidisciplinary care

number of interventions by the multidisciplinary care team at all time points (Supplementary Table 2).

Outcomes

The median observation period was 35 [20–50] months, during which 149 patients (4.9%) died, 747 (24.8%) started RRT, and 66 (2.2%) were lost to follow-up. RRT consisted of hemodialysis in 618 patients (82.7%), peritoneal dialysis in 66 (8.8%), and renal transplantation in 25 (3.5%).

The characteristics and outcomes according to DM status are shown in Table 3. Patients in the DM group were more likely to be male, have comorbid CVD, be younger, and to have higher BMI and UPCR and lower eGFR and serum albumin levels. Kaplan–Meier analysis for the composite endpoint (all-cause mortality and initiation of RRT) revealed a significant difference between the DM and non-DM groups ($P < 0.0001$, log-rank test; Fig. 5). Compared with the non-DM (reference) group, the DM group had a significant higher unadjusted HR for all-cause mortality and initiation of RRT (1.74, 95% CI 1.53–1.99, $P < 0.0001$). After adjustment for background factors, including age, sex, and history of CVD, the HR in the DM group was 1.68 (95% CI 1.47–1.93, $P < 0.0001$). After further adjustment for background factors and laboratory data, including BMI, hemoglobin, serum albumin, eGFR, and UPCR level at



Fig. 4 Changes in urinary protein levels between the time of initiation of MDC and 24 months after initiation of multidisciplinary care according to DM status. ***$P<0.0001$, **$P<0.001$, *$P<0.05$ vs. baseline. Data are shown as the mean. Bars indicates the 95% confidence interval. DM diabetes mellitus

Table 3 Baseline characteristics according to DM status

Variable	DM	Non-DM	*P* value
Patients, *n*	1321	1694	–
Male sex, %	78.1	71.2	< 0.0001
Age, years	69.4 ± 11.4	71.4 ± 11.7	< 0.0001
Body mass index	24.9 ± 4.7	23.7 ± 3.9	< 0.0001
Serum creatinine, mg/dL	2.65 ± 1.5	2.39 ± 1.4	< 0.0001
eGFR, mL/min/1.73 m^2	24.4 ± 12.5	26.5 ± 12.9	< 0.0001
Blood urea nitrogen, mg/dL	37.0 ± 17.5	35.7 ± 17.5	0.040
Hemoglobin, g/dL	11.5 ± 1.9	11.8 ± 1.9	< 0.0001
Serum albumin, g/dL	3.6 ± 0.6	3.8 ± 0.5	< 0.0001
Urinary protein, g/gCr	2.20 [0.57–4.90]	0.62 [0.15–1.79]	< 0.0001
Comorbid CVD, *n* (%)	436 (33.0)	449 (26.5)	0.0004
HbA_{1c} (in DM patients), %	6.6 ± 1.1	–	–
CKD stage, *n* (%)			0.0005
3 (3a + 3b)	406 (30.7)	635 (37.5)	
3a	106 (8.0)	174 (10.3)	
3b	300 (22.7)	461 (27.2)	
4	561 (42.5)	687 (40.6)	
5	354 (26.8)	372 (21.9)	
Observation period, months	33 [17–48]	36 [22–52]	< 0.0001
All-cause death, *n* (%)	75 (5.7)	75 (4.4)	0.132
All-cause death, per 1000 person-years	20.3	14.2	0.031
Initiation of RRT, *n* (%)	416 (31.5)	331 (19.5)	< 0.0001
Initiation of RRT, per 1000 person-years	113	62.8	< 0.0001

Data are shown as the number, percentage, mean ± standard deviation, or median [interquartile range]

Cr creatinine, *CKD* chronic kidney disease, *CVD* cardiovascular disease, *DM* diabetes mellitus, *eGFR* estimated glomerular filtration rate, *RRT* renal replacement therapy



Fig. 5 Kaplan–Meier curves for the incidence of all-cause death and initiation of renal replacement therapy in Japanese patients with CKD according to DM status. CKD chronic kidney disease, DM diabetes mellitus

Table 4 All-cause mortality and initiation of renal replacement therapy according to DM status in Cox proportional hazards models adjusted for confounding factors in Japanese patients with CKD

Group	Unadjusted			Model 1			Model 2		
	HR	95% CI	*P* value	HR	95% CI	*P* value	HR	95% CI	*P* value
Non-DM	1.00	Reference	–	1.00	Reference	–	1.00	Reference	–
DM	1.74	1.53–1.99	< 0.0001	1.68	1.47–1.93	< 0.0001	1.28	1.09–1.51	< 0.0001

Model 1 was adjusted for basic factors, including age, sex, and history of cardiovascular disease, and model 2 was adjusted in the same way as model 1 but with additional adjustment for body mass index, hemoglobin, serum albumin, estimated glomerular filtration rate, and urinary protein level at baseline

CI confidence interval, *CKD* chronic kidney disease, *DM* diabetes mellitus, *eGFR* estimated glomerular filtration rate, *HR* hazard ratio

baseline, the DM group had a significantly higher HR (1.28, 95% CI 1.09–1.51, $P < 0.0001$) (Table 4). Kaplan–Meier analysis revealed a significant difference in all-cause mortality between the DM and non-DM groups ($P = 0.031$, log-rank test; Supplementary Fig. 2). After adjustment for background factors, including age, sex, and history of CVD, the HR in the DM group compared with the non-DM group (reference) was 1.49 (95% CI 1.08–2.06). After further adjustment for background factors and laboratory data, including BMI, hemoglobin, serum albumin, eGFR, and UPCR level at baseline, the HR was significantly higher in the DM group (1.49, 95% CI 1.01–2.19, $P = 0.044$) (Supplementary Table 3).

Patient characteristics and outcomes according to CKD stage are shown in Table 5. BMI, hemoglobin, the serum albumin level, and the glycated hemoglobin value (for patients with diabetes) decreased while the UPCR level increased with progression though the stages of CKD. All-cause mortality and the RRT initiation rate were dependent on the disease stage. Significant differences (all $P < 0.0001$, log-rank test) were found in the composite endpoint (all-cause death or RRT initiation) according to CKD stage at baseline in Japanese patients with CKD (Fig. 6). Kaplan–Meier analysis revealed that all-cause mortality varied significantly depending on the CKD stage at baseline ($P = 0.0009$, log-rank test; Supplementary Fig. 2). After adjustment for basic factors, including age, sex, history of CVD, and DM status, the HRs in the G3b, G4, and G5 groups when compared with the G3a (reference) group were 2.43 (95% CI 1.04–7.08), 2.49 (95% CI 1.11–7.17), and 3.77 (95% CI 1.61–11.0), respectively. However, after adjustment for basic factors and laboratory data, including BMI, hemoglobin, serum albumin, and UPCR level, only the G5 group had a significantly higher HR (3.03, CI 1.01–9.11, $P = 0.048$; Supplementary Table 4).

Table 5 Comparison of patient characteristics and outcomes according to CKD stage at baseline

Variable	Stage 3a	Stage 3b	Stage 4	Stage 5	*P* value
Patients, *n*	280	761	1248	726	–
Male sex, %	77.5	77.9	74.4	68.9	0.0005
Age, years	65.7 ± 12.1	70.3 ± 10.9	71.7 ± 11.6	70.6 ± 11.8	< 0.0001
Body mass index, kg/m^2	24.9 ± 4.3	24.2 ± 4.1	24.3 ± 4.4	23.7 ± 4.3	0.001
Serum creatinine, mg/dL	1.07 ± 0.14	1.44 ± 0.23	2.31 ± 0.53	4.44 ± 1.37	< 0.0001
eGFR, mL/min/1.73 m^2	51.0 ± 3.9	36.4 ± 4.2	21.8 ± 4.4	10.8 ± 2.7	< 0.0001
Blood urea nitrogen, mg/dL	18 [15–21]	23 [20–27]	34 [28–42]	53 [44–64]	< 0.0001
Hemoglobin, g/dL	13.7 ± 1.6	12.6 ± 1.8	11.4 ± 1.6	10.4 ± 1.5	< 0.0001
Serum albumin, g/dL	3.9 ± 0.5	3.9 ± 0.5	3.7 ± 0.5	3.6 ± 0.5	< 0.0001
Urinary protein, g/gCr	0.33 [0.08–1.32]	0.33 [0.09–1.43]	1.20 [0.32–3.21]	2.59 [1.26–4.98]	< 0.0001
Comorbid CVD, *n* (%)	71 (25.4)	211 (27.8)	394 (31.6)	209 (28.8)	0.0002
HbA1c (in DM patients), %	6.7 ± 1.1	6.5 ± 1.1	6.4 ± 1.0	6.2 ± 0.9	< 0.0001
Primary cause of CKD, *n* (%)					0.0024
Diabetes	106 (37.9)	299 (39.3)	561 (45.0)	354 (48.8)	
Hypertension	97 (34.6)	245 (32.2)	381 (30.5)	171 (23.6)	
Glomerulonephritis	39 (13.9)	97 (12.8)	146 (11.7)	102 (14.0)	
PCKD	6 (2.1)	24 (3.2)	35 (2.8)	23 (3.2)	
Other	32 (11.4)	95 (12.5)	125 (10.0)	76 (10.4)	
Observation period, months	44 [30–56]	40 [28–53]	36 [23–51]	29 [9–37]	< 0.0001
All-cause mortality, *n* (%)	5 (1.8)	37 (4.9)	69 (5.5)	39 (5.4)	< 0.0001
All-cause mortality, per 1000 person-years	5.0	14.6	17.8	25.4	< 0.0001
RRT initiation, *n* (%)	9 (3.2)	30 (4.0)	268 (21.5)	440 (60.6)	< 0.0001
RRT initiation, per 1000 person-years	8.9	11.8	69.1	278	< 0.0001

Data are shown as the number (percentage), mean ± standard deviation, or median [interquartile range]

Cr creatinine, *CKD* chronic kidney disease, *CVD* cardiovascular disease, *DM* diabetes mellitus, *eGFR* estimated glomerular filtration rate, *HbA*$_{1c}$ glycated hemoglobin, *PCKD* polycystic kidney disease, *RRT* renal replacement therapy



Fig. 6 Kaplan–Meier curves for the incidence of all-cause death and initiation of renal replacement therapy initiation at baseline in Japanese patients with CKD according to CKD stage. CKD chronic kidney disease

Table 6 Cox proportional hazard ratios of the associations of the number of multidisciplinary care team members and the number of interventions by the multidisciplinary care team with the composite endpoint

Variables	HR	95% CI	*P* value
Number of MDC team members (increase by 1)	0.85	0.80–0.89	< 0.0001
Number of interventions by MDC team (increase by 1)	0.97	0.96–0.98	< 0.0001

CI confidence interval, *MDC* multidisciplinary care, *HR* hazard ratio



Fig. 7 Association between specialty composition of the multidisciplinary care team and composite endpoint stratified by with or without the presence of each professional on the team. Circles indicate the adjusted hazard ratio (HR) for all-cause mortality and initiation of renal replacement therapy. Error bars indicate 95% confidence intervals (CI). The HR for the composite endpoint (95% CI) was derived from Cox proportional hazards models adjusted for all covariate values, including age, sex, history of cardiovascular disease, the presence or absence of diabetes, body mass index, hemoglobin, serum albumin, and urinary protein levels at baseline

There was a significant association between the number of multidisciplinary care team members and the composite endpoint. The HR decreased significantly with increasing numbers of multidisciplinary care team members. Also, there was a significant association between the number of interventions by the multidisciplinary care team and the composite endpoint; that is, the prognosis of the composite outcome improved as the number of interventions increased (Table 6). When we compared composite endpoints according to the specialty composition of the multidisciplinary care team, there were significantly lower HRs when registered dietitians (HR 0.47, 95% CI 0.35–0.63, $P < 0.0001$) and physical therapists (HR 0.39, 95% CI 0.31–0.48, $P < 0.0001$) were included in the multidisciplinary care team (Fig. 7).

Presence of diabetes, being a male, history of CVD, hemoglobin, eGFR, and UPCR levels at baseline and interventions by registered dieticians and physical therapists were all identified as independent predictors of the composite outcome using multivariate Cox proportional hazard regression analysis (Table 7).

Discussion

Our nationwide cohort study included 3015 individuals from 24 facilities in Japan, 22 (91.7%) of which employ CKDEs and these 22 facilities provided intervention to 98.2% of all participating patients. Thus, the major strengths of this study are its large sample size recruited from multiple centers. Moreover, the observation period was relatively long, and a comparatively high number of elderly patients were included. Although the mean age of patients in the previous studies was younger than 70 years, our mean age was 70.5 years, reflecting our aging CKD population in Japan [12]. This study is the first to indicate that multidisciplinary care of CKD in Japan may be able to prevent worsening kidney function regardless of the underlying etiology. Multidisciplinary care was effective for patients with CKD regardless of whether they had DM. Furthermore, multidisciplinary care might be effective in the earlier stages of CKD. A multidisciplinary care team should include a nephrologist, nurse, and professionals from other fields and is recommended for patients with CKD stage 3–5. Our results suggest that the greater the number of professionals in a multidisciplinary care team, especially registered dietitians and physical therapists, the greater the number of interventions provided, which likely improves prognosis. Moreover, Japanese patients with CKD have an overwhelmingly higher rate of initiation of RRT than of mortality. The incidence of all-cause mortality in our patients with stage 3–5 CKD increased as eGFR declined but at a very low rate at all CKD stages under multidisciplinary care.

In addition to treatment and management of CKD, various lifestyle adjustments and self-management behaviors are required from the early stage of CKD through to the time of initiation and maintenance of RRT. Patients with CKD require holistic care and support, including dietary modification, maintenance and improvement of medication adherence, self-monitoring, early detection of complications, and the financial resources needed to continue treatment. Such support cannot be provided by medical staff alone and must be carried out by a medical team consisting of multiple professionals. To achieve good outcomes, multidisciplinary care teams that include nephrologists,

Table 7 The multidisciplinary care team's multivariate Cox proportional hazard ratios of the variables connected to the composite endpoint

Variables	HR	95%CI	*P* value
Age (increase by 1 year)	0.99	0.97–1.01	0.095
Sex (male)	1.25	1.06–1.48	0.009
Diabetes (yes)	1.34	1.14–1.58	0.0003
Comorbid CVD (yes)	1.30	1.13–1.49	0.0002
Body mass index (increase by 1 kg/m^2)	0.98	0.95–1.00	0.063
Hemoglobin (increase by 1 g/dL)	0.90	0.86–0.95	0.0002
Albumin (increase by 1 g/dL)	0.91	0.77–1.07	0.275
Baseline eGFR (increase by 1 ml/min/1.73m^2)	0.91	0.90–0.92	< 0.0001
Baseline urinary protein (increase by 1 g/gCr)	1.08	1.05–1.11	< 0.0001
Nurses (yes)	0.89	0.55–1.42	0.617
Dieticians (yes)	0.49	0.36–0.66	0.035
Pharmacists (yes)	1.07	0.92–1.27	0.361
Physical therapists (yes)	0.46	0.22–0.93	0.017
Other professionals (yes)	0.91	0.62–1.33	0.651

CI confidence interval, *Cr* creatinine, *CVD* cardiovascular disease, *eGFR* estimated glomerular filtration rate, *HR* hazard ratio

nurses, registered dietitians, pharmacists, physical therapists, occupational therapists, and medical social workers should be involved and have shared goals for individual patients.

Multidisciplinary care has been shown to decrease all-cause mortality, reduce the need for temporary catheterization for dialysis, and decrease the hospitalization rate in patients with CKD [13–16]. In contrast, some studies have not identified significant differences in these variables according to whether patients receive multidisciplinary care [17–19]. However, a meta-analysis revealed that multidisciplinary care could decrease all-cause mortality in patients with CKD, reduce the need for temporary catheterization in patients receiving dialysis, and decrease the hospitalization rate, but only in patients with stage 4–5 disease [12]. Moreover, the CKD-JAC study found that all-cause mortality and cardiovascular event rates were lower in Japanese patients with CKD who are under the care of a nephrologist than in their Western counterparts [20–22]. The lower mortality rate in our study is consistent with the findings of the previous studies. It is thought that Japanese patients with CKD who are under the care of a nephrologist with strict management of blood pressure, metabolism, and blood glucose are at much lower risk of cardiovascular events and death than patients with CKD in Western countries, although racial differences may affect the risk [20]. Further research is needed to determine whether clinical outcomes are better in patients who receive multidisciplinary care than in those who are cared for by nephrologists alone.

The composition of the participating multidisciplinary care teams varied greatly from facility to facility in this study. It has been reported that the ideal multidisciplinary care model for patients with CKD consists of a nurse, dietician, pharmacist, and social worker in addition to a nephrologist [23]. Although some studies have found no significant difference in all-cause mortality between multidisciplinary care and non-multidisciplinary care when the multidisciplinary team included a nephrologist and a nurse [17, 19], other studies have demonstrated a significant difference in all-cause mortality when the multidisciplinary team included a nephrologist, nurse, dietician, and pharmacist [15, 16]. A meta-analysis found no significant difference in all-cause mortality when the team included a nephrologist and a nurse [12]; however, all-cause mortality was lower if the team included a nephrologist, nurse, and health care professionals from other disciplines. The present study found that addition of a nurse or dietician compared to a nephrologist alone significantly slowed the decline in eGFR. Furthermore, recent studies have identified that a higher physical activity level can slow the decline in kidney function in patients with CKD [24–27]. A guideline for exercise therapy in patients with pre-dialysis CKD and those on dialysis has been published by the Japanese Society of Renal Rehabilitation [28]. Some of the facilities in our cohort include physical therapists in their multidisciplinary care teams. Further investigations are needed to determine which and how many health care professionals are required in a multidisciplinary care team to achieve the best outcomes.

In the aforementioned meta-analysis, there was no significant difference in the all-cause mortality or hospitalization rate according to whether multidisciplinary care was received in patients with CKD stage 1–5; however, multidisciplinary care decreased both all-cause mortality and the hospitalization rate in patients with CKD stage 4–5 [12]. It is known that all-cause mortality and hospitalization rates are

associated with the stage of CKD, so patients with advanced CKD (stage 4–5) would have a higher rate of cardiovascular complications and higher risk of death and hospitalization because of decreasing kidney function. Therefore, the effect of multidisciplinary care on all-cause mortality is more difficult to demonstrate in short-term studies of patients with earlier stages of CKD, which may last 1–3 years, than in those with CKD stage 4–5, in whom the effect of multidisciplinary care would be more marked. Referral to a nephrologist is recommended for patients with CKD who reach stage 4 according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines and for patients who reach stage 3b or higher according to the Japanese Society of Nephrology guidelines [29, 30]. However, the findings of our study, which included a long-term observation period of 6 years, suggest that multidisciplinary care can prevent worsening kidney function even in patients with stage 3 CKD.

The present study revealed that the reduction in proteinuria and improvement in ΔeGFR were seen in the DM group over a period of 24 months. Likewise, the improvement in ΔeGFR in the non-DM group was seen over 24 months, but the reduction in proteinuria was evident at just 6 months after starting multidisciplinary care. The rate of nephrosclerosis caused by hypertension in the non-DM group was high, reflecting the aging of the CKD population in Japan. Nephrosclerosis caused by hypertension is characterized by lower proteinuria and a slower decline in eGFR compared with diabetic nephropathy [31]. This was why we found a relationship between the reduction in proteinuria and the improvement in ΔeGFR in the DM group but not in the non-DM group. In addition, no significant difference in ΔeGFR was seen in the stage G3a group over the 24-month period. This may be because of a slower decline in eGFR, fewer or less frequent interventions, or proportionately fewer patients in stage G3a than in other stages. Therefore, the stage G3a group included patients who were not judged by nephrologists to require more intensive treatment via multidisciplinary intervention, since their eGFR values were relatively well preserved.

This study has several limitations. First, it did not include a control group. However, the previously reported meta-analysis found that multidisciplinary care was associated with a lower risk of all-cause mortality in cohort studies but not in randomized controlled trials [19]. Moreover, we could not confirm whether multidisciplinary care contributed to a decrease in the number of patients requiring dialysis. Therefore, further randomized controlled trials and large epidemiological studies that include control groups will be required to confirm the efficacy of multidisciplinary care in patients with CKD. Second, we did not investigate changes in prescriptions, blood pressure, body weight, glycemic control, or laboratory findings other than for kidney function. These factors, which can be influenced by multidisciplinary care, might play an important role in the improvement of both eGFR and proteinuria. It has been reported that the number of medications and prescription patterns among board-certified nephrologists in Japan did not change after the advent of multidisciplinary care [7, 8]. In addition, interventions by registered dieticians and physical therapists were identified as independent predictors of kidney outcomes. However, we could not evaluate what factors contributed most to improving kidney outcomes, such as whether the reduction of salt intake by registered dietitians or exercise therapy by physical therapists lowered blood pressure. Therefore, further investigations are needed to determine the contributing factors of improved adherence to prescription medications, dietary modification, and exercise therapies to prevent the worsening of kidney function. Finally, there may have been some degree of facility and selection bias as a result of variations in the types of health care professionals comprising the multidisciplinary care team and in the educational program between facilities as a result of differences in practice and patient populations. Therefore, educational programs should be standardized to improve the standard of treatment for patients with CKD and an effective and efficient care curriculum should be established.

In conclusion, our findings indicate that multidisciplinary care may significantly slow the decline of eGFR in patients with CKD and be effective regardless of the primary disease. Furthermore, they suggest that multidisciplinary care might be effective even in the earlier stages of CKD. Therefore, multidisciplinary care should be recommended for patients with CKD stage 3–5. Further research is needed to confirm that the CKDE system contributes to improving the standard of medical care for patients with CKD.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10157-023-02338-w.

Acknowledgements We thank the members of the Committee on Evaluation and Dissemination for Certified Kidney Disease Educators and the Japan Kidney Association for all their efforts, as well as the staff members at the participating facilities. Particularly, we thank the following medical professionals and hospitals: Takashi Maruyama, Division of Nephrology, Hypertension and Endocrinology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan; Toshihiro Shindo, Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan; Kunihiro Yamagata and Chie Saito, Department of Nephrology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan; Kimihiko Nakatani, Department of Nephrology, Kyoto Yamashiro General Medical Center, Kyoto, Japan; Isao Ohsawa, Saiyu Soka Hospital, Saitama, Japan; Hiroaki Io, Department of Nephrology, Juntendo University Nerima Hospital, Tokyo, Japan; Hiroshi Kado, Oumihachiman Community Medical Center, Shiga, Japan; Katsuhito Mori, Department of Nephrology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; Aya Sakurai, St. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, Japan; Akira Ishii and Motoko Yanagita, Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Tatsuo Yamamoto, Fujieda Municipal General Hospital, Shizuoka, Japan; Seigo Hiraga, JCHO Mishima General Hospital, Shizuoka, Japan;

Mamiko Shimamoto, Division of Nephrology, Sapporo City General Hospital, Sapporo, Japan; Masaru Matsui, Department of Nephrology, Nara Prefecture General Medical Center, Nara, Japan; Yuriko Yonekura, Divison of Nephrology, Department of Medicine, AIJINKAI Healthcare Corporation Akashi Medical Center, Hyogo, Japan; Katsuyuki Tanabe, Okayama University Hospital, Okayama, Japan; Tatsuo Tsukamoto, Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, Osaka, Japan; Ryouhei Horii and Satoshi Suzuki, Seirei Sakura Citizen Hospital, Chiba, Japan; Katsuhiko Morimoto, Nara Prefectural Seiwa Medical Center, Nara, Japan; Kenta Torigoe and Tomoya Nishino, Nagasaki University Hospital, Nagasaki, Japan; Saori Nishio, Department of Rheumatology, Endocrinology, and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan; Kazue Ueki and Takayuki Matsumoto, Dialysis and Nephrology Center, Sanshikai TOHO Hospital, Gunma, Japan.

Author contributions MA wrote the manuscript and analyzed the data. TH, YI, TS, and TM designed the study and contributed to data collection. MA, TH, YI, TM, and SK discussed the results and contributed to the final manuscript. All authors read and approved the final manuscript.

Funding This work was supported by Health Labour Sciences Research Grant 20FD1003.

Availability of data and materials The data used in this article are available from the corresponding author upon reasonable request.

Declarations

Conflict of interest MA is an associate editor of *Clinical and Experimental Nephrology*. The other authors declare that they have no other relevant financial interests. Publication of this report was not supported by any grants.

Ethical approval and consent to participate The study was approved by the ethics committee of Nihon University Itabashi Hospital (Permission number RK-220412-10). The need for informed consent was waived due to the use of de-identified information. The study is registered in the University Hospital Medical Information Network (UMIN000049995).

Consent for publication Not applicable.

References

1. Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, Ura N, Kiyohara Y, Moriyama T, Ando Y, Fujimoto S, Konta T, Yokoyama H, Makino H, Hishida A, Matsuo S. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621–30.
2. Nagai K, Asahi K, Iseki K, Yamagata K. Estimating the prevalence of definitive chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2021;25(8):885–92.
3. Nitta K, Goto S, Masakane I, Hanafusa N, Taniguchi M, Hasegawa T, Nakai S, Wada A, Hamano T, Hoshino J, Joki N, Abe M, Yamamoto K, Nakamoto H. Annual dialysis data report for 2018, JSDT Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality. Renal Replace Ther. 2020;6:41.
4. United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020.
5. Vassalotti JA, Centor R, Turner BJ, Greer RC, Choi M, Sequist TD, National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Practical approach to detection and management of chronic kidney disease for the primary care clinician. Am J Med. 2016;129(2):153-62.e7.
6. Rettig RA, Norris K, Nissenson AR. Chronic kidney disease in the United States: a public policy imperative. Clin J Am Soc Nephrol. 2008;3(6):1902–10.
7. Imamura Y, Takahashi Y, Hayashi T, Iwamoto M, Nakamura R, Goto M, Takeba K, Shinohara M, Kubo S, Joki N. Usefulness of multidisciplinary care to prevent worsening renal function in chronic kidney disease. Clin Exp Nephrol. 2019;23(4):484–92.
8. Machida S, Shibagaki Y, Sakurada T. An inpatient educational program for chronic kidney disease. Clin Exp Nephrol. 2019;23(4):493–500.
9. https://j-ka.or.jp/ckd/download/.
10. https://jsn.or.jp/jsn_new/iryou/kaiin/free/primers/pdf/2021allpage.pdf.
11. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
12. Shi Y, Xiong J, Chen Y, Deng J, Peng H, Zhao J, He J. The effectiveness of multidisciplinary care models for patients with chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol. 2018;50(2):301–12.
13. Chen YR, Yang Y, Wang SC, Chiu PF, Chou WY, Lin CY, Chang JM, Chen TW, Ferng SH, Lin CL. Effectiveness of multidisciplinary care for chronic kidney disease in Taiwan: a 3-year prospective cohort study. Nephrol Dial Transplant. 2013;28(3):671–82.
14. Chen YR, Yang Y, Wang SC, Chou WY, Chiu PF, Lin CY, Tsai WC, Chang JM, Chen TW, Ferng SH, Lin CL. Multidisciplinary care improves clinical outcome and reduces medical costs for pre-end-stage renal disease in Taiwan. Nephrology (Carlton). 2014;19(11):699–707.
15. Wu IW, Wang SY, Hsu KH, Lee CC, Sun CY, Tsai CJ, Wu MS. Multidisciplinary predialysis education decreases the incidence of dialysis and reduces mortality—a controlled cohort study based on the NKF/DOQI guidelines. Nephrol Dial Transplant. 2009;24(11):3426–33.
16. Chen PM, Lai TS, Chen PY, Lai CF, Yang SY, Wu V, Chiang CK, Kao TW, Huang JW, Chiang WC, Lin SL, Hung KY, Chen YM, Chu TS, Wu MS, Wu KD, Tsai TJ. Multidisciplinary care program for advanced chronic kidney disease: reduces renal replacement and medical costs. Am J Med. 2015;128(1):68–76.
17. Barrett BJ, Garg AX, Goeree R, Levin A, Molzahn A, Rigatto C, Singer J, Soltys G, Soroka S, Ayers D, Parfrey PS. A nurse-coordinated model of care versus usual care for stage 3/4 chronic kidney disease in the community: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6(6):1241–7.
18. Rognant N, Alamartine E, Aldigier JC, Combe C, Vendrely B, Deteix P, Cluzel P, Juillard L, Vrtovsnik F, Maurice C, Fave S, Laville M. Impact of prior CKD management in a renal care

network on early outcomes in incident dialysis patients: a prospective observational study. BMC Nephrol. 2013;14:41.
19. Peeters MJ, van Zuilen AD, van den Brand JA, Bots ML, van Buren M, Ten Dam MA, Kaasjager KA, Ligtenberg G, Sijpkens YW, Sluiter HE, van de Ven PJ, Vervoort G, Vleming LJ, Blankestijn PJ, Wetzels JF. Nurse practitioner care improves renal outcome in patients with CKD. J Am Soc Nephrol. 2014;25(2):390–8.
20. Tanaka K, Watanabe T, Takeuchi A, Ohashi Y, Nitta K, Akizawa T, Matsuo S, Imai E, Makino H, Hishida A, CKD-JAC Investigators. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017;91(1):227–34.
21. Denker M, Boyle S, Anderson AH, Appel LJ, Chen J, Fink JC, Flack J, Go AS, Horwitz E, Hsu CY, Kusek JW, Lash JP, Navaneethan S, Ojo AO, Rahman M, Steigerwalt SP, Townsend RR, Feldman HI, Chronic Renal Insufficiency Cohort Study Investigators. Chronic renal insufficiency cohort study (CRIC): overview and summary of selected findings. Clin J Am Soc Nephrol. 2015;10:2073–83.
22. Norris K, Bourgoigne J, Gassman J, Hebert L, Middleton J, Phillips RA, Randall O, Rostand S, Sherer S, Toto RD, Wright JT Jr, Wang X, Greene T, Appel LJ, Lewis J, AASK Study Group. Cardiovascular outcomes in the African American study of kidney disease and hypertension (AASK) trial. Am J Kidney Dis. 2006;48:739–51.
23. Wang SM, Hsiao LC, Ting IW, Yu TM, Liang CC, Kuo HL, Chang CT, Liu JH, Chou CY, Huang CC. Multidisciplinary care in patients with chronic kidney disease: a systematic review and meta-analysis. Eur J Intern Med. 2015;26(8):640–5.
24. Guo C, Tam T, Bo Y, Chang LY, Lao XQ, Thomas GN. Habitual physical activity, renal function and chronic kidney disease: a cohort study of nearly 200000 adults. Br J Sports Med. 2020;54:1225–30.
25. Robinson-Cohen C, Littman AJ, Duncan GE, Weiss NS, Sachs MC, Ruzinski J, Kundzins J, Rock D, de Boer IH, Ikizler TA, Himmelfarb J, Kestenbaum BR. Physical activity and change in estimated GFR among persons with CKD. J Am Soc Nephrol. 2014;25:399–406.
26. Chen IR, Wang SM, Liang CC, Kuo HL, Chang CT, Liu JH, Lin HH, Wang IK, Yang YF, Chou CY, Huang CC. Association of walking with survival and RRT among patients with CKD stages 3–5. Clin J Am Soc Nephrol. 2014;9:1183–9.
27. Hiraki K, Otobe Y, Izawa KP, Sakurada T, Shibagaki T. Physical activity in patients with pre-dialysis chronic kidney disease is associated with decreased renal function. Clin Exp Nephrol. 2021;25:683–4.
28. Yamagata K, Hoshino J, Sugiyama H, et al. Clinical practice guideline for renal rehabilitation: systematic reviews and recommendations of exercise therapies in patients with kidney diseases. Renal Replace Ther. 2019;5:28.
29. Andrassy KM. Comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.' Kidney Int. 2013;84(3):622–3.
30. Okada H, Research Team for a Grant-in-Aid for Research on Advanced Chronic Kidney Disease (REACH-J); Practical Research Project for Renal Diseases from Japan Agency for Medical Research and Development, AMED. Essentials from clinical practice guidelines for CKD stage G3b–5 2017. Clin Exp Nephrol. 2018;22(2):245–8.
31. Abe M, Okada K, Maruyama N, Takashima H, Oikawa O, Soma M. Comparison of clinical trajectories before initiation of renal replacement therapy between diabetic nephropathy and nephrosclerosis on the KDIGO guidelines heat map. J Diabetes Res. 2016;2016:5374746.

frontiers | Frontiers in Endocrinology

TYPE Original Research
PUBLISHED 20 June 2023
DOI 10.3389/fendo.2023.1180477

OPEN ACCESS

EDITED BY
Jun Wada,
Okayama University, Japan

REVIEWED BY
Masao Toyoda,
Tokai University School of Medicine, Japan
Yoshinari Yasuda,
Nagoya University, Japan

*CORRESPONDENCE
Masanori Abe
abe.masanori@nihon-u.ac.jp

RECEIVED 06 March 2023
ACCEPTED 24 May 2023
PUBLISHED 20 June 2023

CITATION
Abe M, Hatta T, Imamura Y, Sakurada T and Kaname S (2023) Inpatient multidisciplinary care can prevent deterioration of renal function in patients with chronic kidney disease: a nationwide cohort study. *Front. Endocrinol.* 14:1180477. doi: 10.3389/fendo.2023.1180477

Inpatient multidisciplinary care can prevent deterioration of renal function in patients with chronic kidney disease: a nationwide cohort study

Masanori Abe[1,2]*, Tsuguru Hatta[1,3], Yoshihiko Imamura[1,4], Tsutomu Sakurada[1,5] and Shinya Kaname[1,6]

[1]The Committee of the Evaluation and Dissemination for Certified Kidney Disease Educator, Japan Kidney Association, Tokyo, Japan, [2]Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan, [3]Department of Medicine, Hatta Medical Clinic, Kyoto, Japan, [4]Department of Nephrology, Nissan Tamagawa Hospital, Tokyo, Japan, [5]Department of Nephrology and Hypertension, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, [6]Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan

Background: Multidisciplinary care is necessary to prevent worsening renal function and all-cause mortality in patients with chronic kidney disease (CKD) but has mostly been investigated in the outpatient setting. In this study, we evaluated the outcome of multidisciplinary care for CKD according to whether it was provided in an outpatient or inpatient setting.

Methods: This nationwide, multicenter, retrospective, observational study included 2954 Japanese patients with CKD stage 3–5 who received multidisciplinary care in 2015–2019. Patients were divided into two groups: an inpatient group and an outpatient group, according to the delivery of multidisciplinary care. The primary composite endpoint was the initiation of renal replacement therapy (RRT) and all-cause mortality, and the secondary endpoints were the annual decline in the estimated glomerular filtration rate (ΔeGFR) and the changes in proteinuria between the two groups.

Results: Multidisciplinary care was provided on an inpatient basis in 59.7% and on an outpatient basis in 40.3%. The mean number of health care professionals involved in multidisciplinary care was 4.5 in the inpatient group and 2.6 in the outpatient group ($P < 0.0001$). After adjustment for confounders, the hazard ratio of the primary composite endpoint was significantly lower in the inpatient group than in the outpatient group (0.71, 95% confidence interval 0.60-0.85, $P = 0.0001$). In both groups, the mean annual ΔeGFR was significantly improved, and proteinuria significantly decreased 24 months after the initiation of multidisciplinary care.

Conclusion: Multidisciplinary care may significantly slow deterioration of eGFR and reduce proteinuria in patients with CKD and be more effective in terms of reducing initiation of RRT and all-cause mortality when provided on an inpatient basis.

KEYWORDS

certified kidney disease educator, chronic kidney disease, estimated glomerular filtration rate, inpatient educational program, multidisciplinary care, outpatient guidance, renal replacement therapy

1 Introduction

Increasing numbers of patients have chronic kidney disease (CKD) worldwide (1). In Japan, nearly 15 million adults were estimated to have CKD in 2015 (2), and increasing numbers of patients with end-stage kidney disease are starting renal replacement therapy (RRT) each year, with more than 340,000 patients now receiving dialysis (3). The prevalence of dialysis in Japan is 2682 per million population, second only to Taiwan (4). A comprehensive approach to management is needed because CKD increases the risk of not only ESKD but also cardiovascular mortality. Thus it is necessary to control blood pressure, glycemic status, anemia, bone mineral status, and low-density lipoprotein cholesterol alongside lifestyle modification, dietary guidance, and measures to ensure adherence with medication (5, 6). It has been reported that comprehensive multidisciplinary care can reduce all-cause mortality, the likelihood of temporary catheterization for patients on dialysis, and the hospitalization rate as well as slow decline in the estimated glomerular filtration rate (eGFR) (7–10). In these studies, comprehensive multidisciplinary care was provided by teams that included nephrologists, specialist nurses, dieticians, pharmacists, and social workers.

The Certified Kidney Disease Educator (CKDE) system was established in Japan by the Japan Kidney Association in 2017 with the aims of preventing progression of CKD and improving and maintaining quality of life for patients with CKD. Nurses, registered dieticians, and pharmacists who meet certain requirements are eligible to qualify as a CKDE. All CKDEs have acquired the basic skills for managing patients with CKD, including providing guidance on lifestyle modification, dietary counseling, and medical therapy according to disease stage. Generally, multidisciplinary care for patients with CKD and diabetes is performed on an outpatient basis, as reflected in the Steno-2 and MASTERPLAN studies (11–14). However, in Japan, widespread multidisciplinary care for patients with CKD is provided not only on an outpatient basis but also on an inpatient basis because of lack of time during outpatient appointments to cover lifestyle modification, dietary restriction, and medication adherence in sufficient depth. Currently, however, there is limited information on whether these multidisciplinary interventions in the inpatient setting improve the prognosis of CKD.

We conducted this nationwide study to assess the outcome of multidisciplinary intervention in patients with CKD according to whether it was provided in an outpatient or inpatient setting.

2 Methods

2.1 Study design and participants

This nationwide multicenter retrospective cohort study was performed by members of the Japan Kidney Association Committee for Evaluation and Dissemination of CKDE. To reflect practice patterns across most of Japan, around 3000 Japanese patients were participated at any of 24 selected health care institutions in Japan that play a central role in the treatment of patients with CKD. All-cause mortality and the start of RRT were tracked until the end of 2020 for patients with CKD who had data on kidney function available for the 12 months before to and 24 months after receiving multidisciplinary therapy between January 2015 and December 2019. The following exclusion requirement were used: age < 20 years; CKD stage 1 and 2 (i.e., eGFR ≥ 60 mL/min/1.73 m^2); patients who were hospitalized for another reason other than CKD; short-term follow-up of 6 months or less; received multidisciplinary care in the past; active malignant disease; transplant recipient; history of long-term dialysis; and data missing for age, sex, kidney function, or results. In Japan, multidisciplinary care for patients with CKD was conducted in outpatient or inpatient settings based on the hospital functions, nephrologists' judgment, and the patient's wishes. As a result, the enrolled patients were classified into an outpatient and an inpatient group based on the approach and place of intervention by the multidisciplinary care team at the start of the intervention (baseline). They were further divided into subgroups based on whether they had diabetes. A group of inpatient patients were admitted to the hospital and received multidisciplinary care in accordance with each facility's inpatient educational program.

The main efficacy composite endpoint was the initiation of RRT and all-cause mortality at the end of 2020. The secondary efficacy endpoint was the annual decline in eGFR (ΔeGFR) and the annual change in urinary protein level between 12 months before and 6, 12, and 24 months after the initiation of multidisciplinary intervention.

The study was approved by the ethics committee of Nihon University Itabashi Hospital and conducted in accordance with the Declaration of Helsinki, Japanese privacy protection laws, and the Ethical Guidelines for Medical and Health Research Involving Human Subjects published by the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Health, Labour and Welfare in 2015. The need for informed consent was waived in view of the use of de-identified data. The study is registered in the University Hospital Medical Information Network (UMIN000049995).

2.2 Multidisciplinary care

The definition of multidisciplinary care adopted was (1) a multidisciplinary care team composed of nephrologists and other professionals (i.e., specialist nurses, registered dieticians, pharmacists, physical therapists, social workers, clinical engineers, and clinical laboratory technicians) and (2) an operational model of multidisciplinary care comprising patient education, medical management, and lifestyle modification according to CKD stage. The quality of the educational content provided was maintained based on the text created by the Japanese Society of Nephrology, the Japanese Society for Dialysis Therapy, the Japan Society for Transplant, and the Japanese Society for Clinical Renal Transplantation or the CKD Teaching Guidebook for Certified Kidney Disease Educators published by the Japan Kidney Association (15, 16).

2.3 Data collection

Patient demographics and data on clinical characteristics were collected, including age, sex, history of cardiovascular disease (CVD), primary etiology of CKD, body mass index (BMI), hemoglobin, serum albumin, urea nitrogen, creatinine (Cr), eGFR, and urinary protein. Information on glycated hemoglobin (HbA1c) was also collected for patients with diabetes at baseline. CVD was defined as coronary artery disease, ischemic stroke, hemorrhagic stroke, or limb amputation. eGFR was calculated according to the following formula for Japanese patients: eGFR (mL/min/1.73 m^2) = 194 × serum $Cr^{-1.094}$ × $age^{-0.287}$ (× 0.739 for women) (17). Urinary protein was calculated as the urinary protein to Cr ratio (UPCR). The data on method and place of intervention (outpatient or inpatient), the number or duration of interventions (number of visits for outpatient intervention or the number of hospitalization days for inpatients), and the type and number of health care professionals involved in the multidisciplinary care team were also collected. Data were collected for the primary composite endpoint, which included the date attained or the end of 2020, whichever came first (initiation of RRT and all-cause mortality). Also noted was the RRT's kind (kidney transplantation, peritoneal dialysis, or hemodialysis).

2.4 Statistical analysis

Data are reported as the number and proportion, mean ± standard deviation, or median [interquartile range] as appropriate. Intragroup comparisons were made using two-tailed paired t-tests. Categorical variables were examined using the chi-squared test and continuous variables using the t-test. The composite outcome was estimated using the Kaplan–Meier method and compared between groups using the log-rank test. A univariate analysis was performed according to the method and place of intervention (i.e., outpatient-based or inpatient-based). Multivariate survival analyses were performed using Cox proportional hazards models with adjustment for confounding factors to examine the method and place of intervention and the composite outcome during the 6 years of follow-up. Model 1 was used to calculate hazard ratios (HRs) adjusted for basic factors, including age, sex, history of CVD, eGFR, and UPCR at baseline, and model 2 was adjusted for BMI, hemoglobin, and serum albumin level in addition to the factors included in model 1. A subgroup analysis was performed according to the diabetes status and the CKD stage (G3a, G3b, G4, or G5) at baseline. A further subdivision analysis in the inpatient group based on the presence or absence of physical therapists was performed. In patients with diabetes, model 1 was used to calculate the HRs with adjustment for basic factors (e.g., age, sex, history of CVD, HbA1c, eGFR, and UPCR at baseline), and model 2 was adjusted for BMI, hemoglobin, and serum albumin level in addition to the factors included in model 1. In patients without diabetes, model 1 was used to calculate the HRs adjusted for basic factors, including age, sex, history of CVD, eGFR, and UPCR at baseline and model 2 was adjusted for BMI, hemoglobin, and serum albumin level in addition to the factors included in model 1. The results from the models are reported as HRs with 95% confidence intervals (CIs) and P-values. For the regression analyses, imputation of missing data was performed by conventional methods as appropriate. All analyses were performed using JMP® version 13.0 (SAS Institute Inc., Cary, NC, USA). Statistical significance was set at P-values less than 0.05.

3 Results

3.1 Patient characteristics at time of initiation of multidisciplinary care

Overall, of the 3296 patients enrolled, 342 were removed (CKD stage 1 or 2, n = 118; age younger than 20 years, n = 3; follow-up for 6 months or less, n = 124; lack of data for baseline kidney function, n = 13), which left 2954 patients for inclusion in the analysis. Patient characteristics at the time of initiation of multidisciplinary care are shown in Table 1. The mean age was 70.5 ± 11.6 years, and 74.1% of the patients were male. The mean eGFR was 26.3 ± 12.5 mL/min/1.73 m^2 and the median UPCR was 1.09 g/gCr [0.23, 2.98]. The most common etiology of CKD was diabetic kidney disease (42.7%), followed by nephrosclerosis (30.8%) and chronic

10.3389/fendo.2023.1180477

TABLE 1 Baseline characteristics of all study participants.

Variable	
Patients, n (% male)	2954 (74.1)
Age, years	70.5 ± 11.6
Body mass index	24.2 ± 4.3
Serum creatinine, mg/dL	2.02 [1.46, 3.02]
eGFR, mL/min/1.73 m^2	26.3 ± 12.5
Serum urea nitrogen, mg/dL	31 [23–43]
Hemoglobin, g/dL	11.7 ± 1.9
Serum albumin, g/dL	3.8 ± 0.5
Urinary protein, g/gCr	1.09 [0.23, 2.98]
Comorbid CVD, n (%)	846 (28.6)
HbA1c (in patients with diabetes), %	6.4 ± 1.0
Primary cause of CKD, n (%)	
Diabetic kidney disease	1263 (42.7)
Nephrosclerosis	909 (30.8)
Chronic glomerulonephritis	374 (12.6)
Polycystic kidney disease	87 (3.0)
Other	321 (10.9)
CKD stage, n (%)	
G3 (G3a + G3b)	1059 (35.9)
G3a	288 (9.8)
G3b	771 (26.1)
G4	1251 (42.4)
G5	644 (21.8)
Number of professionals on MDC team, n (%)	
Total number of professionals on MDC team, n	3.8 ± 1.2
2	656 (22.2)
3	398 (13.5)
4	902 (30.5)
5	976 (33.0)
6	22 (0.8)
Members of MDC team, n (%)	
Nurses	2545 (86.2)
Registered dieticians	2703 (91.5)
Pharmacists	1885 (63.8)
Physical therapists	772 (26.1)
Clinical laboratory technicians	171 (5.8)
Social workers	68 (2.3)
Others	24 (0.8)

Data are shown as the number (percentage), mean ± standard deviation, or median [interquartile range] as appropriate. CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; MDC, multidisciplinary care.

glomerulonephritis (12.6%). The most common CKD stage was G4 (42.4%), followed by G3b (26.1%) and G5 (21.8%).

3.2 Type and number of professionals in the multidisciplinary care team

Details of the interventions implemented by the multidisciplinary care team are shown in Table 1. The mean number of multidisciplinary care team members, including nephrologists, was 3.8 ± 1.2. It was most common for the multidisciplinary care team to include five professionals (33.0%), followed by four (30.5%) and the two (22.2%). Registered dieticians were the most common members of the multidisciplinary care team (91.5%), followed by specialist nurses (86.2%), pharmacists (63.8%), and physical therapists (26.1%).

3.3 Outcomes

The median observation period was 36 months [22, 52], during which 128 patients (4.3%) died, 648 (21.9%) initiated RRT, and 66 (2.2%) were lost to follow-up; 2112 (71.6%) of all patients were alive without RRT at the end of the study period. RRT consisted of hemodialysis in 559 patients (86.2%), peritoneal dialysis in 66 (10.2%), and kidney transplantation in 23 (3.6%).

3.3.1 Comparison between outpatient and inpatient groups

The baseline characteristics of the patients in the inpatient and outpatient groups are shown in Table 2. Intervention was provided in an inpatient setting for more than half of the patients (59.7%) and on an outpatient basis for the remainder (40.3%). The baseline kidney function, including eGFR, serum Cr and UPCR, was comparable between the two groups, but patients in the inpatient group were more likely to be female and older and to have a higher BMI and comorbid CVD. However, rates of diabetic kidney disease and CKD stage G5 were lower in the inpatient group than in the outpatient group. The mean number of multidisciplinary care team members was significantly higher in the inpatient group (4.5 ± 0.6 *vs.* 2.6 ± 0.7, P < 0.0001).

Kaplan–Meier analysis for the composite endpoint (initiation of RRT and all-cause mortality) revealed a significant difference between the outpatient and inpatient groups (P = 0.0003, log-rank test; Figure 1). Compared with the outpatient (reference) group, the inpatient group had a significantly lower unadjusted HR for the composite endpoint (0.78, 95% CI 0.68–0.91, P = 0.0004). After adjustment for basic factors, including age, sex, history of CVD, eGFR, and UPCR at baseline, the HR in the inpatient group was 0.73 (95% CI 0.63–0.88, P = 0.0001). After further adjustment for basic factors and BMI, hemoglobin, and serum albumin at baseline, the HR was significantly lower in the inpatient group (0.71, 95% CI 0.60–0.85, P = 0.0001) (Table 3).

3.4 Subgroup analysis according to diabetes status

Kaplan–Meier analysis revealed that there was no significant difference in the composite endpoint between patients with diabetes in the outpatient group and those in the inpatient group (P = 0.133, log-rank test; Figure 2). Cox proportional analysis revealed no significant difference in the unadjusted HR for the composite endpoint between the inpatient and outpatient groups (Table 4). However, after adjustment for basic factors, including age, sex, history of CVD, HbA1c, eGFR, and UPCR at baseline, the HR in the inpatient group was 0.75 (95% CI 0.61–0.93, P = 0.010). After further adjustment for basic factors and BMI, hemoglobin, and serum albumin level at baseline, the inpatient group had a significantly lower HR (0.74, 95% CI 0.59–0.95, P = 0.018) (Table 4).

In patients without diabetes, Kaplan–Meier analysis revealed a significant difference in the composite endpoint between the outpatient and inpatient groups (P = 0.009, log-rank test; Figure 3). Compared with the outpatient group, the inpatient group had a significantly lower unadjusted HR for the composite endpoint (0.75, 95% CI 0.61–0.93, P = 0.009). After adjustment for basic factors, including age, sex, history of CVD, eGFR, and UPCR at baseline, the HR in the inpatient group was 0.75 (95% CI 0.59–0.94, P = 0.015). After further adjustment for basic factors and BMI, hemoglobin, and serum albumin level at baseline, the inpatient group had a significantly lower HR (0.76, 95% CI 0.59–0.98, P = 0.034) (Table 5).

3.5 Subgroup analysis according to the CKD stage at baseline

All-cause mortality and RRT initiation were dependent on the disease stage. The Kaplan–Meier analysis revealed that the composite endpoint varied significantly depending on the CKD stage at baseline in both groups (P < 0.0001, log-rank test; Figure 4). After the adjustment of basic factors, including age, sex, comorbid CVD, and the presence or absence of diabetes, the HRs in the G3b, G4, and G5 groups were compared with the G3a (reference) group and were significantly higher in both. However, after the adjustment of basic factors and laboratory data, including BMI, hemoglobin, serum albumin, and UPCR level, the G4 and G5 groups had significantly higher HRs (Tables 6, 7).

3.6 Subgroup analysis based on the presence or absence of physical therapists in the inpatient group

The patients in the inpatient group were subdivided into two groups with and without a physical therapist in the

10.3389/fendo.2023.1180477

TABLE 2 Baseline characteristics in the outpatient and inpatient groups.

Variable	Outpatient group	Inpatient group	P-value
Patients, n (% male)	1190 (79.3)	1764 (70.6)	< 0.0001
Age, years	69.6	71.2	0.0004
Body mass index	23.6 ± 3.9	24.5 ± 4.4	< 0.0001
Serum creatinine, mg/dL	2.08 [1.45, 3.16]	1.99 [1.47, 2.93]	0.165
eGFR, mL/min/1.73 m^2	26.1 ± 12.9	26.4 ± 12.3	0.786
Serum urea nitrogen, mg/dL	32 [23, 45]	31 [23, 42]	0.239
Hemoglobin, g/dL	11.8 ± 1.9	11.7 ± 1.9	0.123
Serum albumin, g/dL	3.8 ± 0.5	3.7 ± 0.5	< 0.0001
Urinary protein, g/gCr	1.20 [0.27, 3.25]	1.01 [0.22, 2.87]	0.218
Comorbid CVD, n (%)	334 (28.1)	512 (29.0)	< 0.0001
HbA1c (in patients with diabetes), %	6.4 ± 0.9	6.4 ± 1.1	0.188
Primary cause of CKD, n (%)			< 0.0001
Diabetic kidney disease	579 (48.6)	684 (38.8)	
Nephrosclerosis	259 (21.8)	650 (36.8)	
Chronic glomerulonephritis	126 (10.6)	248 (14.0)	
Polycystic kidney disease	45 (3.8)	42 (2.4)	
Others	321 (15.2)	140 (8.0)	
CKD stage, n (%)			0.005
G3 (G3a + G3b)	431 (36.2)	624 (35.6)	
G3a	129 (10.8)	159 (9.0)	
G3b	302 (25.4)	469 (26.6)	
G4	469 (39.4)	782 (44.3)	
G5	290 (24.4)	354 (20.1)	
Number of interventions, n or days	4 [1, 10]	7 [5, 12]	—
Total number of professionals on MDC team, n	2.6 ± 0.7	4.5 ± 0.6	< 0.0001
Number of professionals on MDC team, n (%)			< 0.0001
2	641 (53.9)	17 (1.0)	
3	363 (30.5)	33 (1.9)	
4	178 (15.0)	724 (41.0)	
5	6 (0.5)	970 (55.0)	
6	2 (0.1)	20 (1.1)	
Members of MDC team, n (%)			
Nurses	790 (66.4)	1755 (99.5)	< 0.0001
Registered dieticians	948 (79.6)	1755 (99.5)	< 0.0001
Pharmacists	172 (14.5)	1713 (97.1)	< 0.0001
Physical therapists	0 (0)	772 (43.8)	< 0.0001
Clinical laboratory technicians	0 (0)	171 (9.7)	< 0.0001

(Continued)

TABLE 2 Continued

Variable	Outpatient group	Inpatient group	P-value
Social workers	5 (0.4)	63 (3.6)	< 0.0001
Others	21 (1.8)	3 (0.2)	< 0.0001

Data are shown as the number (percentage), mean ± standard deviation, or median [interquartile range] as appropriate. CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; MDC, multidisciplinary care.



FIGURE 1
Kaplan–Meier curves showing the incidence of initiation of renal replacement therapy and all-cause mortality in Japanese patients with chronic kidney disease according to whether they received outpatient or inpatient multidisciplinary care.

multidisciplinary care team. The baseline characteristics of the two groups are shown in Supplementary Table 1. The group with physical therapists had higher eGFR and lower proteinuria at baseline, with a higher rate of comorbid CVD and diabetic kidney disease. The Kaplan–Meier analysis revealed a significant difference in the composite endpoint between the two groups (P < 0.0001, log-rank test; Figure 5). Compared with the group without physical therapists, the group with physical therapists had a significantly lower unadjusted HR for the composite endpoint (0.52, 95% CI 0.42–0.63, P < 0.0001). After the adjustment of basic factors, including age, sex, history of CVD, eGFR, and UPCR at baseline, the HR in the group with physical therapists was 0.51 (95% CI 0.41–0.64, P < 0.0001). After further adjustment of basic factors and BMI, hemoglobin, and serum albumin level at baseline, the group with physical therapists had a significantly lower HR (0.55, 95% CI 0.42–0.71, P < 0.0001) (Supplementary Table 2).

3.7 ΔeGFR and change in UPCR before and after multidisciplinary care in all patients

The mean ΔeGFR was significantly improved from −5.89 ± 7.17 before multidisciplinary intervention to −0.44 ± 5.21 at 6 months, −1.52 ± 6.09 at 12 months, and −1.48 ± 3.78 at 24 months after intervention (all P < 0.0001; Figure 6A). The median UPCR was significantly decreased from 1.09 g/gCr [0.23, 2.98] at baseline to 1.00 g/gCr [0.24, 2.71] at 6 months, 0.89 g/gCr [0.21, 2.38] at 12 months, and 0.82 g/gCr [0.20, 2.22] at 24 months (all P < 0.0001; Figure 6B).

3.7.1 ΔeGFR and change in UPCR before and after multidisciplinary care in the two groups

The mean ΔeGFR before and after multidisciplinary intervention in each group is shown in Figure 7. There was no significant between-group difference in mean ΔeGFR before intervention (Supplementary Table 3). The mean ΔeGFR was -6.09 ± 7.65 before intervention and -0.52 ± 5.23 at 6 months, -1.32 ± 6.01 at 12 months, and -1.32 ± 3.64 at 24 months after intervention in the outpatient group (all P < 0.0001; Figure 7A); the respective values in the inpatient group were -5.81 ± 7.43, -0.40 ± 5.20, -1.63 ± 6.15, and -1.56 ± 3.84 (all P < 0.0001; Figure 7B). There was no significant between-group difference in mean ΔeGFR at any time point after intervention (Supplementary Table 3).

Changes in the median UPCR after intervention by the multidisciplinary care team are shown for each group in Figure 8. There was no significant between-group difference in UPCR at baseline. However, in the outpatient group, the median UPCR decreased significantly from 1.20 g/gCr [0.27, 3.25] at baseline to 1.10 g/gCr [0.29, 2.98] at 6 months, 0.94 g/gCr [0.22, 2.42] at 12 months, and 0.88 g/gCr [0.24, 2.36] at 24 months (all P <0.0001; Figure 8A); the respective values in the inpatient group were 1.01 g/gCr [0.22, 2.87], 0.92 g/gCr [0.21, 2.61], 0.82 g/gCr [0.21, 2.37], and 0.79 g/gCr [0.17, 2.28] (all P < 0.0001; Figure 8B). Furthermore, there was no significant between-group difference in the median UPCR at any time point after intervention (Supplementary Table 4).

TABLE 3 Comparison of initiation of renal replacement therapy and all-cause mortality between the outpatient and inpatient groups in Cox proportional hazards models adjusted for confounding factors in Japanese patients with chronic kidney disease.

Group	Unadjusted			Model 1			Model 2		
	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
Outpatient	1.00	Reference	—	1.00	Reference	—	1.00	Reference	—
Inpatient	0.78	0.68–0.91	0.0004	0.73	0.63–0.88	0.0001	0.71	0.60–0.85	0.0001

Model 1 was adjusted for basic factors, including age, sex, history of cardiovascular disease, estimated glomerular filtration rate, and urinary protein level at baseline. Model 2 was adjusted for body mass index, hemoglobin, and serum albumin level at baseline in addition to the factors included in model 1. CI, confidence interval; HR, hazard ratio.



FIGURE 2
Kaplan–Meier curves showing the incidence of initiation of renal replacement therapy and all-cause mortality in Japanese diabetes patients with chronic kidney disease according to whether they received outpatient or inpatient multidisciplinary care.



FIGURE 3
Kaplan–Meier curves for the incidence of initiation of renal replacement therapy and all-cause mortality in Japanese non-diabetes patients with chronic kidney disease in the outpatient and inpatient groups.

4 Discussion

This nationwide cohort study included 2954 individuals from 24 facilities in Japan. We found that patients with CKD currently receive multidisciplinary care more often in hospitals (59.7%) than in an outpatient setting (40.3%) in Japan. The major strengths of this study are its large sample population recruited from multiple centers, the relatively long observation period, and inclusion of a comparatively high number of elderly patients. Although the mean age of patients in the previous studies was younger than 70 years, our mean age was 70.5 years, reflecting our aging CKD population in Japan (5, 7–10). This study is the first to suggest that multidisciplinary care may be able to prevent worsening kidney function in Japanese patients with CKD regardless of whether it is provided on an outpatient or inpatient basis. The rate of RRT initiation and all-cause mortality over the longer observation period of 6 years were the key composite endpoints, and although there was no significant difference between the two groups' baseline eGFR levels, there was a significant between-group difference in both variables. Therefore, our results suggest that multidisciplinary care for patients with CKD might be more beneficial in terms of outcomes in the inpatient setting than in the outpatient setting. Furthermore, multidisciplinary care was effective for patients with CKD regardless of whether or not they had diabetes and should be provided at CKD stage G4 at the latest. A multidisciplinary care team should include a nephrologist, a specialist nurse, a physical therapist, and professionals from other fields and is recommended for the management of patients with CKD.

Inpatient education programs have been reported to improve glycemic control, prevent diabetic complications, and reduce hospitalization rates in patients with diabetes (18–20). However, there is little information on the efficacy of multidisciplinary intervention for patients with CKD according to whether the intervention is inpatient-based or outpatient-based. This is the first study to indicate that inpatient multidisciplinary care improves the all-cause mortality risk and initiation of RRT in patients with CKD. Inpatient education programs for patients with CKD have not been implemented extensively in Western countries, probably reflecting differences in the medical insurance system between Japan and Western countries. Although education provided in an outpatient setting is reimbursed for patients with diabetic kidney disease in Japan, it is not reimbursed for patients with other etiologies of CKD. However, full reimbursement is available for these patients if they are admitted to hospital. A few single-center studies in Japan have evaluated the effectiveness of education programs for CKD to date. One study found that the annual rate of decline in eGFR was improved by an inpatient education program, which was continued for 2 years (21). Furthermore, the interval between the start of stage G5 and the start of RRT was longer in patients who received an inpatient education program than in those who did not (22). The patients who received an inpatient education program also had better survival after initiation of dialysis (23). Therefore, multidisciplinary care would be associated with a decreased hospitalization rate, a

TABLE 4 Comparison of initiation of renal replacement therapy and all-cause mortality between the outpatient and inpatient groups in Cox proportional hazards models adjusted for confounding factors in Japanese patients with chronic kidney disease and diabetes.

Group	Unadjusted			Model 1			Model 2		
	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
Outpatient	1.00	Reference	—	1.00	Reference	—	1.00	Reference	—
Inpatient	0.86	0.71–1.05	0.138	0.75	0.61–0.93	0.01	0.74	0.59–0.95	0.018

Model 1 was adjusted for basic factors, including age, sex, history of cardiovascular disease, glycated hemoglobin, estimated glomerular filtration rate, and urinary protein level at baseline. Model 2 was adjusted for body mass index, hemoglobin, and serum albumin at baseline in addition to the factors included in model 1. CI, confidence interval; HR, hazard ratio.

TABLE 5 Comparison of all-cause mortality between the outpatient and inpatient groups according to Cox proportional hazards models adjusted for confounding factors in Japanese patients with chronic kidney disease but no diabetes.

Group	Unadjusted			Model 1			Model 2		
	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
Outpatient	1.00	Reference	—	1.00	Reference	—	1.00	Reference	—
Inpatient	0.75	0.61–0.93	0.009	0.75	0.59–0.94	0.015	0.76	0.59–0.98	0.034

Model 1 was adjusted for basic factors, including age, sex, history of cardiovascular disease, estimated glomerular filtration rate, and urinary protein level at baseline. Model 2 was adjusted for body mass index, hemoglobin, and serum albumin at baseline in addition to the factors included in model 1. CI, confidence interval; HR, hazard ratio.

longer time until initiation of dialysis, and a shorter hospital stay at the start of dialysis, which could lead to a reduction of medical costs. However, the content of the education program and the delivered systems varied according to each facility. Nevertheless, the number of days of hospitalization and the time spent on education should be analyzed. Also, the reasons why it could not be achieved on an outpatient basis should be confirmed. Therefore, further research is required to confirm that the cost-effectiveness of the inpatient setting is superior to that of the outpatient setting.

A meta-analysis revealed that the reduction in all-cause mortality depended on the disciplines represented in the multidisciplinary care team and the stage (24). With only nephrologists and specialist nurses on the team, there was no significant difference in all-cause mortality between patients receiving multidisciplinary care and those who were not. By contrast, when the multidisciplinary care team comprised nephrologists, specialist nurses, and professionals from other disciplines (e.g., dieticians, pharmacists, or social workers), multidisciplinary care was associated with a lower risk of all-cause mortality (25). The FROM-J (Frontier of Renal Outcome Modifications in Japan) study reported that lifestyle and dietary advice provided by a registered dietician in an outpatient setting slowed the rate of deterioration of kidney function in patients with CKD when compared with controls (26). However, the findings were not significant for all stages of CKD and were limited to stage 3; moreover, the multidisciplinary care team comprised only doctors and registered dieticians. In our study, multidisciplinary care was provided by a mean of 4.5 ± 0.6 professionals in the inpatient group and by 2.6 ± 0.7 in the outpatient group. A possible explanation for this result is that when the multidisciplinary care team consists of nephrologists and nurses, the multidisciplinary care model is similar to a conventional model, in which non-multidisciplinary care may be provided by nephrologists and nurses. When the multidisciplinary care group does not include other professionals (e.g., registered dieticians and pharmacists), the education provided for patients with CKD may be insufficient, such that guidelines for dietary protein restriction and other targets are not met, thereby contributing to worsening of kidney function. Patients with CKD require holistic care and support, including dietary modification, maintenance and improvement of medication adherence, education on self-monitoring and early detection of complications, and adequate financial resources to continue treatment. These supports cannot be provided by nephrologists alone and must be implemented by a medical team consisting of multiple professionals. To achieve good outcomes, multidisciplinary care teams that include nephrologists, nurses, registered dieticians, pharmacists, physical therapists, and medical social workers should be involved and have shared goals in terms of individual patients. However, we have no definitive conclusions on how many different cooperating disciplines are needed to achieve optimal outcomes, and further investigations are required to confirm this.

This study has several limitations. First, it did not include a non-multidisciplinary control group. Although multidisciplinary care was not associated with a lower risk of all-cause mortality in previous randomized controlled trials, the risk was found to be reduced in one cohort study (14, 26–28). In addition, the patients could not be randomly allocated to outpatient and inpatient groups because the environment in which multidisciplinary care could be provided varied depending on each facility. Therefore, further prospective randomized



FIGURE 4
Kaplan–Meier curves for the incidence of initiation of renal replacement therapy and all-cause mortality in Japanese patients with chronic kidney disease according to the baseline stages in the **(A)** outpatient and **(B)** inpatient groups.

10.3389/fendo.2023.1180477

TABLE 6 All-cause mortality and initiation of renal replacement therapy according to the CKD stage at baseline in Cox proportional hazards models adjusted for confounding factors in the outpatient group.

Group	Unadjusted			Model 1			Model 2		
	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
G3a	1.00	Reference	—	1.00	Reference	—	1.00	Reference	—
G3b	2.63	1.21–6.92	0.013	1.76	0.80–4.42	0.164	1.41	0.57–3.99	0.468
G4	7.87	3.82–20.0	<0.0001	5.65	2.83–13.4	<0.0001	3.65	1.67–9.59	0.001
G5	22.8	11.1–58.9	<0.0001	21.0	10.63–49.7	<0.0001	12.8	5.91–33.8	<0.0001

Model 1 was adjusted for basic factors, including age, sex, history of cardiovascular diseases, presence or absence of diabetes, and urinary protein levels at baseline. Model 2 was adjusted the same as Model 1 but with additional adjustments for body mass index, hemoglobin, and serum albumin levels at baseline. CI, confidence interval; CKD, chronic kidney disease; HR, hazard ratio.

TABLE 7 All-cause mortality and initiation of renal replacement therapy according to the CKD stage at baseline in Cox proportional hazards models adjusted for confounding factors in the inpatient group.

Group	Unadjusted			Model 1			Model 2		
	HR	95% CI	P-value	HR	95% CI	P-value	HR	95% CI	P-value
G3a	1.00	Reference	—	1.00	Reference	—	1.00	Reference	—
G3b	2.63	1.21–6.92	0.013	2.94	1.34–7.73	0.005	2.18	0.98–5.80	0.056
G4	7.87	3.82–20.0	<0.0001	9.08	4.38–23.1	<0.0001	5.58	2.64–14.3	< 0.0001
G5	22.8	11.1–58.9	<0.0001	27.9	13.5–71.5	<0.0001	15.2	7.10–39.8	< 0.0001

Model 1 was adjusted for basic factors, including age, sex, history of cardiovascular diseases, presence or absence of diabetes, and urinary protein levels at baseline. Model 2 was adjusted the same as Model 1 but with additional adjustments for body mass index, hemoglobin, and serum albumin levels at baseline. CI, confidence interval; CKD, chronic kidney disease; HR, hazard ratio.

controlled trials and large epidemiological studies that include control groups are needed to confirm the efficacy of multidisciplinary care in patients with CKD. Second, we did not investigate changes in blood pressure or laboratory findings other than for kidney function. Salt restriction by multidisciplinary intervention may have lowered blood pressure, reduced proteinuria, and maintained kidney function. We were unable to investigate whether there was any difference in the reduction of salt intake or blood pressure between the study groups.



FIGURE 5
Kaplan–Meier curves for the initiation of renal replacement therapy and all-cause mortality in Japanese patients with chronic kidney disease based on the presence or absence of physical therapists in the inpatient subgroups.

Third, adding or changing medications during the observation period might have affected laboratory findings and kidney function. Renin–angiotensin system inhibitors and sodium-glucose cotransporter-2 inhibitors are recommended for patients with albuminuria, and statins are recommended for all patients with diabetes and CKD (29). Treatment of renal anemia with erythropoiesis-stimulating agents plays an important role in kidney survival (30, 31). Further investigations are needed to determine the contribution of improved adherence with prescribed medication and dietary modification to prevention of worsening kidney function. Finally, there may have been some degree of patient selection and facility bias. Inpatient programs are longer and more expensive than outpatient programs. It is possible that the inpatient group included patients with high self-management ability and a strong desire to prevent progression of their CKD. Therefore, multidisciplinary care in an inpatient setting may be associated with improved patient health literacy. In this study, the participants were divided into two groups by the first intervention method. Therefore, some patients may have been treated in both the inpatient and outpatient settings. Patients might have received multidisciplinary care as an inpatient first, followed by an outpatient setting, or vice versa. However, most facilities in this study provided outpatient or inpatient educational programs based on the hospital functions and human resources. In addition, the content of the education program and the makeup of the patient population varied between the outpatient and inpatient groups from facility to facility. Therefore, the effects of simultaneous participation in outpatient and inpatient sessions should be verified, and educational programs should be standardized to improve the level of care for patients with CKD.



FIGURE 6
Annual change in eGFR in the 12 months before and 24 months after starting multidisciplinary care in all patients **(A)**. Data are shown as the mean. Bars indicate the 95% confidence interval. *P < 0.0001 *vs*. before start of MDC. Changes in the urinary protein level between time of initiation of MDC and 24 months later **(B)**. Data are shown as the median and interquartile range. *P < 0.0001 *vs*. baseline. ΔeGFR, change in eGFR; eGFR, estimated glomerular filtration rate; MDC, multidisciplinary care.



FIGURE 7
Annual change in eGFR in the 12 months before and 24 months after starting MDC in the outpatient group **(A)** and in the inpatient group **(B)**. *P < 0.0001 *vs*. before start of MDC. Data are shown as the mean. Bars indicate the 95% confidence interval. ΔeGFR, change in eGFR; eGFR, estimated glomerular filtration rate; MDC, multidisciplinary care.



FIGURE 8
Changes in the urinary protein level between the time of starting multidisciplinary care and 24 months later in the outpatient **(A)** and inpatient **(B)** groups. Data are shown as the median and interquartile range. *P < 0.0001 *vs*. baseline.

In conclusion, our findings indicate that multidisciplinary care may significantly slow the decline of eGFR, reduce proteinuria in patients with CKD and be effective regardless of diabetes status. Furthermore, this study suggests that multidisciplinary care might be more effective when inpatient-based than when outpatient-based in terms of reducing the all-cause mortality risk and initiation of RRT. Further research is needed to devise a standardized program of multidisciplinary care for both outpatients and inpatients with CKD and to determine which professionals should be involved to achieve the best outcomes for these patients.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by The ethics committee of Nihon University Itabashi Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

MA wrote the manuscript and analyzed the data. TH, YI, TS, and SK designed the study and contributed to data collection. MA, TH, YI, TS, and SK discussed the results and contributed to the final manuscript. All authors read and approved the final manuscript. All authors contributed to the article.

Funding

This work was supported by Health Labour Sciences Research Grant 20FD1003.

Acknowledgments

We thank the members of the Committee of the Evaluation and Dissemination for Certified Kidney Disease Educator, Japan Kidney Association for all their efforts, as well as the staff members at the participating facilities. In particular, we thank the following medical professionals and hospitals: Takashi Maruyama, Division of Nephrology, Hypertension and Endocrinology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan; Toshihiro Shindo, Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan; Kunihiro Yamagata and Chie Saito, Department of Nephrology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan; Kimihiko Nakatani, Department of Nephrology, Kyoto Yamashiro General Medical Center, Kyoto, Japan; Isao Ohsawa, Saiyu Soka Hospital, Saitama, Japan; Hiroaki Io, Department of Nephrology, Juntendo University Nerima Hospital, Tokyo, Japan; Hiroshi Kado, Oumihachiman Community Medical Center, Shiga, Japan; Katsuhito Mori, Department of Nephrology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; Aya Sakurai, St. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, Japan; Akira Ishii and Motoko Yanagita, Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Tatsuo Yamamoto, Fujieda Municipal General Hospital, Shizuoka, Japan; Seigo Hiraga, JCHO Mishima General Hospital, Shizuoka, Japan; Mamiko Shimamoto, Division of Nephrology, Sapporo City General Hospital, Sapporo, Japan; Masaru Matsui, Department of Nephrology, Nara Prefecture General Medical Center, Nara, Japan; Yuriko Yonekura, Divison of Nephrology, Department of Medicine, AIJINKAI Healthcare Corporation Akashi Medical Center, Hyogo, Japan; Katsuyuki Tanabe, Okayama University Hospital, Okayama, Japan; Tatsuo Tsukamoto, Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, Osaka, Japan; Ryouhei Horii and Satoshi Suzuki, Seirei Sakura Citizen Hospital, Chiba, Japan; Katsuhiko Morimoto, Nara Prefectural Seiwa Medical Center, Nara, Japan; Kenta Torigoe and Tomoya Nishino, Nagasaki University Hospital, Nagasaki, Japan; Saori Nishio, Department of Rheumatology, Endocrinology, and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan; Kazue Ueki and Takayuki Matsumoto, Dialysis and Nephrology Center, Sanshikai TOHO Hospital, Gunma, Japan.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2023.1180477/full#supplementary-material

References

1. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. *Lancet* (2018) 392:2052–90. doi: 10.1016/S0140-6736(18)31694-5

2. Nagai K, Asahi K, Iseki K, Yamagata K. Estimating the prevalence of definitive chronic kidney disease in the Japanese general population. *Clin Exp Nephrol* (2021) 25:885–92. doi: 10.1007/s10157-021-02049-0

3. Nitta K, Goto S, Masakane I, Hanafusa N, Taniguchi M, Hasegawa T, et al. Annual dialysis data report for 2018, JSDT renal data registry: survey methods, facility data, incidence, prevalence, and mortality. *Ren Replace Ther* (2020) 6:41. doi: 10.1186/s41100-020-00286-9

4. United States Renal Data System. *2020 USRDS annual data report: epidemiology of kidney disease in the united states*. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (2020).

5. Chen PM, Lai TS, Chen PY, Lai CF, Yang SY, Wu V, et al. Multidisciplinary care program for advanced chronic kidney disease: reduces renal replacement and medical costs. *Am J Med* (2015) 128:68–76. doi: 10.1016/j.amjmed.2014.07.042

6. Wang SM, Hsiao LC, Ting IW, Yu TM, Liang CC, Kuo HL, et al. Multidisciplinary care in patients with chronic kidney disease: a systematic review and meta-analysis. *Eur J Intern Med* (2015) 26:640–5. doi: 10.1016/j.ejim.2015.07.002

7. Chen YR, Yang Y, Wang SC, Chiu PF, Chou WY, Lin CY, et al. Effectiveness of multidisciplinary care for chronic kidney disease in Taiwan: a 3-year prospective cohort study. *Nephrol Dial Transplant* (2013) 28:671–82. doi: 10.1093/ndt/gfs469

8. Chen YR, Yang Y, Wang SC, Chou WY, Chiu PF, Lin C, et al. Multidisciplinary care improves clinical outcome and reduces medical costs for pre-end-stage renal disease in Taiwan. *Nephrol (Carlton)* (2014) 19:699–707. doi: 10.1111/nep.12316

9. Wu IW, Wang SY, Hsu KH, Lee CC, Sun CY, Tsai CJ, et al. Multidisciplinary predialysis education decreases the incidence of dialysis and reduces mortality–a controlled cohort study based on the NKF/DOQI guidelines. *Nephrol Dial Transplant* (2009) 24:3426–33. doi: 10.1093/ndt/gfp259

10. Imamura Y, Takahashi Y, Hayashi T, Iwamoto M, Nakamura R, Goto M, et al. Usefulness of multidisciplinary care to prevent worsening renal function in chronic kidney disease. *Clin Exp Nephrol* (2019) 23:484–92. doi: 10.1007/s10157-018-1658-z

11. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* (2003) 348:383–93. doi: 10.1056/NEJMoa021778

12. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med* (2008) 358:580–91. doi: 10.1056/NEJMoa0706245

13. Fogelfeld L, Hart P, Miernik J, Ko J, Calvin D, Tahsin B, et al. Combined diabetes-renal multifactorial intervention in patients with advanced diabetic nephropathy: proof-of-concept. *J Diabetes Complications* (2017) 31:624–30. doi: 10.1016/j.jdiacomp.2016.11.019

14. Peeters MJ, van Zuilen AD, van den Brand JA, Bots ML, van Buren M, Ten Dam MA, et al. Nurse practitioner care improves renal outcome in patients with CKD. *J Am Soc Nephrol* (2014) 25:390–8. doi: 10.1681/ASN.2012121222

15. Japan Kidney Association. *Chronic kidney disease* (2018). Available at: https://j-ka.or.jp/ckd/download/ (Accessed March 05, 2023).

16. Japanese Society of Nephrology. *Guide for kidney disease* (2020). Available at: https://jsn.or.jp/jsn_new/iryou/kaiin/free/primers/pdf/2021allpage.pdf (Accessed March 05, 2023).

17. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis* (2009) 53:982–92. doi: 10.1053/j.ajkd.2008.12.034

18. Wexler DJ, Beauharnais CC, Regan S, Nathan DM, Cagliero E, Larkin ME. Impact of inpatient diabetes management, education, and improved discharge transition on glycemic control 12 months after discharge. *Diabetes Res Clin Pract* (2012) 98:249–56. doi: 10.1016/j.diabres.2012.09.016

19. Fritsche A, Stumvoll M, Goebbel S, Reinauer KM, Schmülling RM, Häring HU. Long term effect of a structured inpatient diabetes teaching and treatment programme in type 2 diabetic patients: influence of mode of follow-up. *Diabetes Res Clin Pract* (1999) 46:135–41. doi: 10.1016/s0168-8227(99)00081-9

20. Healy SJ, Black D, Harris C, Lorenz A, Dungan KM. Inpatient diabetes education is associated with less frequent hospital readmission among patients with poor glycemic control. *Diabetes Care* (2013) 36:2960–87. doi: 10.2337/dc13-0108

21. Machida S, Shibagaki Y, Sakurada T. An inpatient educational program for chronic kidney disease. *Clin Exp Nephrol* (2019) 23:493–500. doi: 10.1007/s10157-018-1660-5

22. Takagi WH, Osako K, Machida S, Koitabashi K, Shibagaki Y, Sakurada T. Inpatient educational program delays the need for dialysis in patients with chronic kidney disease stage G5. *Clin Exp Nephrol* (2021) 25:166–72. doi: 10.1007/s10157-020-01979-5

23. Yoshida K, Shimizu S, Kita Y, Takagi WH, Shibagaki Y, Sakurada T. Impact of inpatient educational programs on mortality after the start of dialysis therapy. *Clin Exp Nephrol* (2022) 26:819–26. doi: 10.1007/s10157-022-02211-2

24. Shi Y, Xiong J, Chen Y, Deng J, Peng H, Zhao J, et al. The effectiveness of multidisciplinary care models for patients with chronic kidney disease: a systematic review and meta-analysis. *Int Urol Nephrol* (2018) 50:301–12. doi: 10.1007/s11255-017-1679-7

25. Yamagata K, Makino H, Iseki K, Ito S, Kimura K, Kusano E, et al. Effect of behavior modification on outcome in early- to moderate-stage chronic kidney disease: a cluster-randomized trial. *PloS One* (2016) 11:e0151422. doi: 10.1371/journal.pone.0151422

26. Barrett BJ, Garg AX, Goeree R, Levin A, Molzahn A, Rigatto C, et al. A nurse-coordinated model of care versus usual care for stage 3/4 chronic kidney disease in the community: a randomized controlled trial. *Clin J Am Soc Nephrol* (2011) 6:1241–7. doi: 10.2215/CJN.07160810

27. Yu YJ, Wu IW, Huang CY, Hsu KH, Lee CC, Sun CY, et al. Multidisciplinary predialysis education reduced the inpatient and total medical costs of the first 6 months of dialysis in incident hemodialysis patients. *PloS One* (2014) 9:e112820. doi: 10.1371/journal.pone.0112820

28. Chan JC, So WY, Yeung CY, Ko GT, Lau IT, Tsang MW, et al. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. *Diabetes Care* (2009) 32:977–82. doi: 10.2337/dc08-1908

29. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO). *Kidney Int* (2022) 102:974–89. doi: 10.1016/j.kint.2022.08.012.

30. Akizawa T, Tsubakihara Y, Hirakata H, Watanabe Y, Hase H, Nishi S, et al. A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM study. *Clin Exp Nephrol* (2016) 20:885–95. doi: 10.1007/s10157-015-1225-9

31. Evans M, Carrero JJ, Bellocco R, Barany P, Qureshi AR, Seeberger A, et al. Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients. *Nephrol Dial Transplant* (2017) 32:1892–901. doi: 10.1093/ndt/gfw328

Original Article

Kidney Res Clin Pract 2025;44(2):249-264
pISSN: 2211-9132 • eISSN: 2211-9140
https://doi.org/10.23876/j.krcp.23.026

KIDNEY RESEARCH AND CLINICAL PRACTICE

Examine the optimal multidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study

Masanori Abe[1,2], Tsuguru Hatta[1,3], Yoshihiko Imamura[1,4], Tsutomu Sakurada[1,5], Shinya Kaname[1,6]

[1]*The Committee of the Evaluation and Dissemination for Certified Kidney Disease Educator, Japan Kidney Association*
[2]*Division of Nephrology, Hypertension and Endocrinology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan*
[3]*Department of Medicine, Hatta Medical Clinic, Kyoto, Japan*
[4]*Department of Nephrology, Nissan Tamagawa Hospital, Tokyo, Japan*
[5]*Department of Nephrology and Hypertension, St. Marianna University School of Medicine, Kanagawa, Japan*
[6]*Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan*

Background: Multidisciplinary team-based integrated care (MDC) has been recommended for patients with chronic kidney disease (CKD). However, team-based specific structured care systems are not yet established. Therefore, we investigated the efficacy of MDC system and the optimal number of professionals that make up the team for maintaining kidney function and improving prognosis.

Methods: This nationwide, multicenter, observational study included 2,957 Japanese patients with CKD who received MDC from 2015 to 2019. The patients were divided into four groups according to the number of professionals in the MDC team. Groups A, B, C, and D included nephrologists and one, two, three, and four or more other professionals, respectively. Changes in the annual decline in estimated glomerular filtration rate before and after MDC were evaluated. Cox regression was utilized to estimate the correlation between each group and all-cause mortality and the start of renal replacement therapy (RRT) for 7 years.

Results: The change in eGFR significantly improved between before and at 6, 12, and 24 months after MDC in all groups (all $p < 0.0001$). Comparing group D to group A (reference), the hazard ratio (HR) for all-cause mortality and the start of the RRT was 0.60 (95% confidence interval, 0.48–0.73; $p < 0.0001$) after adjustment for multiple confounders. Lower HR in group D was confirmed in both diabetes and nondiabetes subgroups.

Conclusion: An MDC team comprised of five or more professionals might be associated with improvements in mortality and kidney prognosis. Furthermore, MDC might be effective for treating CKD other than diabetes.

Keywords: Certified kidney disease educator, Chronic kidney disease, Estimated glomerular filtration rate, Kidney function, Multidisciplinary care, Renal replacement therapy

Introduction

With the global population aging, the number of patients with chronic kidney disease (CKD) is increasing [1]. Between 2005 and 2015, the number and prevalence of CKD in the adult Japanese population increased from 13.3 mil-

Received: February 12, 2023; **Revised:** March 6, 2023; **Accepted:** March 31, 2023
Correspondence: Masanori Abe
Division of Nephrology, Hypertension and Endocrinology, Department of Medicine, Nihon University School of Medicine, 30-1 Ohyaguchi kami-cho, Itabashi-ku, Tokyo 173-8610, Japan. E-mail: abe.masanori@nihon-u.ac.jp
ORCID: https://orcid.org/0000-0002-9156-5415

lion to 14.8 million and from 12.9% to 14.6%, respectively [2]. Diabetes, hypertension, old age, dyslipidemia, obesity, smoking, and lifestyle-related diseases are well known to increase the risk of CKD, which is not only the primary risk factor for end-stage kidney disease but also one of the most significant risk factors for cardiovascular disease (CVD) [3–5]. Delaying disease progression, reducing complications, and improving quality of life are the main objectives of CKD therapy. Therefore, multifactorial intervention, including blood pressure control and glycemic control, in combination with lifestyle modification and dietary advice, with multidisciplinary team-based integrated care, has been highlighted as an important therapeutic strategy to reach this objective [6].

The comprehensive treatment model is an interdisciplinary medical care system that integrates a variety of professions with different but complementary abilities, knowledge, and experience to improve healthcare and produce the best results to suit patients' needs both physically and psychologically [7,8]. In Japan, the Certified Kidney Disease Educator (CKDE) system was established by the Japan Kidney Association (JKA) in 2017 to prevent disease progression and improve and maintain the quality of life for patients with CKD [9]. Nurses, registered dietitians, and pharmacists who were trained and meet certain requirements are eligible for qualification as a CKDE [9]. However, even if multidisciplinary interventions are provided to patients with CKD, no established systems for successful treatment and care exist. Therefore, in this nationwide multicenter cohort study, we analyzed the results of our investigation into the impact of multidisciplinary care systems on CKD patients. Moreover, we investigated the optimal number of healthcare professionals that make up a multidisciplinary care team for maintaining kidney function and improving prognosis.

Methods

The Ethics Committee of Nihon University Itabashi Hospital approved the study (No. RK-220412-10), which was conducted according to the 2015 Ethical Guidelines for Medical and Health Research Involving Human Subjects published by the Ministry of Education, Culture, Sports, Science, and Technology and the Ministry of Health, Labor, and Welfare and Japanese privacy laws. All procedures were performed based on the Helsinki Declaration. The use of de-identified data allowed the requirement for informed consent to be omitted. The registration number of the study in the University Hospital Medical Information Network is UMIN000049995.

Study design and participants

Approximately 3,000 Japanese patients who were enrolled at 24 chosen medical institutions in Japan, which play a key role in the treatment of CKD patients in each area, were included in this nationwide multicenter study, which was conducted by the committee for the evaluation and dissemination of CKDE in the JKA. The study was intended to reflect the treatment methods used by most Japanese people. A total of 19 tertiary hospitals and five secondary hospitals were included. Patients with CKD who received continuous multidisciplinary care and had data on kidney function available for the 12 months before and the 24 months after receiving multidisciplinary care in Japan were tracked through the end of 2021, and the study period covered January 2015 to December 2019. Patients with CKD who had at least one visit to a nephrologist and were examined by a nephrologist to require more intensive treatment with a multidisciplinary intervention were eligible. The following criteria were used to exclude participants: age younger than 20 years; CKD stages 1 and 2, i.e., ≥60 mL/min/ 1.73 m^2 for estimated glomerular filtration rate (eGFR); acute kidney injury; active malignant disease; transplant recipient; history of long-term dialysis; received multidisciplinary care in the past; and missing data on age, sex, or kidney function. According to the number of healthcare professionals on the multidisciplinary care team, the patients were divided into groups A, B, C, and D. The patients in group A were defined as patients who received multidisciplinary medical care from nephrologists and another professional, either nurses or registered dieticians. Patients in group B were defined as patients who received multidisciplinary medical care from three professionals, such as nurses and registered dieticians, besides nephrologists. Patients in group C were defined as patients who received multidisciplinary medical care from four professionals, such as nurses, registered dieticians, and pharmacists, besides nephrologists. Patients in group D were defined as those who received multidisciplinary

medical care from five or more professionals, including nurses, registered dieticians, pharmacists, physical therapists, clinical laboratory technicians, and social workers, besides nephrologists. The patients were further separated into two subgroups based on whether they had diabetes or not. The quality of the educational content, which included medical management, dietary recommendations, and lifestyle changes, provided was maintained according to the most recent CKD treatment manual or CKD Teaching Guidebook for CKDEs published by the JKA [9,10]. Physical therapists guide exercise therapy to prevent frailty and sarcopenia, according to the Guideline for the Japanese Society of Renal Rehabilitation (JSRR) [11]. Clinical laboratory technicians explain the target values and significance of kidney-related inspection items to patients with all stages of CKD. Social workers provide patients and families with information on available care services and social resources.

Data collection

The demographic and clinical parameters of the patients, such as their age, sex, history of CVD, primary cause of CKD, and body mass index (BMI), were recorded, as well as hemoglobin, creatinine (Cr), urinary protein, serum albumin, urea nitrogen, eGFR, and glycated hemoglobin (HbA1c) for diabetes patients at baseline. CVD was defined as hemorrhagic stroke, limb amputation, coronary artery disease, and ischemic stroke. For Japanese patients, the following formula was used to determine the eGFR: eGFR (mL/min/1.73 m^2) = 194 × serum $Cr^{-1.094}$ × $age^{-0.287}$ (×0.739 for female) [12]. The eGFR values were obtained at 12 months before the intervention by multidisciplinary care and at 6 months, 1 year, and 2 years after the intervention. The annual change in the eGFR (mL/min/1.73 m^2/year) was calculated at each time point of measurement using the following four formulas:

(1) [eGFR (baseline) – eGFR (at 12 months before multidisciplinary care)];
(2) [eGFR (at 6 months after multidisciplinary care) – eGFR (baseline)] × 2;
(3) [eGFR (at 12 months after multidisciplinary care) – eGFR (baseline)]; and
(4) [eGFR (at 24 months after multidisciplinary care) – eGFR (baseline)] × 1/2.

Urinary protein was calculated as the ratio of urinary protein to creatinine (UPCR). The UPCR values were measured at the start of the intervention and at intervals of 6, 12, and 24 months. Method and place of intervention (outpatient or inpatient), number or duration of the intervention (number of visits for intervention for outpatients or hospitalization days for inpatients), and type and number of professionals were collected. The frequency of intervention in outpatient settings, only visits for multidisciplinary care were counted, not every facility visit. Composite outcomes, including dates of all-cause death or the initiation of RRT, were recorded until the composite endpoint was reached or the end of 2021, whichever came earlier. Furthermore, types of RRT, which are hemodialysis, peritoneal dialysis, or kidney transplantation, were recorded.

Statistical analysis

The number and proportion of the data, the mean and standard deviation, or the median (interquartile range [IQR]) are presented. The intragroup comparison was analyzed using two-tailed paired t tests. The chi-squared test was used to analyze categorical variables, and the t test was used to evaluate continuous variables. The repeated-measures analysis of variance was used to compare four groups, with the appropriate use of the Kruskal-Wallis or Tukey's honestly significant difference tests. The log-rank test was used to evaluate the composite endpoint between groups after the Kaplan-Meier technique was used to estimate it. There were both univariate and multivariate analyses using Cox proportional hazards models adjusted for confounders to examine associations between the number of specialists in multidisciplinary intervention and the composite outcome during 7 years of follow-up. Age, sex, CVD history, and presence or absence of diabetes were considered when calculating the hazard ratios (HRs) using model 1. In addition to the variables in model 1, eGFR and UPCR levels at baseline were considered when calculating the HRs using model 2. In addition to the variables in model 2, model 3 was adjusted for baseline BMI, serum albumin, and hemoglobin levels. Furthermore, based on whether a subject had diabetes or not, subgroup analysis was performed. Additionally, subgroup analysis was performed to evaluate the composite endpoint as per CKD stages at baseline in each group, four groups in each CKD stage at baseline,

and according to different intervention settings, i.e., inpatient-based or outpatient-based. HRs with 95% confidence intervals (CIs) and p-values are used to express the model results. For the regression analyses, the imputation of missing data was performed using conventional methods, as necessary. JMP version 13.0 (SAS Institute Inc.) was utilized for all analyses. Statistics were deemed significant at a p-value of <0.05.

Results

Patient features at the multidisciplinary care initiation

Overall, 3,296 patients were enrolled in this study, but only 2,957 were eligible to proceed after 339 were discarded (Fig. 1). Table 1 displays the patient characteristics at the start of multidisciplinary care. Of the patients, 74.1% were male, with a mean age of 70.5 ± 11.6 years. UPCR level was 1.09 g/gCr (0.23–2.98 g/gCr), and the mean eGFR level was 25.8 ± 12.5 mL/min/1.73 m^2. Diabetic kidney disease (42.9%) was the most common primary disease of CKD, followed by hypertensive nephropathy (33.0%) and chronic glomerulonephritis (13.4%). In terms of CKD stages, the most frequent stage was G4 (42.3%), followed by G3b (26.1%) and G5 (21.9%). The average number of professionals on the multidisciplinary care team, including nephrologists, was 3.8 ± 1.2, and it differed significantly between secondary hospitals and tertiary hospitals, 4.3 ± 0.6 and 3.5 ± 1.2, respectively (p < 0.0001). The number of multidisciplinary



Figure 1. Flowchart of study participants.
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate.

Table 1. All participants' baseline data

Variable	Value
No. of patients	2,957
Male sex	2,192 (74.1)
Age (yr)	70.5 ± 11.6
Body mass index (kg/m^2)	24.2 ± 4.3
Serum Cr (mg/dL)	2.43 ± 1.29
eGFR (mL/min/1.73 m^2)	25.8 ± 12.5
Annual decline of eGFR (mL/min/1.73 m^2/yr)	−5.9 ± 7.2
Serum urea nitrogen (mg/dL)	31 (23–43)
Hemoglobin (g/dL)	11.7 ± 1.9
Serum albumin (g/dL)	3.8 ± 0.5
Urinary protein (g/gCr)	1.09 (0.23–2.98)
Comorbidity of CVD	846 (28.6)
Comorbidity of diabetes	1,432 (48.4)
Glycated hemoglobin (for diabetes)	6.4 ± 1.0
Primary cause of CKD	
Diabetic kidney disease	1,269 (42.9)
Hypertensive nephropathy	975 (33.0)
Chronic glomerulonephritis	397 (13.4)
PCKD	87 (2.9)
Others	229 (7.8)
CKD stage	
G3 (G3a + G3b)	1,060 (35.8)
G3a	288 (9.7)
G3b	772 (26.1)
G4	1,251 (42.3)
G5	646 (21.9)
No. of professionals of MDC team	3.8 ± 1.2
2	656 (22.2)
3	398 (13.5)
4	902 (30.5)
5	976 (33.0)
6	22 (0.8)
Membership of MDC team	
Nurses	2,545 (86.2)
Registered dieticians	2,703 (91.5)
Pharmacists	1,885 (63.8)
Physical therapists	772 (26.1)
Clinical laboratory technicians	171 (5.8)
Social workers	68 (2.3)
Others	24 (0.8)

Data are expressed as number only, number (%), mean ± standard deviation, or median (interquartile range).
CKD, chronic kidney disease; Cr, creatinine; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; MDC, multidisciplinary care; PCKD, polycystic kidney disease.

care team members comprising five professionals was most common (33.0%), followed by four (30.5%) and two (22.2%). Most of the multidisciplinary care team members were registered dieticians (91.5%), followed by specific nurses (86.2%), pharmacists (63.8%), and physical therapists (26.1%).

The baseline patient characteristics were compared between the four groups based on the number of members of the multidisciplinary care team. Table 2 compares the baseline characteristics of the patients in the four groups according to the number of multidisciplinary care providers. Male dominance, outpatient settings, higher levels of urinary protein and serum albumin, and a higher rate of diabetic kidney disease characterized groups A and B. Regarding kidney function severity, group A had the lowest eGFR levels at baseline and included the highest rate of stage G5. Conversely, groups C and D were characterized with higher rate of female patients, inpatient settings, lower urinary protein levels, and a higher rate of hypertensive nephropathy and stage G3.

Table 3 shows the details of the membership of the multidisciplinary care team in the four groups. group A

Table 2. Comparison of patient's characteristics according to the number of the multidisciplinary care team

Variable	Group A	Group B	Group C	Group D	p-value
No. of patients	658	399	902	998	<0.0001
Male sex	481 (73.1)	371 (92.9)	630 (69.9)	710 (71.1)	
Age (yr)	69.2 ± 12.5	71.2 ± 10.6	69.9 ± 12.1	71.9 ± 10.8	<0.0001
Place of intervention					<0.0001
Outpatient	641 (97.4)	366 (91.7)	178 (19.7)	8 (0.8)	
Inpatient	17 (2.6)	33 (8.3)	724 (80.3)	990 (99.2)	
Body mass index (kg/m^2)	23.7 ± 4.1	23.4 ± 3.5	24.5 ± 4.6	24.4 ± 4.2	<0.0001
Serum Cr at baseline (mg/dL)	2.57 ± 1.38	2.30 ± 1.07	2.46 ± 1.36	2.26 ± 1.17	<0.0001
eGFR before 12 mo (mL/min/1.73 m^2)	31.6 ± 15.2	34.4 ± 14.1	34.1 ± 15.8	32.9 ± 12.7	0.13
eGFR at baseline (mL/min/1.73 m^2)	24.8 ± 13.0	26.5 ± 12.2	26.1 ± 12.9	27.1 ± 12.2	0.004
Serum urea nitrogen (mg/dL)	34 (24–49)	31 (24–41)	31 (3–44)	30 (23–41)	<0.0001
Hemoglobin (g/dL)	11.7 ± 1.8	11.7 ± 1.9	11.8 ± 2.0	11.7 ± 1.9	0.39
Serum albumin (g/dL)	3.8 ± 0.5	3.8 ± 0.5	3.7 ± 0.6	3.7 ± 0.5	0.008
Urinary protein (g/gCr)	1.30 (0.35–3.20)	1.39 (0.25–3.34)	1.16 (0.26–3.43)	0.86 (0.17–2.43)	0.048
Comorbidity of CVD	203 (30.9)	91 (22.8)	220 (24.4)	333 (33.4)	<0.0001
Comorbidity of diabetes	319 (48.5)	258 (64.7)	352 (39.0)	503 (50.4)	<0.0001
Glycated hemoglobin (for diabetes)	6.4 ± 1.0	6.3 ± 0.8	6.5 ± 1.1	6.4 ± 1.1	0.009
Primary cause of CKD					<0.0001
Diabetic kidney disease	300 (45.7)	234 (58.5)	301 (33.4)	434 (43.5)	
Hypertensive nephropathy	164 (24.8)	96 (24.4)	361 (40.0)	354 (35.5)	
Chronic glomerulonephritis	101 (15.4)	37 (9.0)	133 (14.8)	126 (12.6)	
PCKD	18 (2.7)	25 (6.3)	31 (3.4)	13 (1.3)	
Others	75 (11.4)	7 (1.8)	76 (8.4)	71 (7.1)	
CKD stage					<0.0001
G3 (G3a + G3b)	215 (32.8)	141 (35.2)	332 (36.8)	372 (37.3)	
G3a	68 (10.4)	33 (8.3)	97 (10.7)	90 (9.0)	
G3b	147 (22.4)	108 (26.9)	235 (26.1)	282 (28.3)	
G4	263 (40.0)	177 (44.7)	356 (39.5)	455 (45.6)	
G5	180 (27.2)	81 (20.1)	214 (23.7)	171 (17.1)	
All-cause death	30 (4.6)	16 (4.0)	44 (4.9)	38 (3.8)	0.66
Initiation of RRT	172 (28.4)	73 (19.1)	240 (28.5)	159 (16.9)	<0.0001

Data are expressed as number (%), mean ± standard deviation, or median (interquartile range).
Cr, creatinine; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; PCKD, polycystic kidney disease; RRT, renal replacement therapy.

Table 3. Healthcare professionals of the MDC teams in the four groups

Variable	Group A	Group B	Group C	Group D	p-value
No. of patients	658	399	902	998	-
Membership of MDC team					
Nurses	248 (37.7)	399 (100)	902 (100)	998 (100)	<0.0001
Registered dieticians	410 (62.3)	395 (99.5)	901 (99.9)	998 (100)	<0.0001
Pharmacists	0 (0)	0 (0)	889 (98.6)	996 (99.8)	<0.0001
Physical therapists	0 (0)	0 (0)	1 (0.1)	771 (77.3)	<0.0001
Clinical laboratory technicians	0 (0)	0 (0)	0 (0)	171 (17.1)	<0.0001
Social workers	0 (0)	0 (0)	1 (0.1)	67 (6.7)	<0.0001
Others	0 (0)	2 (0.5)	12 (1.3)	10 (1.0)	0.03

Data are expressed as number (%).
MDC, multidisciplinary care.

was composed of nephrologists and specific nurses or registered dieticians. Group B was mostly composed of nephrologists, nurses, and registered dieticians (99.5%). Group C was mostly composed of nephrologists, nurses, registered dieticians, and pharmacists (98.6%). Group D included physical therapists, clinical laboratory technicians, and social workers, besides nephrologists, nurses, registered dieticians, and pharmacists. Most of the nurses and registered dieticians were included in groups B, C, and D, whereas pharmacists were included in groups C and D. Frequency of multidisciplinary care for outpatient was 9.1 ± 4.5 times and duration of hospital stay for inpatient were 7 days (5–12 days).

Changes in Δestimated glomerular filtration rate and urinary protein to creatinine levels before and after multidisciplinary care in the four groups

The mean annual decline in eGFR (ΔeGFR) was significantly improved from –5.89 ± 7.17 mL/min/1.73 m^2/year before multidisciplinary intervention to –0.44 ± 5.21 mL/min/1.73 m^2/year at 6 months, –1.52 ± 6.09 mL/min/1.73 m^2/year at 12 months, and –1.48 ± 3.78 mL/min/1.73 m^2/year at 24 months after intervention (for all of them, $p < 0.0001$) (Supplementary Fig. 1, available online). As shown in Fig. 2, the mean ΔeGFR was significantly improved from before the multidisciplinary intervention to all time points after intervention in all groups. The mean ΔeGFR before intervention (ΔeGFR [–1 year]) in groups B and C was –6.50 ± 6.24 mL/min/1.73 m^2/year, and –6.61 ± 7.97 mL/min/1.73 m^2/year, respectively, and a significant difference existed between the groups ($p = 0.005$) (Supplementary Table 1, available online). However, the ΔeGFR values for the four groups did not significantly differ after 6, 12, or 24 months, following the intervention.

The median UPCR level was significantly decreased from 1.09 g/gCr (0.23–2.98 g/gCr) at baseline to 1.00 g/gCr (0.24–2.71 g/gCr) at 6 months, 0.89 g/gCr (0.21–2.38 g/gCr) at 12 months, and 0.82 g/gCr (0.20–2.22 g/gCr) at 24 months ($p < 0.0001$ for all of them) (Supplementary Fig. 2, available online). Fig. 3A shows that the median UPCR levels in group A significantly decreased from baseline to 6 and 12 months after the intervention. Conversely, the UPCR levels in groups B, C, and D significantly decreased from baseline at all time points after intervention (Fig. 3B–D). The four groups had significantly different median UPCR levels at baseline, and this difference persisted for 24 months after the intervention (Supplementary Table 2, available online).

Outcomes

The median observation period was 36 months (IQR, 22–52 months), during which 128 patients (4.3%) died, 649 (22.0%) initiated RRT, and 59 (2.0%) were lost to follow-up; 2,121 patients (71.7%) of all patients were alive without RRT. RRT consisted of hemodialysis in 527 patients (81.2%), peritoneal dialysis in 61 (9.4%), and kidney transplantation in 23 patients (3.5%).

Comparison of composite endpoints between the four groups

There was a significant difference between the four groups



Figure 2. Annual changes in eGFR decline (ΔeGFR) in the 12 months before and 24 months after initiation of MDC. (A) Group A, (B) group B, (C) group C, and (D) group D. Data are shown as the mean. Bars indicate the 95% confidence interval. *p < 0.0001 vs. before the start of MDC.
eGFR, estimated glomerular filtration rate; MDC, multidisciplinary care.

according to the Kaplan-Meier analysis for the composite endpoint (all-cause mortality and the start of RRT; p < 0.0001, log-rank test) (Fig. 4). Compared with group A (reference), the unadjusted HR for group D was significantly lower, at 0.60 (95% CI, 0.49–0.74; p < 0.0001) (Table 4). When background characteristics including age, sex, CVD history, and whether or not one has diabetes have been taken into account (model 1), a significantly decreased HR of 0.57 (95% CI, 0.47–0.71; p < 0.0001) was observed in group D. After adjusting for baseline eGFR and UPCR levels in addition to the components in model 1 (model 2), group D had a significantly lower HR of 0.57 (95% CI, 0.46–0.70; p < 0.0001). Following another adjustment for BMI, serum albumin, and hemoglobin levels at baseline in addition to factors of model 2, group D had a significantly lower HR (0.60; 95% CI, 0.48–0.73; p < 0.0001).

Subgroup analysis of the four groups based on whether they had diabetes or not

The patients were split into two groups based on whether they had diabetes or not. The composite endpoint for diabetes patients differed significantly across the four groups according to Kaplan-Meier analysis (p < 0.0001, log-rank test) (Fig. 5A). Cox proportional analysis revealed the unadjusted HR for the composite endpoint. Compared to that



Figure 3. Changes in urinary protein levels between the time of initiation of MDC and 24 months after initiation of MDC. (A) Group A, (B) group B, (C) group C, and (D) group D. Data are shown as the median and interquartile range. ***p < 0.0001, **p < 0.001, *p < 0.01 vs. baseline.
MDC, multidisciplinary care; UPCR, urinary protein to creatinine ratio.

in group A (reference), the HRs in groups B and D were noticeably lower, which were at 0.70 (95% CI, 0.51–0.95; p = 0.02) and 0.59 (95% CI, 0.46–0.77; p < 0.0001) (Table 5). Once background variables including sex, age, and CVD history have been taken into account (model 1), the HRs in groups B and D were 0.72 (95% CI, 0.52–0.98; p = 0.04) and 0.60 (95% CI, 0.46–0.78; p = 0.0001), respectively. Another adjustment for HbA1c, eGFR, and UPCR level at baseline in addition to the factors of model 1 (model 2), the HR in groups B and D were 0.69 (95% CI, 0.49–0.97; p = 0.03) and 0.57 (95% CI, 0.43–0.76; p = 0.0002), respectively. After further adjustment for BMI, serum albumin, and hemoglobin levels at baseline in addition to the factors of model 2, only group D had a significantly lower HR of 0.55 (95% CI, 0.41–0.75; p = 0.0002).

In patients with no diabetes, Kaplan-Meier analysis for the composite endpoint revealed a significant difference between all four groups (p < 0.0001, log-rank test) (Fig. 5B).



Numbers at risk

Group A	656	617	496	371	273	171	79
Group B	403	390	298	239	122	67	34
Group C	902	861	700	554	405	291	162
Group D	998	977	831	699	485	309	157

Figure 4. Japanese chronic kidney disease patients' Kaplan-Meier curves for the occurrence of all-cause mortality and the start of renal replacement therapy in four groups according to the number of professionals consisting of the multidisciplinary care team. Group A vs. group B, p = 0.30; group A vs. group C, p = 0.41; group A vs. group D, p < 0.0001; group B vs. group C, p = 0.054; group B vs. group D, p < 0.0001; group C vs. group D, p < 0.0001.

Group D had a considerably lower unadjusted HR for the composite endpoint than group A (reference) (0.54; 95% CI, 0.39–0.74; p = 0.0001). The HR in group D was 0.53 (95% CI, 0.40–0.73; p = 0.0001) after background characteristics, including age, sex, and a history of CVD, were adjusted (model 1). After further adjustment for eGFR and UPCR levels at baseline in addition to the factors of model 1 (model 2), the HR in group D was 0.70 (95% CI, 0.51–0.98; p = 0.04). After further adjustment for BMI, serum albumin, and hemoglobin levels at baseline in addition to factors of model 2, group D had a significantly lower HR of 0.68 (95% CI, 0.48–0.96; p = 0.03) as shown in Table 6.

Subgroup analysis based on chronic kidney disease stages at baseline in each group, four groups in each chronic kidney disease stage, and the inpatient or outpatient setting

All-cause mortality and the RRT initiation rate depended on the disease stage in all groups. Substantial differences (all p < 0.0001, log-rank test) were found in the composite endpoint as per the CKD stage at baseline in each group (Supplementary Fig. 3, available online). There was a significant difference between the four groups in only stage G4 according to the Kaplan-Meier analysis for the composite endpoint (all-cause mortality and the start of RRT; p < 0.0001, log-rank test) (Supplementary Fig. 4, available online). There was no significant difference between the four groups in other CKD stages.

The setting of multidisciplinary care was different between groups A, B and groups C, D. Subgroup analysis was conducted according to outpatient and inpatient settings. Composite endpoint was compared between groups A and B in outpatient setting (Supplementary Fig. 5A, available online), and between groups C and D in inpatient setting (Supplementary Fig. 5B, available online). Although there was no significant difference in groups A and B in outpa-

Table 4. In patients with chronic kidney disease, Cox proportional hazards models adjusted for confounding factors were used to compare the groups according to the number of professionals, all-cause mortality, and the start of renal replacement therapy

Group	Unadjusted		Model 1		Model 2		Model 3	
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
A	1.00 (Reference)	-	1.00 (Reference)	-	1.00 (Reference)	-	1.00 (Reference)	-
B	0.88 (0.69–1.12)	0.30	0.78 (0.61–1.00)	0.05	0.89 (0.68–1.15)	0.37	0.81 (0.87–1.29)	0.13
C	1.08 (0.89–1.31)	0.41	1.15 (0.95–1.40)	0.16	1.17 (0.95–1.45)	0.13	1.06 (0.87–1.29)	0.51
D	0.60 (0.49–0.74)	<0.0001	0.57 (0.47–0.71)	<0.0001	0.57 (0.46–0.70)	<0.0001	0.60 (0.48–0.73)	<0.0001

Age, sex, cardiovascular disease history, and the presence or absence of diabetes mellitus were all basic characteristics that were adjusted for in model 1. Model 2 was adjusted for estimated glomerular filtration rate and urinary protein levels at baseline in addition to factors of model 1. Model 3 was adjusted for body mass index, serum albumin, and hemoglobin levels at baseline in addition to factors of model 2.
Nephrologists in group A plus one professional; nephrologists in group B plus two professionals; nephrologists in group C plus three professionals; and nephrologists in group D plus four or more professionals.
CI, confidence interval; HR, hazard ratio.

tient setting (Supplementary Table 3, available online), group D showed significantly lower HR of 0.56 (95% CI, 0.45–0.69; $p < 0.0001$) compared with group C (reference) after adjusted for all confounders in inpatient setting (Supplementary Table 4, available online).

Discussion

Our nationwide cohort study demonstrated that the multidisciplinary care conducted by nephrologists with at least another specialist could prevent the decline of eGFR and reduce proteinuria levels for 2 years after multidisciplinary care. Furthermore, the multifactorial intervention provided by a team comprised of five or more professionals, including nephrologists, has been shown to improve patient outcomes for 7 years. The present study included 2,957 individuals from 24 facilities in Japan; therefore, the large sample size drawn from a multicenter study is one of its main advantages, along with the relatively long observation and the inclusion of a comparatively high number of elderly patients. This study is the first to indicate that a multidisciplinary care team with five or more professionals may be able to prevent initiating RRT and reduce all-cause mortality regardless of whether the CKD patients have diabetes or not. A multidisciplinary care team should include a nephrologist and other professionals from other fields and is recommended for those with stages 3 to 5 of CKD.

The mean annual decline of eGFR before multidisciplinary care was –5.9 mL/min/1.73 m^2 in this study. It has been reported that when the eGFR falls below 45 mL/min/1.73 m^2, it declines at a rate of –9.9 mL/min/1.73 m^2/year in diabetic nephropathy and –4.8 mL/min/1.73 m^2/year in hypertensive nephropathy until the initiation of dialysis in Japanese CKD patients [13]. Furthermore, the annual decline rate of eGFR from 45 mL/min/1.73 m^2 to dialysis initiation was greater than the decline rate of eGFR from 60 mL/min/1.73 m^2 to 45 mL/min/1.73 m^2 [13]. Therefore, annual decline of eGFR was higher in the present study because the mean eGFR levels at baseline was 25.8 ± 12.5 mL/min/1.73 m^2. According to reports, poor drug adherence has been linked to problems, CKD progression, unplanned hospitalization, higher medical expenses, early impairment, and mortality [14,15]. Across disease states, treatment protocols, and age groups, men have relatively high discontinuous visit rates; the first few months of treatment are when this rate is highest [16]. Most patients with CKD, particularly those in stage 3, are asymptomatic, and interruption of visits is one of their significant issues. Reportedly, multidisciplinary care improves adherence to management targets given in CKD guidelines, and this adherence leads to an enhanced renal prognosis even in patients with CKD stage G3 [17]. Collaborative integration by multidisciplinary care professionals is critical in helping patients modify their lifestyles and efficiently achieve treatment goals established by guidelines [18]. Although the present study included 2,957 patients, only 2% of follow-up on some patients was lost. However, we could not evaluate whether the multidisciplinary care in this study was able to successfully achieve behavioral modification, improve patient compliance and adherence, and reduce the discontinuation rate of outpatient visits. Nevertheless, we believe that multidisciplinary care may be associated



Numbers at risk

Group A	319	296	230	172	118	70	33
Group B	258	250	197	157	77	45	23
Group C	352	327	260	188	128	99	52
Group D	503	487	406	336	245	153	76



Numbers at risk

Group A	339	323	268	201	156	102	47
Group B	141	136	106	82	46	26	15
Group C	550	534	440	366	272	192	110
Group D	495	490	425	363	240	156	81

Figure 5. Kaplan-Meier curves for the incidence of all-cause death and the start of renal replacement therapy in these patients. Japanese chronic kidney disease patients with (A) and without (B) diabetes are divided into four groups based on the number of professionals who make up the multidisciplinary care team. (A) Group A vs. group B, p = 0.002; group A vs. group C, p = 0.78; group A vs. group D, p < 0.0001; group B vs. group C, p = 0.0004; group B vs. group D, p = 0.69; group C vs. group D, p < 0.0001. (B) Group A vs. group B, p = 0.70; group A vs. group C, p = 0.82; group A vs. group D, p = 0.0001; group B vs. group C, p = 0.80; group B vs. group D, p = 0.02; group C vs. group D, p < 0.0001.

Table 5. Diabetes patients with chronic kidney disease are compared between the four groups for all-cause mortality and the start of renal replacement therapy using Cox proportional hazards models adjusted for confounding variables

Group	Unadjusted		Model 1		Model 2		Model 3	
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
A	1.00 (Reference)	-	1.00 (Reference)	-	1.00 (Reference)	-	1.00 (Reference)	-
B	0.70 (0.51–0.95)	0.02	0.72 (0.52–0.98)	0.04	0.69 (0.49–0.97)	0.03	1.13 (0.87–1.46)	0.34
C	1.04 (0.81–1.32)	0.78	1.06 (0.83–1.35)	0.67	1.06 (0.80–1.41)	0.66	0.88 (0.70–1.12)	0.30
D	0.59 (0.46–0.77)	<0.0001	0.60 (0.46–0.78)	0.0001	0.57 (0.43–0.76)	0.0002	0.55 (0.41–0.75)	0.0002

Age, sex, and cardiovascular disease history were all basic characteristics that were adjusted for in model 1. Model 2 was adjusted for estimated glomerular filtration rate and urinary protein levels at baseline in addition to factors of model 1. Model 3 was adjusted for body mass index, serum albumin, and hemoglobin levels at baseline in addition to factors of model 2.
Nephrologists in group a plus one other professional; nephrologists in group B plus two other professionals; nephrologists in group C plus three other professionals; nephrologists in group D plus four or more other professionals.
CI, confidence interval; HR, hazard ratio.

Table 6. Comparison of the all-cause mortality and the start of renal replacement therapy in patients without diabetes but with chronic kidney disease between the four groups using Cox proportional hazards models adjusted for confounding factors

Group	Unadjusted		Model 1		Model 2		Model 3	
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
A	1.00 (Reference)	-	1.00 (Reference)	-	1.00 (Reference)	-	1.00 (Reference)	-
B	0.92 (0.59–1.38)	0.70	0.95 (0.61–1.45)	0.83	1.32 (0.83–1.05)	0.24	1.25 (0.72–2.07)	0.41
C	0.97 (0.74–1.28)	0.82	1.03 (0.78–1.35)	0.86	1.15 (0.86–1.55)	0.35	1.06 (0.78–1.46)	0.71
D	0.54 (0.39–0.74)	0.0001	0.53 (0.40–0.73)	0.0001	0.70 (0.51–0.98)	0.04	0.68 (0.48–0.96)	0.03

Age, sex, and cardiovascular disease history were all basic characteristics that were adjusted for in model 1. Model 2 was adjusted for estimated glomerular filtration rate and urinary protein levels at baseline in addition to factors of model 2. Model 3 was adjusted for body mass index, serum albumin, and hemoglobin levels at baseline in addition to factors of model 2.
Nephrologists in group A plus one other professional; nephrologists in group B plus two other professionals; nephrologists in group C plus three other professionals; nephrologists in group D plus four or more other professionals.
CI, confidence interval; HR, hazard ratio.

with improved patient health literacy and the prevention of worsening kidney function.

Nephrologists, dieticians, nurses, pharmacists, and social workers generally make up the multidisciplinary care team for patients with CKD, and each of them is crucial to the management of these patients [8]. However, the present study found that the composition of professionals in the multidisciplinary care team varied significantly by institution and intervention method. Regarding intervention methods, multidisciplinary care teams consisting of two or three professionals, including nephrologists, were primarily delivered in outpatient settings, whereas teams of four or more professionals were delivered in the inpatient setting. Inpatient multidisciplinary care programs for patients with CKD have not been implemented extensively in Western countries, probably reflecting differences in the medical insurance system between Japan and Western countries. Although multidisciplinary care provided in an outpatient setting is reimbursed for patients with diabetic kidney disease in Japan, it is not reimbursed for patients with other etiologies of CKD. However, full reimbursement is available for these patients if they are admitted to hospital. Accordingly, interventions by pharmacists and physical therapists are possible in the inpatient setting. Moreover, regarding the number of healthcare professionals consisting of multidisciplinary care teams, registered dieticians are the most common, followed by specific nurses, pharmacists, physical therapists, and the number of physical therapists is greater than that of social workers in Japan. As per recent studies, kidney function is linked to physical activity in people with CKD, and increasing physical activity levels may slow the decline of kidney function [19–22]. There is a guideline for exercise therapy for patients with predialysis CKD and dialysis from the JSRR [11]. Consequently, physical therapists, preferably with CKD knowledge, were widely used to treat CKD patients in Japan, and they must be con-

sidered members of multidisciplinary care teams. Our results showed that the most physical therapists were included in group D. Therefore, further investigation would be needed since the physical therapists might be a key player in improving the prognosis of patients with CKD. According to a meta-analysis, CKD patients receiving multidisciplinary care had a considerably lower chance of dying from any cause than those who were not receiving it [23]. However, when nephrologists and nurses made up the multidisciplinary care teams, there was no significant difference in all-cause mortality between the multidisciplinary and non-multidisciplinary care groups. Furthermore, it has been hypothesized that the all-cause death rate for CKD patients would decrease when the multidisciplinary care team included not just nephrologists and nurses but also experts from other specialties. A multidisciplinary care team that only includes nephrologists and nurses might not be the best choice for improving outcomes for CKD patients according to a meta-analysis [23]. The present study found that the intervention of at least one professional besides nephrologists can prevent the decline of kidney function in CKD patients more than nephrologists alone. Moreover, the present study revealed that a multidisciplinary care team consisting of five or more healthcare professionals could provide the best outcomes, regardless of any underlying CKD disease. However, further investigations are needed to determine which professionals and how many staff members comprise multidisciplinary care teams that achieve the best outcomes.

A self-management program's overarching objective is to empower and enable people to advance their knowledge and abilities in self-management [24]. Therefore, it helps diabetes patients lower their risk of developing long-term microvascular and macrovascular problems, severe hypoglycemia, and diabetic ketoacidosis. Besides maximizing patient well-being, self-management programs seek to enhance the quality of life and achieve treatment satisfaction [25]. Patients with diabetes are frequently given lifestyle management services, such as medical nutrition therapy, physical exercise, weight loss counseling, smoking cessation counseling, and emotional support. Fundamental components of diabetes care include self-management training and assistance. According to reports, patients with diabetes who participate in a program with a planned, patient-centered curriculum and more than 10 hours of contact time each week have the best results [26]. Self-management education, according to the American Diabetes Association, is a continuous process that encourages the information, skills, and competencies required for diabetes self-care. It also combines a patient-centered approach and collaborative decision making [27]. A multidisciplinary care team should deliver the program either one on one or in groups, with support available over the phone or online, according to the National Clinical Institute for Care and Excellence in the United Kingdom. This team should include at least one trained or accredited healthcare professional, such as a registered dietitian or diabetes specialist nurse [28]. A structured self-management education program should be implemented for individuals with diabetes and CKD, according to the KDIGO (Kidney Disease: Improving Global Outcome) clinical practice guideline for 2022 [29]. To provide complete treatment for patients with diabetes and CKD, policymakers and institutional decision makers promote team-based, integrated care with a focus on risk assessment and patient empowerment. Multiple factors related to lifestyle, including diet, exercise, and psychosocial factors, can influence medication noncompliance and worsen outcomes [30–32]. The present study suggested that multidisciplinary care was effective not only in diabetes patients with CKD but even in patients without diabetes but with CKD. Therefore, team-based, integrated care programs based on the structured and patient-centered curriculum should be established, and further preparation and dissemination of multidisciplinary team-based care are required for all CKD patients.

The current study has some limitations. First, we could not investigate blood pressure, body weight, laboratory findings other than kidney function, or medications, which were other unknown confounding factors. Salt restriction through multidisciplinary intervention may have lowered blood pressure, reduced proteinuria, and maintained kidney function. The patients with diabetes in group C had poor prognoses, and HbA1c level was considerably higher. Therefore, patients with higher risk factors that could not be measured or collected in this study might be included. In addition, group B had higher event rate despite ΔeGFR in group B was lower compared to group D. However, group B had higher UPCR levels through 2 years. Reduction of UPCR by multidisciplinary care might be associated with improvement of prognosis, therefore, further study

should be required. Although it has been reported that an early referral to a nephrologist is more useful than a late referral, we could not collect the times and duration of management for nephrologists before multidisciplinary care. We were unable to adequately investigate the important factors involved in maintaining kidney function among the four groups. Second, the current study was excluded from a non-multidisciplinary control group. In cohort studies, multidisciplinary treatment was linked to decreased all-cause mortality, but this was not demonstrated in the randomized control trials for patients with CKD [23]. Therefore, additional prospective randomized controlled trials for patients with CKD are required to validate the efficacy of multidisciplinary therapy. Finally, there may have been some degree of patient selection and facility bias. Bias in the facility and patient selection may have existed to some extent. Although the number of professionals on the multidisciplinary care team did not vary by hospital size, it depended on the functions of each hospital, such as the type and number of healthcare professionals available. The content of the education program, the systems delivered, and the makeup of the patient population varied as per each facility. Further studies are needed to clarify whether multiple education sessions by the same personnel or one session by each personnel is superior to multidisciplinary care in an inpatient setting. Additionally, the role of each professional is not clearly defined. Programs for self-management and education that include content, assessments of duration, contact frequency, and delivery techniques should be established.

In conclusion, a multidisciplinary care team comprised of five or more professionals may be linked to a better prognosis for kidney disease and overall mortality. Furthermore, multidisciplinary team-based treatment is expected to be effective for CKD other than diabetes. To manage patients holistically, multidisciplinary care integrates several professionals and is patient-centered. A multidisciplinary care team should be delivered by nephrologists and other professionals, not only CKDEs such as trained nurses, dieticians, and pharmacists but also physical therapists and social workers, ideally with an understanding of CKD.

Conflicts of interest

All authors have no conflicts of interest to declare.

Funding

This work was supported by Health, Labor, and Sciences Research Grant 20FD1003 and 23FD1001.

Acknowledgments

We thank the members of the Committee on Evaluation and Dissemination for Certified Kidney Disease Educators and the Japan Kidney Association for all their efforts, as well as the staff members at the participating facilities. Particularly, we thank the following medical professionals and hospitals: Takashi Maruyama, Division of Nephrology, Hypertension and Endocrinology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan; Toshihiro Shindo, Department of Nephrology, Hiroshima University Hospital, Hiroshima, Japan; Kunihiro Yamagata and Chie Saito, Department of Nephrology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan; Kimihiko Nakatani, Department of Nephrology, Kyoto Yamashiro General Medical Center, Kyoto, Japan; Isao Ohsawa, Saiyu Soka Hospital, Saitama, Japan; Hiroaki Io, Department of Nephrology, Juntendo University Nerima Hospital, Tokyo, Japan; Hiroshi Kado, Oumihachiman Community Medical Center, Shiga, Japan; Katsuhito Mori, Department of Nephrology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan; Aya Sakurai, St. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, Japan; Akira Ishii and Motoko Yanagita, Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Tatsuo Yamamoto, Fujieda Municipal General Hospital, Shizuoka, Japan; Seigo Hiraga, JCHO Mishima General Hospital, Shizuoka, Japan; Mamiko Shimamoto, Division of Nephrology, Sapporo City General Hospital, Sapporo, Japan; Masaru Matsui, Department of Nephrology, Nara Prefecture General Medical Center, Nara, Japan; Yuriko Yonekura, Divison of Nephrology, Department of Medicine, AIJINKAI Healthcare Corporation Akashi Medical Center, Hyogo, Japan; Katsuyuki Tanabe, Okayama University Hospital, Okayama, Japan; Tatsuo Tsukamoto, Department of Nephrology and Dialysis, Medical Research Institute Kitano Hospital, PIIF Tazuke-Kofukai, Osaka, Japan; Ryouhei Horii and Satoshi Suzuki, Seirei Sakura Citizen Hospital, Chiba, Japan; Katsuhiko Morimoto, Nara Prefectural Seiwa Medical Center, Nara, Japan;

Kenta Torigoe and Tomoya Nishino, Nagasaki University Hospital, Nagasaki, Japan; Saori Nishio, Department of Rheumatology, Endocrinology, and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan; Kazue Ueki and Takayuki Matsumoto, Dialysis and Nephrology Center, Sanshikai TOHO Hospital, Gunma, Japan.

Data sharing statement

The data used in this article are available from the corresponding author upon reasonable request.

Authors' contributions

Conceptualization: MA, TH, TS
Data curation: All authors
Formal analysis: MA
Funding acquisition: MA, SK
Investigation, Methodology: TH, YI, TS
Writing–original draft: MA
Writing–review & editing: All authors
All authors read and approved the final manuscript.

ORCID

Masanori Abe, https://orcid.org/0000-0002-9156-5415
Tsuguru Hatta, https://orcid.org/0009-0007-9548-7411
Yoshihiko Imamura, https://orcid.org/0000-0001-7387-8066
Tsutomu Sakurada, https://orcid.org/0000-0003-2434-0483
Shinya Kaname, https://orcid.org/0000-0002-9507-180X

References

1. Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. *Lancet* 2018;392:2052–2090.
2. Nagai K, Asahi K, Iseki K, Yamagata K. Estimating the prevalence of definitive chronic kidney disease in the Japanese general population. *Clin Exp Nephrol* 2021;25:885–892.
3. Nitta K, Goto S, Masakane I, et al. Annual dialysis data report for 2018, JSDT Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality. Ren Replace Ther 2020;6:41.
4. United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2020.
5. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 2010;375:2073–2081.
6. ElSayed NA, Aleppo G, Aroda VR, et al. 11. Chronic kidney disease and risk management: standards of care in diabetes-2023. *Diabetes Care* 2023;46:S191–S202.
7. Chen PM, Lai TS, Chen PY, et al. Multidisciplinary care program for advanced chronic kidney disease: reduces renal replacement and medical costs. *Am J Med* 2015;128:68–76.
8. Wang SM, Hsiao LC, Ting IW, et al. Multidisciplinary care in patients with chronic kidney disease: a systematic review and meta-analysis. *Eur J Intern Med* 2015;26:640–645.
9. Japan Kidney Association. Spread and enlightenment of chronic kidney disease (CKD) [Internet]. Japan Kidney Association; c2022 [cited 2023 Feb 12]. Available from: https://j-ka.or.jp/ckd/download/
10. Japan Kidney Association. CKD guidance guidebook for nephrology educators [Internet]. Tokyo Igakusha; c2021 [cited 2023 Feb 12]. Available from: https://www.tokyo-igakusha.co.jp/b/show/b/1480.html
11. Yamagata K, Hoshino J, Sugiyama H, et al. Clinical practice guideline for renal rehabilitation: systematic reviews and recommendations of exercise therapies in patients with kidney diseases. *Ren Replace Ther* 2019;5:28.
12. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis* 2009;53:982–992.
13. Abe M, Okada K, Maruyama N, Takashima H, Oikawa O, Soma M. Comparison of clinical trajectories before initiation of renal replacement therapy between diabetic nephropathy and nephrosclerosis on the KDIGO guidelines heat map. *J Diabetes Res* 2016;2016:5374746.
14. Pladevall M, Brotons C, Gabriel R, et al. Multicenter cluster-randomized trial of a multifactorial intervention to improve antihypertensive medication adherence and blood pressure control among patients at high cardiovascular risk (the COM99 study). *Circulation* 2010;122:1183–1191.
15. Denker M, Boyle S, Anderson AH, et al. Chronic Renal Insuffi-

ciency Cohort Study (CRIC): overview and summary of selected findings. *Clin J Am Soc Nephrol* 2015;10:2073–2083.
16. Evans CD, Eurich DT, Remillard AJ, Shevchuk YM, Blackburn D. First-fill medication discontinuations and nonadherence to antihypertensive therapy: an observational study. *Am J Hypertens* 2012;25:195–203.
17. Imamura Y, Takahashi Y, Takeuchi T, et al. Relationship between compliance with management target values and renal prognosis in multidisciplinary care for outpatients with chronic kidney disease. *Clin Exp Nephrol* 2022;26:750–759.
18. Jessup RL. Interdisciplinary versus multidisciplinary care teams: do we understand the difference? *Aust Health Rev* 2007;31:330–331.
19. Guo C, Tam T, Bo Y, Chang LY, Lao XQ, Thomas GN. Habitual physical activity, renal function and chronic kidney disease: a cohort study of nearly 200 000 adults. *Br J Sports Med* 2020;54:1225–1230.
20. Robinson-Cohen C, Littman AJ, Duncan GE, et al. Physical activity and change in estimated GFR among persons with CKD. *J Am Soc Nephrol* 2014;25:399–406.
21. Chen IR, Wang SM, Liang CC, et al. Association of walking with survival and RRT among patients with CKD stages 3-5. *Clin J Am Soc Nephrol* 2014;9:1183–1189.
22.Hiraki K, Otobe Y, Izawa KP, Sakurada T, Shibagaki Y. Physical activity in patients with pre-dialysis chronic kidney disease is associated with decreased renal function. *Clin Exp Nephrol* 2021;25:683–684.
23. Shi Y, Xiong J, Chen Y, et al. The effectiveness of multidisciplinary care models for patients with chronic kidney disease: a systematic review and meta-analysis. *Int Urol Nephrol* 2018;50:301–312.
24. Chatterjee S, Davies MJ, Heller S, Speight J, Snoek FJ, Khunti K. Diabetes structured self-management education programmes: a narrative review and current innovations. *Lancet Diabetes Endocrinol* 2018;6:130–142.
25. Steinsbekk A, Rygg LØ, Lisulo M, Rise MB, Fretheim A. Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus: a systematic review with meta-analysis. *BMC Health Serv Res* 2012;12:213.
26. Pillay J, Armstrong MJ, Butalia S, et al. Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis. *Ann Intern Med* 2015;163:848–860.
27. Powers MA, Bardsley J, Cypress M, et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. *Clin Diabetes* 2016;34:70–80.
28. National Institute for Health and Care Excellence (NICE). Diabetes in adults [Internet]. NICE; c2016 [cited 2023 Jan 31]. Available from: https://www.nice.org.uk/guidance/qs6
29. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. *Kidney Int* 2022;102:S1–S127.
30. Kong AP, Yang X, Luk A, et al. Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: the Hong Kong diabetes registry. *Diabetes Care* 2014;37:1024–1031.
31. Miccoli R, Penno G, Del Prato S. Multidrug treatment of type 2 diabetes: a challenge for compliance. *Diabetes Care* 2011;34:S231–S235.
32. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. *N Engl J Med* 2010;363:1410–1418.

厚生労働科学研究費補助金（腎疾患政策研究事業）
研究課題名：慢性腎臓病(CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究（23FD1001）（研究代表者　要　伸也）

令和6年度　第1回教育プログラム作成WGコアメンバー会議

日時：2025年3月20日(日) 10時30～11時45分

研究代表者：要 伸也
研究分担者：岡田浩一、内田明子、石川祐一、竹内裕紀
研究協力者：櫻田 勉、今村吉彦、八田 告（敬称略）　下線はご欠席

議事録

１．研究代表者より、スライド資料にもとづいて今回の会議の趣旨説明があった。

- 標準プログラムの作成にあたっては、中間評価（スライド33)、ならびに厚労省山田先生のご発言、すなわち、慢性腎臓病指導管理料の通知に記載されている「慢性腎臓病のリスク要因に関する評価を行い、その結果に基づいて、指導計画を作成すること」に答えを出すようなものにしてほしい、とのご要望を念頭におく。
- 追加解析では、G3bA1でも多職種介入効果が見られた。厚労省の啓発ポスターでもeGFR<45で専門医紹介になっていることも考慮すると、将来的にはG3bA1も加算の対象に入るよう働きかけるのがよいと思われる。
- 追加解析の結果を標準プログラム作成にも反映してゆく。
- 作成する教育プログラムは、基本的には外来患者を対象としたものにし、余裕があれば入院教育プログラムの作成も考慮する。

２．チームメンバーの選定について

- 各職種から2～3名を基本に新たな実働メンバーをご推薦いただく。理学療法士にも加わっていただく。遅くとも4月までには確定する。
- 医師は阿部先生に加わっていただく。24施設からは、作成WGへの直接の参加ではなく、WGで作成した教育プログラムに対してご意見をいただき、反映してゆく形で協力いただくこととする。

３．教育プログラム作成の方向性について
以下のような意見交換をおこなった。

- 作成にあたっては、コアプログラムを作って施設ごとにアレンジいただくものにするか、多様性も加味した汎用性の高いもの（すべてに適用できるもの）にするか、を最初に決めておいた方がよい（岡田先生)。

- コアプログラムをベースに、施設ごとの違いを考慮のうえ追記、補充する形がよいかもしれない（要)。
- 遵守項目が多いほどアウトカムがよいことはデータベース研究でも示されている。同様のことを多施設研究でも示せないか？遵守率向上のためには、多職種連携が重要である、ということであろう（岡田)。
- 多施設研究でも、項目達成とアウトカムとの関係を既存のデータから検討予定である。ただし、教育プログラム作成と同時並行で進めるので、作成には間に合わないかもしれない（要、スライド 24)。
- 課題チェックリストを作成し、達成目標を見える化して、指導効果を判定、課題解決につなげられるものにする。これが山田先生のご要望に応えることにもなる（櫻田、岡田)。
- 効果が高かった施設の指導法を基本とするのがよい（内田)。
- プログラムはどの施設も類似のものを持っているはずなので、指導をより効果的にするためにどうすればよいかが重要である。そのためには、研究成果を盛り込むことや、個別性やヒューマンな部分にも配慮しつつどのように行動変容につなげるかが重要であり、そのことについても触れるべきである（内田)。
- 多職種指導が難しい施設ではどのように指導するかについても考慮する（石川)。
- 24 施設の取り組み事例集を盛り込むとよいのでは？（石川）

４．今回の教育プログラムは、多職種連携マニュアル改訂とは別に、今期の成果物として作成することとする（これを、将来の多職種マニュアル改訂に繋げる)。取りまとめのリーダーとして岡田先生になっていただく。

５．今後は、メンバーを確定後、5 月には第 1 回の WG を開催して本格的な作成をスタートする。

厚生労働科学研究費補助金（腎疾患政策研究事業）
研究課題名：慢性腎臓病(CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究（23FD1001）（研究代表者　要　伸也）

令和 6 年度　第 1 回班会議

日時：2024 年 10 月 20 日(日) 17 時～18 時 30 分

（出席）
研究代表者：要 伸也
研究分担者：柏原直樹、金崎啓造、内田明子、石川祐一、竹内裕紀
研究協力者：櫻田 勉（途中参加)、今村吉彦、八田 告
厚生労働省健康局　難病対策課　がん・疾病対策課：山田洋輔 先生
（欠席）岡田浩一、猪阪善隆、阿部雅紀

（敬称略）

議事録（案）
冒頭、要研究代表者より会議参加への御礼の言葉があり、今回からご参加の研究協力者 3 名の先生からご挨拶があった。

１．ご挨拶：厚生労働省健康局 難病対策課 がん・疾病対策課の山田洋輔先生からご挨拶があった。

２．研究概要、研究計画進捗状の説明（要）（添付スライド資料参照）
次に、研究代表者から、本研究班の研究目的と 5 つの柱について説明があり、前研究班の多施設多職種介入研究の説明に続いて、研究結果をふまえた上での追加解析・追加調査案について、現在の進捗状況の説明があった。

１）追加解析・調査について
多施設介入研究の結果をふまえ、追加解析・追加調査案を CKD チーム医療検 WG コアメンバー会議およびメール、多施設研究説明会（2024 年 10 月 20 日実施）などで検討した。その結果、下記のような追加解析を行うことになり、現在これを進めている。また、下線の計画については、24 施設に追加調査を依頼することになった。

●リサーチクエスチョンと追加検討案は以下の通り：

① 介入効果は何によるか？（職種、介入数以外）
- （すでにデータがあるもの） Hb, 血糖, BMI

- （追加調査）血圧, UA, LDL-C, 通院頻度（継続率）など（ご依頼予定）

データ収集後、今村論文（CEN2017）にならって遵守率を検討する予定。

（新たな前向き研究）塩分摂取量, 服薬アドヒアランス、ヘルスリテラシー評価

② どのような患者群に有効であったか？（DM/非 DM、ステージ以外）

- ①介入時の尿蛋白量, ②介入前の ΔeGFR による違い（解析中）

③ 施設ごとの介入効果の違い、及びこれに関連する因子は何か？

- ①改善の大きい施設の特徴（解析中）⇒ 教育プログラム作成の参考とする

④ 介入後早期に効果を予測する因子はないか？

- ①介入後早期（6 カ月）の尿蛋白減少度と腎機能改善度（解析中）

⑤ 介入効果はいつまで持続するか？

- （追跡調査） 2020 年 12 月以降（3 年以降）の効果を検討（ご依頼予定）

⑥ 経済効果： Gonryo 研究を historical control として G5 患者の透析導入率改善度より概算することも可能だが、精緻な解析ではないため、現在、CEN 論文のうち、透析導入になった患者について途中までの eGFR スロープを年率に換算して加えたデータを用いて、同様の手法でシミュレーションができないか検討中である。Event 数は CKD-JAC（Kidney Int 20217)から推計する（解析中） （Odawara M, Nishi H, et al. Cost-effectiveness of empagliflozin in chronic kidney disease with or without albuminuria.CJASN2024, in press）

⑦ 教育入院と外来指導との比較：すでに終了

⑧ オレンジゾーンの患者に対する効果（とくに G3bA1）：解析予定

２）教育プログラム作成について（WG）

今後、24 施設より収集した多職種介入方法、教育資材を参考に、追加解析・追加調査の結果を随時反映しながら、標準的な多職種教育プログラムの作成を開始することになった。

(WG メンバー） 全体の取りまとめ：要　伸也　（〇各職種のリーダー）

研究分担者：〇岡田浩一、阿部雅紀、金崎啓造、

〇内田明子、〇石川祐一、〇竹内裕紀

研究協力者： 櫻田 勉　今村吉彦　八田 告

看護師、管理栄養士、薬剤師の各領域から、多施設研究参加施設を含めた実働メンバーにご参加いただくよう人選いいただく。また、運動療法が重要なことから、理学療法士の先生にも参加いただくことになった。

3．**質疑応答：**発表内容をふまえて参加者間で質疑応答を行った。
（要点）詳細は後述の発言内容の議事録を参照。

1）遵守率に関する課題と教育の効果（内田先生）

- 遵守率の定義について確認。
- 患者が療養生活に必要なことをどれだけ守れているかが重要である。それらを調査できないかご提案（たとえば受診継続できない理由をアンケート調査する、など）
- 単なる知識補充以外にも、職種間の情報共有や患者の社会的背景の影響を指摘。

2）遵守率の説明（今村先生）

- 単施設研究では、血圧や貧血などの治療目標をガイドラインに基づいて評価。各項目（コレステロール、血圧、HbA1c など）に対する達成度を遵守率として算出したことのご説明があり、多施設研究でもこれに準じた解析ができる。

5）教育プログラムと指導方法の違い（石川先生）

- 病院とクリニックで指導方法に違いがあるため、各施設に適した教育プログラムが必要だとご提案。

6）薬剤師の役割（竹内先生）

- 外来指導においては現実的に薬局薬剤師の役割が重要であること、これを教育プログラムにも盛り込む必要があることをご指摘。
- 外来患者に対する薬剤師の関与を促進すべきとご提案。

7）介入効果と今後の課題（金崎先生）

- 多施設研究の方法論に関するご質問があった（Fig 3 では透析導入患者は除外されていることの確認）
- 新たな研究を計画する際には、糖尿病患者に対する SGLT2 阻害薬の使用を前提とした介入が必要である。投与できない場合の対応も含めたデザインをご提案。
- 運動療法が重要になっているので、教育プログラム作成WGに理学療法士を加えた方がいい。

8）教育入院の重要性（八田先生）

- 教育入院が患者と家族の理解を深める上で重要である。外来指導だけでは教育できない部分をカバーできる。
- 教育入院の効果は証明済みなので、推進のためのインセンティブが求められる。

9）モダリティの解析と今後の調査（櫻田先生）

- 教育介入効果（入院および外来）がもたらす腎不全治療モダリティー選択（血液透析、腹膜透析、腎移植）への影響を調査することをご提案。腎不全治療モダリティーの選択とそれと関連する要因などを検討することが有用である（例えば eGFR スロープの傾きが大きい患者は PD や腎移植を選択されにくい？，介入した職種数とモダリティーとの関連，etc）
- 多職種介入研究で、非糖尿病患者の効果は蛋白尿減少と独立していると考えられるため、その因子が何かを検討することをご提案
- WG 編成の際、多施設研究に参加された各施設のコメディカルスタッフの協力を仰ぐことをご提案。

１０）山田先生より：標準プログラムの作成にあたっては、慢性腎臓病指導管理料の通知に記載されている、「慢性腎臓病のリスク要因に関する評価を行い、その結果に基づいて、指導計画を作成すること」に答えを出すようプログラムを作成してもらいたいとのご要望のご説明があった。

４．今後の展開

２つの WG でそれぞれ追加解析・追加調査、標準的な多職種教育プログラム作成を進め、追加結果の報告（論文化）と多職種連携マニュアルの改訂を目指す。

最後に、山田先生からご挨拶があり、会議終了となった。

●スライド説明後の質疑応答（基本的にはご発言内容通りですが、分かりやすくなるよう一部手を加えさせていただいています）（発言者の敬称略）

内田：ご報告を聞いていてちょっと確認させて欲しいのは、遵守率っていう数字はどのように作っているんでしょうか？何を見て遵守率といっているのか、患者さんが療養生活に必要なことを遵守しているっていうふうな意味の遵守率ですか?
要：血圧や貧血の治療の目標が一応ガイドラインとかで決まっていますよね？スライドでお示しした遵守率は、それがちゃんと守られているかという意味だと思います。今村先生の論文もそうですね？
今村先生：はいそうです。診療ガイドライン 2023 にある程度数字の目標値が出ていますので、例えばコレステロー-ル 120 未満っていうのをどれぐらい遵守しているか、それでそれを各項目いくつかあったらそれが何パーセント守られていたかということです。追加すると、項目はそうなんですけども。
あとは、一人一人どうだったか見るのは、糖尿病以外の方は血圧、それから尿酸、LDL コレストロール等々の 6 項目のうち何項目、糖尿病の方は HbA1c を加えて何項目なんですけど、CKD と DKD では HbA1c が加わるので項目数が違ってきましたので、しょうがなくパーセントで出しました。同じ項目で示すのであれば、岡田先生ら報告されているように 6 項目とか、5 項目で示した方がはっきりと分かったかなと思います。
要：はい。解析方法は細かいことはありますけども、一応そのようなことをこの多施設研究もできないかということを考えているということですね。
内田：ありがとうございました。
要は、いろんな関わり方があるんですけれども、最終的に遵守率は患者さんの検査データがガイドラインに示すデータのどのぐらい標準値にあるかというふうなことを見ているってことですよね？そうすると、具体的に何が効果があって遵守されているのかっていうのをもう少し明らかにしていかなきゃいけないのかなとご報告を聞きながら受けたんですけど。看護の視点から見ると、腎臓病の病態や療養生活で守らなければいけないことのような、知識を補充する教育的な関わりだけが効果があった理由ではないのではないかと感じています。その他に重要な要素があるのではないか、例えばその一つが、職種間の情報共有だったり、あと看護師や療養指導に関わる職員が、患者さんの個別のどの辺に焦点を当てて関わることによって例えば受診率が維持できるとか、そういう知識補充型だけじゃないものの要素が人間なのであるのかなと。例えば患者さんの経済状況とか、今の患者さんの社会的役割の有無だったり、そういういろんな要素に影響を受けているのかなというふうにはちょっと感じたんですね。ただ、全部を調査できないというか、できないとは思うのですけれども、教育プログラムを作るときに、ある程度注意して関わるべきことみたいなのが少し出てくると、実効力のあるプログラムになるのかなという印象がありました。あと教育プログラムの教育というのは患者教育なのか、指導する側の関わる職員の教育プログラムなのかどっ

ちなのかなっていうのを考えていました。
要：ありがとうございます。たしかに患者さんへの関わり方とか数字にあらわれない部分が重要で、どう盛り込むかということですね。おっしゃる通りで、そういったところを本当は知りたいんですけど、今あるデータからは分かりません。追加調査で何かそういったところを取れるものがあれば追加で聞いてみることは可能なので、何かご提案いただければと思います。
内田：私は、治療継続ができなかったら話にならないんじゃないかなって思うんですね。そうするとやっぱり、受診継続がキーな数字なのかなとちょっと思っています。そうなると患者さんに聞けないかなと思いました。受診継続している理由というか、例えば病状のことが心配だからとか薬がなくなるからとか、たとえば心配してくれる医療従事者がいるからとか、受診継続を考えたとしたら実際に中断してしまう理由と継続できている理由というのが少し調査できると違うかなという気がします。
要：アンケートを作って、参加いただいた患者さんに一部でもお答えいただくことはできるかもしれません。ありがとうございます
内田：その数字に、例えば教育入院と外来指導に違いがあるのかとか、その後の受診継続に。そういう数字と絡められると少し関わり方を工夫できるようになるのかなっていう気はちょっとしました
要：ありがとうございました。検討してみましょう。あと、教育プログラム作成ワーキンググループにご参加お願いしたいと思うんですけど、よろしくお願いします。
内田：はい分かりました。何人かちょっと実働メンバーを検討します。
要：はいありがとうございます。それでは次に石川先生、ワークグループご参加いただきたいのと、管理栄養士の立場から何かご意見ございますでしょうか。先ほどの大雑把にお話ししたことはベースにして、今後ワーキンググループで話し合っていくことですけど、この場でも何かございましたらお願いします。
石川：先ほど、今村先生のところの教育プログラムを見せていただきまして、とても素晴らしい内容だなと思って拝見したのですが、今村先生のところのような基幹病院というか、総合病院的なところでやる指導と、クリニックでやる指導というのは、またパターンが違うのかなということをちょっと思っています。私も今、慢性腎臓病透析予防の指導をクリニックで少しだけお手伝いさせてもらっているんですけれども、クリニックは非常に回転を早くしないとということがあってですね、コンパクトに時間を組んでいるんですね。
1 職種も 10 分、15 分ぐらいで回していくような流れになっていまして、このあたりの組み方を、施設に応じ変えたほうがいいのかどうという検討は必要なのかなと思いました。
あとはやはりクリニックになると、問題抽出型というんでしょうか、この患者の問題点が何かをピックアップしてそこだけワンポイントで指導するみたいな形でやっていたり、そういったところが、初診で導入する患者さんに対する指導と、継続的にやっていく患者さんでパターンがいろいろ出てくるのかなというところが少し気になりました。実働メンバーゼ

ひ加えさせていただければありがたいかなと思いますし、私もその中で一緒にやらせていただければと思っております。今気がついたところは以上です。
要：はいありがとうございます。非常に重要なポイントですね、施設に応じてというとこ。こちらで標準的なプログラムを作ってもなかなか実際できないということがあっては困りますので、その辺をどのような形にするか、たとえクリニックと病院に分けるとか、いろいろやり方があると思うんですが、その辺りもまた具体的に検討していければと思います。ワーキンググループの方よろしくお願いいたします。それでは、竹内先生よろしくお願いいたします。
竹内：よろしくお願いいたします。薬剤師の方は今回の診療報酬の方では必須ではなくて望ましいということになっていますけれども、薬剤師としては外来についてはほとんど病院の薬剤師が関与できていない、人数の問題あるんですけど、ただ体系的にやっぱり今は医薬分業で院外処方になっていますので、管理外来患者のお薬は他の疾患でもそうですけどもやっぱり薬局薬剤師に服薬指導とか管理をしていただいていますし、現在その薬局薬剤師の方では薬基法も変わって服薬情報の確認とかも必須になっていますので、外来患者に関しては他の職種と違って薬局薬剤師の関与っていうところをもっと入れて解析できればいいのかなっていうところは思っているところでございます。今トレーシングレポートとかいろいろ病薬連携、薬薬連携もかなり他の疾患でもですね、今回の改正でも心不全の方は調剤の方の診療報酬がついていますし、そういう面で外来患者に関しては薬の指導は薬局薬剤師を絡めて進められたらいいのかなというふうに思っています。以上になります。
（追記：新たな前向き研究に関して、療養生活に関する評価をすることになっているが、問診・質問表などのアンケートでの評価が現実的に可能な方法か思いますので、内田先生のご意見のように、患者の療養生活に必要なことをどれだけ守れているかの調査は必要と思う）
要：ありがとうございます。エビデンスとしては薬局薬剤師の関与というのは盛り込めないとは思いますが、先ほどのスライドでも薬局薬剤師について入れましたように、やはり今回プログラムを作っていく上では、現実問題として薬局薬剤師の先生方にどのように指導に加わっていただくか、考えてゆく必要があるかなと思いますので、その辺りもまたご指導いただければなというふうに思います。あとワーキンググループの方もよろしくお願いいたします。
金崎:：一つ質問は、Ｇ５ の方で透析を除いてとおっしゃっていましたけど、その透析に対しては除いてもベースの低下はマイナス８で下がっていてその後介入で０.７になったという解釈ですか？
要：はい、そうですね、あのデータは透析を除いたら、ということですね。
金崎：透析前もですか？
要：そうだと思います。Ｇ３、Ｇ４は（透析になった患者はほとんどいないので）あまり変わらないと思うんですが、Ｇ５に関しては除いていますので、実際よりは良く見えているかもしれません。実は導入になった人はもうちょっと早いかもしれませんが、今回は除いてい

るんです。ですのでそこは年率に換算して加えないといけない、つまりそのデータをプラスするとおそらく経済効果を解析できるということで今話をしています。
金崎：はい。あともう一点はちょっと今のやっぱり 5 年ぐらい前ともだいぶ時代が変わってやっぱり色々考え方も変わってですね、例えば微量アルブミン尿が出ている糖尿病の方は SGLT2 阻害薬を入れないのは倫理的におかしいことになっているので、こういう多職種連携の時も SGLT2 阻害薬ありきの介入みたいなことが特に糖尿病者も絶対そうならないとおかしいと思うんですね。逆に使えない人どうするんやという時に、使えない人でも例えば栄養をちゃんと取ってもらって使えるようにするとか、そういうことが求められるのが多職種介入の形じゃないかなというふうに思うわけです。ですので、私は次組まれるときの試験としては、エビデンスとある薬、SGLT2 阻害薬を中心にまず投与した、できるところをした状態で介入するというようなデザイン、少なくとも eGFR15 以上という腎臓学会と糖尿病学会のガイドラインであるようなところではやっぱり必要なんじゃないかと思っています。
要：ありがとうございます。そうですね、今後は絶対考えていかないといけないですね。投与できない人にはじゃあどうするかということは今回の介入経験まあそれは一つのヒントになるかもしれませんけど、追加調査、追跡調査するときもそこは必ず聞いて、分かるような形でデータ取っていきたと思います。
金崎：やっぱり投与してない状態で長く引っ張って効果を待っているっていうことが
完全な不利益になってしまうので、そこはやっぱり絶対避けないとダメなので、ぜひともそういうふうにすべきだというふうに思っているところであります。
要：分かりました。ワーキンググループでもご助言いただければと思います。
金崎：はい、いつお声掛けいただきありがとうございます。
要：あと、糖尿病で似たような標準的なプログラムみたいなものってあるんですか?
金崎：いわゆる糖尿指導管理病の形だと思いますけど、ただ今の病院とかそういう入院とかで指導が厳しくなっているのが現実でありまして、それがなかなか伸びている病院と伸びていない病院があるのも事実で、難しいところでもあります。あとはやっぱり運動療法がなかなか入れられないというところがあって、本当はその運動療法がすごく大事なはずなんですけれども、それをなんとかできたらなといつも思っているところであります。
要：ありがとうございます。先ほど思っていて言うの忘れていたのですが、教育プログラムを作っていくにあたっても、今回の診療報酬でも理学療法士さんの介入望ましいって書いてありますので、理学療法士さんの運動療法についても入れていく必要があるんじゃないかと思っていました。
金崎：いやもう絶対そうだと思いますよね。いま腎臓にいいという薬が全部、糖尿病の方はとくに筋肉とか減ったりすることも多いですから、やはり食事もしっかりとりながら運動もするというという時代に来ているというふうに思います。ぜひともお願いしたいと思います。

要：それでは、ワーキンググループに理学療法士さんに加わっていただく方向で検討してみたいと思います。具体的な教育プログラムを作るにあたってご協力していただけそうな理学療法士の先生方がもしいらっしゃったら、また皆さんからもご推薦いただければと思います。
山田：私からも少しよろしいですか。画面共有させていただきたいんですけど。プログラムを作る上で、これは慢性腎臓病指導管理料の通知になるわけなんですけど、こちらの透析予防診療チームは「慢性腎臓病のリスク要因に関する評価を行い、その結果に基づいて、指導計画を作成すること」であるとかこういった指定がされているところではありますので、ぜひここに答えを出すような形でお願いできるととても使いやすいなというふうに思っております。あとこの評価結果指導計画及び実施した指導内容を診療録などに添付パターンを記載することとかですね。どういったことを計画すればいいのかなっていうことが分かるとより臨床で使いやすいのかなというふうに思っております。
要：ありがとうございました。承知いたしました。この通知文も意識したプログラムにしていきたいと思います。さきほど遵守率のところのいくつかの項目のところが、みなリスク要因ですので、ひとつの答えになるかなとは思っています。一点、リスク要因に関しては、ガイドラインの遵守率というところで検討されている岡田先生にメールさせていただきましたところ、例えば糖尿病では 5 本の指で示されているような、いくつかにしぼる、あるいはリスクの重み付けっていうのは CKD ではなかなか難しいということのようです。ガイドラインの推奨度の高い項目を選ぶくらいかとおっしゃっていましたが、この点はもう 1 回岡田先生にも確認してみたいと思います。今回の追加研究でそういったことをある程度言えるかもしれないというのがありますが、いずれにしましても、何らかの形でリスク要因に関し検討していきたいと思っています。ご指導ありがとうございます。
八田先生：よろしいでしょうか。3 点あるんですけども。1 つは、e G FR など非常に檀れいさんがアストラゼネカと共催してコマーシャルをすることで、GFR が下がってきて心配になって受診する人がかなり増えているように思います。そういう効果は非常に絶大だと思っていて、実際に私も外勤行っている病院、近江八幡の病院で腎臓専門外来をやろうとして、僕の患者さんはこの CK D の透析予防の管理の説明をしたら、皆さん受けては下さるんですけども、結構受けてくれないことも、お金がプラスになることとか、時間がどうだとかいうことで、始まってみたものの現場では結構苦労しているところもあります。一方で一般市民の方で、腎臓病は透析になって自分の人生を快適に過ごせなくなる可能性もあるので早めに病院に行って相談して、こういうチームがあるところに相談しましょうという社会的なプロモーションをすることで病院もやりやすくなるんじゃないかなというふうに思います。それは、石川先生のおっしゃったクリニックもそうだし、病院もそうなんですけど、クリニックは、八田医院でも来年 4 月から始めるところでまだまだ整ってないんですけども、やりやくくなると思うので、例え JKA がアストラゼネカなど他の会社とも組んでいると思うので、動画を作って流してもらうっていうのもちょっと一つ考えていただければと思い

ます。
要：柏原先生にお伝えしたいと思います。
八田：みなさんやりやくなると思いますし、診療報酬がつきましたので是非生かしたいと思います。それから、今回エビデンスを出した 3000 名のうち 1600 名は教育入院のデータなんですね。もちろん今村先生の素晴らしいプログラムは多分トップレベルだと思うんですが、他の病院であそこまでトップレベルのことができているかと僕ちょっと疑問ではあるんですが、やっぱり教育入院のデー、たとえば聖マリアンナの桜田先生、近江八幡のデータ、数の多い例えば北野病院とかですね、教育にすごくやっているところがかなりデータを引っ張っている部分はあると思うんですね。一方で、金崎先生がおっしゃったように、教育入院ができなくなっているんですよね、病院が。看護必要度が低いとか、寝ているだけの入院と DPC ケースが一緒ということで、こんなに儲からない入院はさせないと、近江八幡ですら、病院長が外来でしろと言ってきてですね、ちょっと待ってくれエビデンスが出るから、と言って待ってもらっている段階ですので。
ただそれがちょっとしたらエビデンスがすごく良かったのが、教育入院しなくなったことによって、もしかしたら外来だけで限界があるかもしれないので、例えば教育入院をやろうと思っている施設に対して DPC の係数を上乗せしていくようなものができればですね、やっぱりまた教育入院を再開ということがしやすくなるかもしれないので、厚労省で一切教育入院は認めないよっていうふうになれば別なんですが、山田先生にご助言いただいて、ちゃんとしたプログラム遵守してやれば DPC 係数も上げということができれば、このチームでぜひやっていただきたいし、これが私と櫻田先生の悲願でございまして。もう一つはさっきクリニックのれべるで、議論するのはまだちょっと早いかもしれないんですが、次の調査の時にクリニックも入れられたらいいかなと思いました。
要：はいありがとうございました。教育入院に関しましては実際にエビデンス出ているわけですね。今回は加算に関しましては外来に限定していますけども、他の領域で教育入院で何か加算ついているところがあるのかどうかわからないんですけど、何等かの形でインセンティブみたいなものが付けば、教育入院は恐らく効果あるのは間違いないですし、外来の指導にもつながっていくわけですから。CKD だけというのは難しい状況もあるかもしれませんが、教育入院と外来の同じ職種で比較することを除くと、エビデンスとしてはもうだいたい出ていますので。
山田先生：ありがとうございます。おっしゃるとおり教育入院の方についてもそういった声をたくさんいただいております。ちょっと我々の方にも検討したいと思います。
八田：ぜひよろしくお願いいたします
要：そのことは是非今後検討いただくとして、多分我々の方でできるのは、ワーキンググループで検討していくのは、メインは外来教育ですが、教育入院のある程度ひな形的なものをこちらで作ってそれでどうだというふうにこちらで実績を作っていくということも逆に重要かなという気もします。ちょっとそこまで手が回るかどうか分かりませんけども、そうい

ったことも考えてやっていきたいなとは思っています。
八田：ぜひよろしくお願いいたします。入院中に、内田先生がおっしゃった看護師さんとの関わり、家族との関わりというのは、外来だけではなかなか難しい面もあって、櫻田先生も実感されていると思いますけど、やっぱり教育入院したことによってその家族の現状とかどういう人がご飯を作っているんだとか、経済状況とか、いろんなことがやっぱり手に取るように分かって、あと薬剤師さんが必ず介入するんですね。そこに理学療法士入れると、5職種が介入っていう非常に手厚い介入になりますので、いいのだけれど、外来でできればベストだけども、なかなかそういかないので、そういうオプションがあったらいいかなと思っています。すみません、コメントです。
要：いえいえ、ありがとうございました。櫻井先生、何か教育入院だけではなくて全般的なことで結構なんですけどもご意見ございますか？
櫻田：すいません、今日ちょっと遅れてしまいまして申し訳ございません
途中からですが、いくつかちょっと気になることがありましたのでご確認なんですが、センターサイズでの効果ということで検証されるっていうことで前回ワーキングの方でお話をしたんですが、確かにこのセンターサイズでその差が出たところでこの今後の臨床にどう活かしていくかっていうのが非常に悩ましいなと思いました。多分一番データがいいのは八田先生のところ（近江八幡）じゃないかなと思いますので、そうなると数が多いところじゃないと効果がないのかという話になってしまいますとちょっと今後の臨床につなげるのが難しいかなと若干感じたところです。あと 2 点目はですね、前回のデータで集めた透析のモダリティについてのデータはこれまで出してないのかなと思います。これまでのアウトカムはあくまでも死亡と透析導入移植という複合アウトカムなので、それぞれのアウトカムでの検討がされてないではないかなと思います。おそらく 3 100 何名のうち死亡したのが 150 名で、透析移植に入ったのが 700 名以上というところなので、個人的な印象ですけども、おそらく教育を受けた方々は、PD や移植の選択率がおそらくかなり高いんじゃないかなというふうに思ってます。
それはおそらくその結果としては、SDM も含めですけども情報提供も入院であったり外来であったり手厚い対応してるので、そういうモダリティが適切な選択率になってるんじゃないかなと。これはデータまだあるはずですが、解析していなかったんではないかなというふうに思います。さっきデータシート確認していてちょっと思ったので、ここはデータとして出せるんじゃないかなと思す。これまでも SDM すると 30%ぐらいの PD 選択率であったり、移植の選択率はどうだっていうデータは出ていますので、そういったところと比較するという追解析はぜひともちょっと検討していただきたいなというふうに思っています。
あと次なんですが、蛋白尿の減少と eGFR の低下速度の関係ですけど、これはすでに CEN で阿部先生が確か出されていたというふう認識しております。糖尿病の患者さんは介入後に確実に 2 年間通じて蛋白尿が減っていたのが、非糖尿病の患者さんたちは 6 ヶ月後だけが蛋白尿も減ってたんですけど 1 年後 2 年後は確か有意差がなかったんじゃないかという

ふうに思います。そうすると非糖尿病の患者さんたちの eGFR のスロープに影響を与えたのは、蛋白ではないということになるとじゃあ何なのかっていうところに関して、解析をできるんだったらすべきかなというふうにちょっと思いました。最後にすいません、多くて申し訳ないんですが、先ほど要先生の方から実働のコメディカルの方の参加という話あったと思うんですけど、私は可能であればですね今回ご参加いただいたご施設のコメディカルの方々にご協力をお願いするのが、一番成果を出した人たちですので、ご協力をいただくのが一番いいんではないかというふうに思った次第です。すいません以上です

要：はい、ありがとうございました。分析のモダリティに関しましては多分すぐ聞けますよね。一般的なデータとの比較するだけなら、すぐ数字が出ると思いますので、是非追加調査したいと思います。それかご参加いただく追加メンバーをこれから検討するにあたって、参加 24 施設の中の方々ということですね。

櫻田：たぶん資料を提供されたのも多分それらの方だと思いますので、その方々で最適な指導内容を詰めていただくというのがいいのではないかと。

要：ありがとうございます。少なくと 1 名はそういった方々にも入っていただくということがいいかもしれませんね。24 施設だけ言うことになりますと全く知らない先生方かもしれませんので、複数参加いただくというのがいいかなと思いました。その辺りも石川先生、内田先生、竹内先生とご相談させていただければと思います。まずは施設の名簿をお送りいたしますので、それも参考にして人選をお願いしたいなというふうに思います。貴重なご意見ありがとうございました。

八田：今日の会議資料は後ほどいただけるんでしょうか？

要：はい、議事録は少しお時間いただきたいんですけども、今日の資料はすぐに送りいたします。

八田：ちょっと確認したかったことが何点かあったので、すいませんがよろしくお願いします。

要：皆さん方からの発言は一通りいただいたかと思いますけど、ほかにいかがでしょうか。本日は本当に貴重なご意見をどうもありがとうございました。一応今日ご説明したようなスケジュールで今後進めていきたいと思います。いくつか方向性も定まってきましたし、これから取り組み加速していきたいと思いますので、ぜひ皆様ご協力いただければ幸いです。新たに追加解析、追加調査ご提案とかがございましたらお送りいただきたいですし、ワーキンググループの方もぜひよろしくお願いしたいなというふうに思います。えーとそれでは、最後に、本日柏原先生ご欠席ですので、山田先生に締めのお言葉をいただければありがたいです。

山田先生：本日はありがとうございました。大変勉強になりました。まさに先ほどディスカッションをいただいたことはとても重要でして、この多職種連携の慢性腎臓病透析予防指導管理料ついているところではあるんですけれども、やはりまだなかなか具体性だとか、どういったことを進めればよいか、計画ってどういうふうにやったらいいのかとか、リスク因

子って何なのかとかいろんなご意見いただいているところですので、ぜひここで標準化されたプログラムが出ることで、世の中の方々が快適にそれを進められる、それによって CKD の進行が抑えられるとそういったようなプログラムぜひ作っていただきたいと思いますので、引き継ぎ指導の方よろしくお願いいたします
要：ありがとうございました。こちらこご指導のほどよろしくお願いいたします。
そうしましたら、本日は日曜の夕方のお忙しいところ 1 時間半に渡って、さまざま議論いただきましてありがとうございました。

2025年3月20日

厚生労働科学研究費補助金（腎疾患政策研究事業）2023-2025年度
慢性腎臓病(CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究

教育プログラム作成WGスタートアップ会議

研究代表者
要 伸也
（吉祥寺あさひ病院/杏林大学）

0

厚生労働科学研究費補助金（腎疾患政策研究事業）
研究課題名：慢性腎臓病(CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究（23FD1001）（研究代表者　要　伸也）

令和6年度　第1回教育プログラム作成WGコアメンバー会議

日時：2025年3月20日(日) 10時30～12時（予定）

研究代表者：要 伸也
研究分担者：岡田浩一、内田明子、石川祐一、竹内裕紀
研究協力者：櫻田 勉、今村吉彦、八田 告（敬称略）

議事次第
1. 経緯、趣旨説明（前回議事録参照）

2. 今後の進め方
- チームメンバーの選定
- 教育プログラム作成の目標
- 教育プログラムの内容について
  - 介入に加わる職種
  - 介入方法
  - 介入時間・回数/頻度
  - 介入の内容： 用いる教育資材

3. その他、次回の予定

1

厚生労働科学研究費補助金（腎疾患政策研究事業）2023-2025年度
慢性腎臓病(CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究

1. 多職種連携のエビデンス構築：
   前研究班の実証研究の追加解析を行い、残された課題の追加研究を検討する。多職種連携の実態把握や既存のエビデンス収集を継続する。
2. 多職種による教育プログラムの開発：
   実証研究の実施施設を中心に介入方法・資材の収集を行い、有効な介入方法の分析等より、標準化された教育プログラムを開発する。
3. マニュアルの有効活用の推進：
   CKD多職種連携マニュアルの有効活用と普及に努める。腎臓病療養指導士ガイドブック等の改訂に際して、マニュアルの内容や本研究班成果を反映させる。
4. ホームページによる成果の公表：
   得られた成果・コンテンツをホームページ等で公表することにより、全国的な周知と普及を目指す。
5. 課題解決のための戦略案策定

2

厚労科研費 研究班

教育プログラム作成WGコアメンバー

研究代表者：要 伸也
吉祥寺あさひ病院/杏林大学医学部

研究分担者：

柏原直樹	川崎医科大学 腎臓・高血圧内科学
岡田浩一	埼玉医科大学 医学部
猪阪善隆	大阪大学大学院医学系研究科
阿部雅紀	日本大学 医学部 腎臓高血圧内分泌内科学
金崎啓造	島根大学第一内科学
石川祐一	茨城キリスト教大学 生活科学部食物健康科学科
内田明子	さとうクリニック 看護部
竹内裕紀	東京医科大学 薬剤部

研究協力者：

櫻田 勉	聖マリアンナ医科大学
今村吉彦	日産玉川病院
八田 告	八田医院

3

厚生労働科学研究費補助金（腎疾患政策研究事業）2023-2025年度（第2期）
慢性腎臓病(CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究



わが国における多職種連携の介入のエビデンス創出と標準的な教育プログラムの開発

4

今後の展開

◆Plan 1　効果検証WG
1）追加解析/追加調査案を作成

✓介入効果は何によるか？
✓どのような患者に有効であったか？
✓施設間の効果の違いと関連する因子
✓介入早期に効果を予測する因子
✓効果はどこまで持続するか？
✓外来指導と教育入院の違い
✓オレンジゾーンの介入効果
✓経済効果、など

結果報告会後、追加研究を実施

結果の解析 → 報告・論文化

反映

◆Plan 2　標準PG作成WG
2）標準教育プログラム案の作成
24施設から収集した資料をベース）

標準教育プログラムの完成

◆現行の多職種連携マニュアルの普及 → マニュアルの改訂

2つのWG でそれぞれ追加解析・調査と標準的な多職種教育プログラム作成を進め、論文化と多職種連携マニュアルの改訂を目指す。

5

多職種介入研究の患者背景　24施設 3,015名

患者背景

N（男性/女性）	3,015 (2,237/778)
男性(%)	74.2
年齢（歳）	70.5±11.6
原疾患 n (%)	
DKD	1,321 (43.8)
CGN	384 (12.7)
腎硬化症	897 (29.1)
ADPKD	88 (2.9)
その他・不明	328 (10.9)
CVDの既往 n (%)	885 (29.4)
BMI（kg/m2)	24.2 ± 4.3
Hb (g/dL)	11.7 ± 1.9
Alb (g/dL)	3.7 ± 0.5
BUN (mg/dL)	32 [23-45]
Cr (mg/dL)	2.08 [1.48-3.14]
eGFR (mL/分/1.73m2)	23.5 [15.1-34.4]
尿蛋白（g/gCr)	1.13 [0.24-3.1]
HbA1c (%) DM例のみ	6.4 ± 1.0

介入方法

外来/入院 n (%)	1246/1769 (41.3/58.7)
外来回数（回）	4 [1-11]
入院日数（日）	7 [6-12]
職種	
看護師	2600(86.2%)
管理栄養士	2726（90.4%）
薬剤師	1878（62.3%）
理学療法士	781（25.9%）
臨床検査技師	178（5.9%）
ソーシャルワーカー	72 (2.3%)
臨床工学技士	18（0.6%）
その他	31(2.3%)
職種数	4 [3-5]
2職種	700（23.2%）
3職種	416（13.8%）
4職種	882 (29.2%)
5職種	994（33.0%）
6職種以上	23（0.8%）

・日本腎臓病協会腎臓病療養指導士評価普及小委員会腎臓病療養指導士によるCKD 多職種連携（CKD チーム医療）
・CKD 患者に対する外来および入院での教育を検証するワーキンググループ厚生労働科学研究費補助金（腎疾患政策研究事業）
CKD 患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究班

6

多職種介入前後のCKD進行率の比較

全例（n=3,015）での検討



多職種介入

糖尿病例（n=1,321）



非糖尿病例（n=1,696）



・日本腎臓病協会腎臓病療養指導士評価普及小委員会腎臓病療養指導士によるCKD 多職種連携（CKD チーム医療）
・CKD 患者に対する外来および入院での教育を検証するワーキンググループ厚生労働科学研究費補助金（腎疾患政策研究事業）
CKD 患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究班

(Abe M, Kaname S. Clin Exp Nephrol 2023)

7

7

多職種介入前後のCKD進行率の比較（ステージ別）



・日本腎臓病協会腎臓病療養指導士評価普及小委員会腎臓病療養指導士によるCKD 多職種連携（CKD チーム医療）
・CKD 患者に対する外来および入院での教育を検証するワーキンググループ厚生労働科学研究費補助金（腎疾患政策研究事業）
CKD 患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究班

(Abe M, Kaname S. Clin Exp Nephrol 2023)

8

スタッフ数と介入回数が多いほど複合腎アウトカムが改善する

複合アウトカム: 死亡および透析導入

スタッフ数
介入数

Variables	HR	95%CI	P-value
Number of MDC team members (increase by 1)	0.85	0.80-0.89	< 0.0001
Number of interventions by MDC team (increase by 1)	0.97	0.96-0.98	< 0.0001

CI, confidence interval; MDC, multidisciplinary care; HR, hazard ratio; SE standard error.

スタッフ数、介入数が多いほど有効



管理栄養士、理学療法士の介入が有効

(Abe M, Kaname S. Clin Exp Nephrol 2023)

9

職種数による比較



(Abe M, Kaname S, Kid Res Clin Pract 2023)

入院と外来の比較



(Abe M, Kaname S, Front Endocrinol 2023)

・日本腎臓病協会腎臓病療養指導士評価普及小委員会腎臓病療養指導士によるCKD 多職種連携（CKD チーム医療）
・CKD 患者に対する外来および入院での教育を検証するワーキンググループ厚生労働科学研究費補助金（腎疾患政策研究事業）
CKD 患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究班

10

10

Research Question

- ✓ 介入効果は何によるか？
- ✓ どのような患者に有効であったか？
- ✓ 早期に介入効果を予測する因子はないか？
- ✓ 効果はどこまで持続するか？
- ✓ 外来指導と教育入院の違い
- ✓ 施設ごとの介入効果の違いと関連する因子はないか？
- ✓ 経済効果

など

①ヒートマップ別　②介入前のΔeGFR　③介入時の尿蛋白量

11

ヒートマップ別:

ヒートマップ
赤
n=2305

ヒートマップ
オレンジ
n=365

ヒートマップ
黄色
n=137



介入前後のΔeGFR/year

ΔeGFR（ml/min/1.73m2/year）

12

ベースラインの尿蛋白(A1-3区分別)

A1
n=504

A2
n=450

A3
n=1736



蛋白尿量によらず介入効果が認められる

13


ヒートマップ　G3bA1
n=264
尿蛋白量(g/gCr)の変化
G3bA1 (n=264)
0.07 [0.04-1.00]
0.08 [0.05-0.15]
0.09 [0.05-0.14]
0.08 [0.05-0.16]
介入前　6カ月　12カ月　24カ月
ΔeGFR/year
P < 0.0001
P=0.0006
P=0.002
1.01
0.01
-0.85
-3.56
介入前　6カ月　12カ月　24カ月
G3a (n=280)
G3b (n=761)

14


介入前1年間のΔeGFR 4分位
ΔeGFR>-8.8 (mL/min/1.73m2/y) n=366
ΔeGFR -8.8~-5.3 (mL/min/1.73m2/y) n=366
ΔeGFR -5.3 ~-1.89 (mL/min/1.73m2/y) n=365
ΔeGFR <-1.89 (mL/min/1.73m2/y) n=366
-0.20 -1.25 -1.28
-14.8
-0.42 -1.46 -1.60
-7.08
-0.52 -1.49 -1.47
-3.65
-0.90 -1.25 -2.07 -2.54
介入前　6カ月　12カ月　24カ月
p<0.0001
p=0.309
p=0.0002
p=0.025 p=0.012 p=0.029
p=0.738 p=0.364 p=0.576
p=0.199 p=0.419 p=0.870
2.19 1.65 1.20 0.92
1.83 1.69 1.67 1.60
1.15 1.13 1.13 1.13
0.67 0.50 0.58 0.68

15

追加解析：小括

- 多職種介入により、糖尿病・非糖尿病のCKDのG3b以上、オレンジゾーン以上のCKD患者において介入効果が見られた。ステージG3bA1でも有効であった。
- 介入効果は、介入前のeGFRスロープが大きいほど強い傾向があった。
- 一方、介入効果はベースラインの蛋白尿量とは無関係であった。

16

令和６年度診療報酬改定　Ⅲ－５　生活習慣病の増加等に対応する効果的・効率的な疾病管理及び重症化予防の取組推進－④

慢性腎臓病の透析予防指導管理の評価の新設

2024年6月開始

慢性腎臓病の透析予防指導管理の算定要件及び施設基準

- 慢性腎臓病の患者に対して、透析予防診療チームを設置し、日本腎臓学会の「エビデンスに基づくCKD診療ガイドライン」等に基づき、患者の病期分類、食塩制限及び蛋白制限等の食事指導、運動指導、その他生活習慣に関する指導等を必要に応じて個別に実施した場合の評価を新設する。

（新）　慢性腎臓病透析予防指導管理料
1　初回の指導管理を行った日から起算して１年以内の期間に行った場合　300点
2　初回の指導管理を行った日から起算して１年を超えた期間に行った場合　250点
※　情報通信機器を用いて行った場合は、それぞれ261点、218点

［算定要件］（抜粋）
慢性腎臓病の患者（糖尿病患者又は現に透析療法を行っている患者を除く。）であって、医師が透析予防に関する指導の必要性があると認めた入院中の患者以外の患者に対して、医師、看護師又は保健師及び管理栄養士等が共同して必要な指導を行った場合に、月１回に限り算定する。



［施設基準］（抜粋）
（１）当該保険医療機関内に、以下から構成される慢性腎臓病透析予防診療チームが設置されていること。
ア 慢性腎臓病指導の経験を有する専任の医師（５年以上の経験）
イ 慢性腎臓病指導の経験を有する専任の看護師（３年以上の経験）又は保健師（２年以上の経験）
ウ 慢性腎臓病指導の経験を有する専任の管理栄養士（３年以上の経験）
（２）（１）のア、イ及びウに掲げる慢性腎臓病透析予防診療チームに所属する者のいずれかは、慢性腎臓病の予防指導に係る適切な研修を修了した者であることが望ましいこと。
（３）（１）のア及びイに規定する医師、看護師又は保健師のうち、少なくとも１名以上は常勤であること。
（４）（１）に規定する医師、看護師又は保健師及び管理栄養士のほか、薬剤師、理学療法士が配置されていることが望ましいこと。
（５）腎臓病教室を定期的に実施すること等により、腎臓病について患者及びその家族に対して説明が行われていること。
（６）慢性腎臓病透析予防指導管理料を算定する場合は、様式を用いて、患者の人数、状態の変化等について、報告を行うこと。

99

糖尿病以外の保存期CKDに対するチーム医療に対しても加算が新設

17

◎CKDの重症度分類（ステージ）

原疾患		蛋白尿区分		A1	A2	A3
糖尿病		尿アルブミン定量 (mg/日) 尿アルブミン/Cr比 (mg/gCr)		正常	微量アルブミン尿	顕性アルブミン尿
				30未満	30～299	300以上
高血圧 腎炎 多発性嚢胞腎 腎移植 不明、など		尿蛋白定量 (g/日) 尿蛋白/Cr 比 (g/gCr)		正常 (－)	軽度蛋白尿 (±)	高度蛋白尿 (＋～)
				0.15未満	0.15～0.49	0.50以上
GFR区分 (mL/分/1.73m²)	G1	正常または高値	≧90			
	G2	正常または軽度低下	60～89			
	G3a	軽度～中等度低下	45～59			
	G3b	中等度～高度低下	30～44			
	G4	高度低下	15～29			
	G5	高度低下～末期腎不全	＜15			

レッドゾーンが加算の対象

18

Research Question

- ✓ 介入効果は何によるか？
- ✓ どのような患者に有効であったか？
- ✓ 早期に介入効果を予測する因子はないか？
- ✓ 効果はどこまで持続するか？
- ✓ 外来指導と教育入院の違い
- ✓ 施設ごとの介入効果の違いと関連する因子はないか？
- ✓ 経済効果

など

19

早期であるほど透析遅延効果は大きい（シミュレーション）



・日本腎臓病協会腎臓病療養指導士評価普及小委員会腎臓病療養指導士によるCKD 多職種連携（CKD チーム医療）
・CKD 患者に対する外来および入院での教育を検証するワーキンググループ厚生労働科学研究費補助金（腎疾患政策研究事業）
CKD 患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究班

Odawara M, Nishi H, et al. Cost-effectiveness of empagliflozin in chronic kidney disease with or without albuminuria. CJASN2024, in press.

Cardiovascular events and death in Japanese patients with chronic kidney disease

Kenichi Tanaka[1], Tsuyoshi Watanabe[1], Ayano Takeuchi[2], Yasuo Ohashi[3], Kosaku Nitta[4], Tadao Akizawa[5], Seiichi Matsuo[6], Enyu Imai[7], Hirofumi Makino[8] and Akira Hishida[9]; for the CKD-JAC Investigators

CrossMark OPEN

Event数はCKD-JAC（Kidney Int 20217)から推計

FIGURE 1



Table 4. Scenario analysis: Empagliflozin suppressing eGFR decline in negative albuminuria cohorts

		Empagliflozin, Standard therapy
CKD G3a	Cost	¥9.04 million ($64.1 thousand), ¥8.36 million ($59.3 thousand)
	QALY	13.73, 13.62
	ICER (/ QALY)	¥6.43 million ($45.6 thousand)
CKD G3b	Cost	¥11.91 million ($84.5 thousand), ¥11.98 million ($85.0 thousand)
	QALY	13.01, 12.83
	ICER (/ QALY)	Empagliflozin superior
CKD G4 (eGFR>20ml/min/1.73m²)	Cost	¥19.10 million ($135.5 thousand), ¥18.82 million ($133.5 thousand)
	QALY	12.02, 11.93
	ICER (/ QALY)	¥2.91 million ($20.6 thousand)

同様の手法で経済効果の解析が可能か検討中

Research Question

- ✓ 介入効果は何によるか？
- ✓ どのような患者に有効であったか？
- ✓ 早期に介入効果を予測する因子はないか？
- ✓ 効果はどこまで持続するか？
- ✓ 外来指導と教育入院の違い
- ✓ 施設ごとの介入効果の違いと関連する因子はないか？
- ✓ 経済効果

など

達成目標の遵守率、服薬アドヒアランス、減塩効果、通院頻度、など

22

Relationship between compliance with management target values and renal prognosis in multidisciplinary care for outpatients with chronic kidney disease

（CEN 2022）

Yoshihiko Imamura[1] · Yasunori Takahashi[1] · Takato Take
Rie Nakamura[3] · Yuka Ogawara[4] · Kazuyo Takeba[4] · Makot

多職種介入は遵守率の向上を通じて腎生存率を増加させる

対象：CKD G2-5の保存期CKD患者
250名（平均eGFR 31.6）

多職種介入：4回の外来指導
後ろ向き試験



各パラメータの12か月後の遵守率

腎生存率



遵守率：
Group A <30%
Group B 30-60%
Group C 60-80%
Group D >80%

23

追加調査　新たなデータが必要なもの

□ 介入効果は何によるか？

新たな項目を後ろ向きに再調査（介入前後）
→総合的な遵守率

調査施設：コア施設
（＋一部参加施設）

□ 効果はどこまで持続するか？

・2015年1月～2020年12月まで（2年まで）→延長

SGLT2阻害薬の影響も考慮

追跡調査：全参加施設

□ 新たな前向き研究（今後計画）

・塩分摂取量（畜尿or田中の式）
・服薬アドヒアランス測定（Marsなど），ヘルスリテラシー評価（HLS-EU-Q47など）

24

今後の展開

◆Plan 1　効果検証WG
1）追加解析/追加調査案を作成

✓介入効果は何によるか？
✓どのような患者に有効であったか？
✓施設間の効果の違いと関連する因子
✓介入早期に効果を予測する因子
✓効果はどこまで持続するか？
✓外来指導と教育入院の違い
✓オレンジゾーンの介入効果
✓経済効果、など

結果報告会後、追加研究を実施

結果の解析

反映

報告・論文化

◆Plan 2　標準PG作成WG
2）標準教育プログラム案の作成
24施設から収集した資料をベース）

標準教育プログラムの完成

マニュアルの改訂

◆現行の多職種連携マニュアルの普及

2つのWG でそれぞれ追加解析・調査と標準的な多職種教育プログラム作成を進め、論文化と多職種連携マニュアルの改訂を目指す。

25

教育プログラム作成WG　今後の進め方

1. チームメンバーの選定
2. 教育プログラム作成の目標
3. 教育プログラムの内容について
   - 介入に加わる職種
   - 介入方法
   - 介入時間・回数/頻度
   - 介入の内容：用いる教育資材

→ 標準的な教育プログラムの提案

26

	施設名	介入に加わった職種	介入方法	介入の内容	介入の時間	教育資材の有無（＊は資材提供あり）	専門資格の有無（療養士の介入、etc）
1	日産玉川病院	専門知識のある医師・看護師・管理栄養士・薬剤師（4職種）	同じ外来受診日に4職種が療養指導。これを1セットとして、合計4セット実施。	職種毎にプログラムあり。	医師約15分、それ以外は1職種につき約30分	あり＊	あり
2	日本大学医学部附属板橋病院	専門知識のある医師・看護師・管理栄養士（3職種）	外来受診日に3職種が療養指導。これを1セットとし、2～4セット実施。(最低2セット)	初回は看護師と管理栄養士は別々。2回目以降は初回の状況次第で合同で行う。	1職種15～30分(初回30～60分)。2回目以降は計30分。	あり＊	あり：看護師と管理栄養士は腎臓病療養指導士
3	奈良県総合医療センター	専門知識のある医師・看護師・管理栄養士（3職種）	外来受診日に3職種が療養指導。これを1セットとし、1セット実施。カンファレンスで不足があれば、2セット目を追加	看護師と管理栄養士は別々。	DVD	あり(DVD)＊	あり：管理栄養士は腎臓病療養指導士
4	明石医療センター	専門知識のある医師・看護師・管理栄養士（3職種）	外来受診日に3職種がCKD導は複数回実施することも多い（患者や主治医の意向によって決定）	看護師へ、主治医からの指導依頼内容を事前に伝達している。	医師は10～15分、看護師・管理栄養士は原則的に30分であるが変動あり。	あり＊	あり：管理栄養士のうち1名は腎臓病療養指導士
5	田附興風会医学研究所北野病院	専門知識のある医師・看護師・管理栄養士（3職種）	外来受診日に3職種がCKD療養指導。これを1セットとし、1～2セット実施。糖尿病透析予防指導では4回シリーズ。	看護師による生活指導と管理栄養士による栄養指導	医師は10分、それ以外は1職種につき30-60分	あり＊	あり：看護師と管理栄養士は腎臓病療養指導士
6	聖マリアンナ医大病院	専門知識のある医師・看護師・管理栄養士（3職種）	外来受診日に3職種がCKD療養指導。管理栄養士による栄養指導と看護師による生活指導（腎看護相談）は別日に実施。	患者のステージに応じた支援	医師は10-15分、それ以外は1職種につき30分	あり＊　（資材は教育入院用。栄養指導資材は同じものを外来でも使用）	あり：看護師と管理栄養士はほとんどが腎臓病療養指導士
7	聖マリアンナ医大横浜市西部病院	外来で多職種指導は実施できていない。医師より依頼がある時に栄養士が栄養相談実施。	尚、当院には腎臓病療養指導士取得の栄養士はいない。				
8	奈良県総合医療センター	専門知識のある医師・看護師・管理栄養士（3職種）	外来受診日に3職種がCKD療養指導。これを1セットとし、1セット実施。カンファレンスで不足があれば、2セット目を追加	看護師と管理栄養士は別々。	①管理栄養士（30分） ②看護師：DVD視聴（20分）、指導（30分） ③医師診察　10分	あり(DVD・紙)	あり：管理栄養士は腎臓病療養指導士
9	近江八幡市立総合医療センター	専門知識のある医師・看護師・管理栄養士（3職種）	蓄尿検査結果に基づき栄養指導間隔は変動、看護師指導は教育入院後3・6・12・24ヵ月で実施	減塩不良症例（自宅蓄尿）に管理栄養士による継続的な栄養指導、看護師による療養行動における患者行動変容の確認（患者アンケート実施）とその結果に基づく指導	1回15-30分程度	なし	あり：看護師と管理栄養士は腎臓病療養指導士
10	三思会東邦病院	専門知識のある医師・看護師・管理栄養士（3職種）	外来受診日に3職種がCKD療養指導。	看護師と管理栄養士が別々に指導。看護師は腎代替療法について説明、栄養士はCKDに対する食事指導	1職種15～30分	冊子「腎不全治療選択とその実際」、DVD「守りたい あなたらしさ～透析とともに～」JNPO法人腎臓サポート協会などを使用	あり
11	京都大学医学部附属病院	専門知識のある医師・管理栄養士（2職種）	外来受診日に栄養指導を受けて頂く。回数は設定していない。	外来日に合わせて栄養指導をセットし、継続的に指導する。	1職種15分。	なし	あり
12	順天堂大学医学部附属練馬病院	専門知識のある医師・看護師・管理栄養士（3職種）	外来受診日に3職種がCKD療養指導。これを1セットとし、2～4セット実施。(最低2セット)	初回は看護師と管理栄養士は別々。2回目以降は初回の状況次第で合同で行う。	1職種15～30分(初回30～60分)。2回目以降は計30分。	あり＊	あり：看護師と管理栄養士は腎臓病療養指導士
13	長崎大学病院腎臓内科	専門知識のある医師・看護師・管理栄養士（3職種）	外来受診日に医師・看護師でCKD療養指導、必要時管理栄養士を交える(1-2回)。	CKDや透析内容の説明、食事内容の確認。問題があれば栄養士の介入。希望時透析の見学・デモ。	合計30～60分程度	なし	あり
14	大阪公立大学医学部附属病院	糖尿病の透析予防外来として実施（依頼あればCKDも対応）	毎週月曜日に3職種で指導。3ヶ月に1回の頻度で4回を1クール（1年）で一通りの内容を説明。希望があれば繰り返す。	添付する資料をもとに、担当の看護師、管理栄養士から指導	1職種15～30分。	あり＊	あり：（糖尿病・腎臓）専門医・専任看護師・管理栄養士
15	藤枝市立総合病院	専門知識のある医師・透析室看護師・管理栄養士（3職種）	外来日に3職種が療養指導。透析室看護師が家人同伴で初回, eGFR30未満, eGFR15未満の最低3回は行い、以降は患者の病態、理解度、家庭環境などに応じて適宜追加。	栄養指導：管理栄養士が腎臓内科外来受診の待ち時間に実施。 CKD指導：透析室看護師が、3分冊のCKD指導テキストに基づき指導	医師の指導は外来診療時間 栄養指導は20～30分 CKD指導は30～60分	あり＊ 3分冊のCKD指導テキスト	あり：看護師と管理栄養士は腎臓病療養指導士を含む
16	医療法人埼友会埼友草加病院	専門知識のある医師・看護師・管理栄養士・薬剤師・公認心理師・社会福祉士（6職種）	主にCKDステージG4から介入。外来受診毎に職種（医師・看護師・管理栄養士）がCKD療養指導。必要に応じて他の職種も介入・指導	初回は看護師が介入し患者背景を把握する。その状況に応じて初回当日もしくは次の受診時に管理栄養士・薬剤師が介入	医師は10～20分、看護師初回30～60分。他職種含め2回目以降は各20～30分程度	あり	あり：看護師、管理栄養士は腎臓病療養指導士、薬剤師は日本腎臓病薬物療法認定薬剤師

27

27

施設ごとの介入効果の違い



28

CKD 外来　スケジュール 【CKD ステージ 1～5】　日産玉川病院

	第１回	第２回	第３回	第４回
医師	診察 検査結果の説明 処方	診察 検査結果の説明 処方	診察 検査結果の説明 処方	診察 検査結果の説明 処方
看護師	《透析室看護師》 ・問診（既往歴、日常生活など） ・血圧管理について ・体重管理について ・検査結果の説明 「あなたの腎臓を守るために」 ・腎臓の機能について ・自分の腎臓の状態について	《透析室看護師》 「あなたの腎臓を守るために」 ・検査について ・食事療法 ・薬物療法 ・日常生活の注意点 ・検査結果の説明	《透析室看護師》 「あなたの腎臓を守るために」 ・腎代替療法選択指導について ・血圧・体重測定の確認 ・検査結果の説明	《透析室看護師》 ・足のケアについて ・足病変の原因 ・予防 ・フットケア ・検査結果の説明 ・まとめ
栄養士	・腎臓食総論 ・食事調査からのアドバイス （塩分・タンパク質を控える）	・熱量、塩分、タンパク質、カリウム、リンについて ・献立作成・成分調整食品の有効利用について	・美味しく食べるコツ （食品選択、調理法の工夫） ・間食、外食の選び方 ・献立表の提出	・献立内容の考察 ・検査値の確認 ・ストレスなく継続できる食事摂取
薬剤師		・現在内服している薬の確認 ・市販薬の使用について		

29

CKD 外来　スケジュール　【CKD ステージ 1～5】　日産玉川病院

＊定期的に繰り返す（少なくとも●回以上：介入回数は多い方が効果的）

	第１回	第２回	第３回	第４回
医師	診察 検査結果の説明 処方（内容の説明）	診察 検査結果の説明 処方	診察 検査結果の説明 処方	診察 検査結果の説明 処方
看護師	《透析室看護師》 ・問診（既往歴、日常生活など） ・血圧管理について ・体重管理について ・検査結果の説明・脱水の回避 「あなたの腎臓を守るために」 ・腎臓の機能について ・自分の腎臓の状態について	《透析室看護師》 「あなたの腎臓を守るために」 ・検査について ・食事療法 ・薬物療法 ・日常生活の注意点 ・検査結果の説明	《透析室看護師》 「あなたの腎臓を守るために」 ・腎代替療法選択指導について ・血圧・体重測定の確認 ・検査結果の説明	《透析室看護師》 ・足のケアについて ・足病変の原因 ・予防 ・フットケア ・検査結果の説明 ・まとめ
栄養士	・腎臓食総論 ・食事調査からのアドバイス （塩分・タンパク質を控える） ・カロリー、水分を十分に ＊カリウム制限（一般論、高Kなら具体的に）	・熱量、塩分、タンパク質、 カリウム、リンについて ・献立作成・成分調整食品の 有効利用について ・理解度の確認 ・リン制限（高P血症の場合） ＊カリウム制限とその確認	・美味しく食べるコツ （食品選択、調理法の工夫） ・間食、外食の選び方 ・献立表の提出 ・食事遵守状況の確認	・献立内容の考察 ・検査値の確認 ・ストレスなく継続できる 食事摂取
薬剤師		・現在内服している薬の確認 ・市販薬の使用について （内容の確認、必要性の説明） ・服薬の注意点（シックデイ、避けるべき薬、併用禁忌など） ・服薬遵守状況の確認		・理解度の確認 ・服薬遵守状況の確認

＊早めの栄養士の介入が望ましい

＊医師と看護師は毎回情報共有

＊3職種（できれば4職種）で定期的に情報共有するのが望ましい（職種が多い方が効果的）

＊薬剤師の介入が望ましいが、医師または看護師からの指導でも可
＊調剤薬局との連携が望ましい（CKDシールなど）

＊薬剤師の介入が望ましいが、医師または看護師からの指導でも可

＊少なくとも1名は腎臓病療養士指導士が指導にあたることが望ましい

＊可能であれば理学療法士による運動療法の指導も考慮する

30

DMCKD 外来　スケジュール

★CKD 外来指導を受ける方へ　それぞれの指導に 30 分ほどお時間がかかります。腹部エコーや腹部 CT、胃・大腸カメラなどの検査がない方は朝食や昼食を食べて頂いてもかまいません。

	第１回	第２回	第３回	第４回	第５回
医師	・診察 ・検査結果の説明 ・処方	・診察 ・検査結果の説明 ・処方	・診察 ・検査結果の説明 ・処方	・診察 ・検査結果の説明 ・処方	・診察 ・検査結果の説明 ・処方
看護師	《透析室看護師》 ・CKD 外来について ・問診（既往歴、日常生活など） ・血圧と体重測定について ・検査結果の説明 ・自分の腎臓の状態について ・腎臓の機能について	《透析室看護師》 ・検査について ・食事療法 ・薬物療法 ・日常生活の注意点 ・検査結果の説明 ・血圧と体重測定の確認	《透析室看護師》 ・ACP（人生会議について） ・腎代替療法について ・透析室の見学 ・PD デモンストレーション ・検査結果の説明 ・血圧と体重測定の確認	《透析室看護師》 ・フットケア ・足の観察方法 ・足病変の予防について ・検査結果の説明 ・血圧・体重測定の確認 ・振り返りやまとめ	≪内科看護師≫ ・糖尿病合併症を進行させないためには ・検査結果の説明 ・血圧と体重管理について
栄養士	・腎臓病食総論 ・食事調査からのアドバイス （塩分・タンパク質を控える）	・熱量、塩分、タンパク質、 カリウム、リンについて ・献立作成・成分調整食品の 有効利用について	・美味しく食べるコツ （食品選択、調理法の工夫） ・間食、外食の選び方 ・献立表の提出	・献立内容の考察 ・検査値の確認 ・ストレスなく継続できる 食事摂取	・献立内容の考察 ・検査値の確認 ・ストレスなく継続できる 食事摂取
薬剤師		・現在内服している薬の確認 ・市販薬の使用について			

31

ご提案のまとめ（前回議事録からの抜粋）

- 看護師、管理栄養士、薬剤師の各領域から、多施設研究参加施設を含めた実働メンバーにご参加いただくよう人選いただく。また、運動療法が重要なことから、理学療法士の先生にも参加いただく。多施設研究に参加された各施設のコメディカルスタッフの協力を仰ぐとよい。
- 病院とクリニックで指導方法に違いがあるため、各施設に適した教育プログラムが必要。
- 外来指導においては現実的に薬局薬剤師の役割が重要であること、これを教育プログラムにも盛り込む必要がある。外来患者に対する薬剤師の関与を促進すべき。
- 教育入院が有効であることを盛り込む。可能であれば外来とは別のプログラムを作成する。
- 改善の大きい施設の特徴が分かれば、これを教育プログラムに反映する。

山田先生より:
標準プログラムの作成にあたっては、慢性腎臓病指導管理料の通知に記載されている、「慢性腎臓病のリスク要因に関する評価を行い、その結果に基づいて、指導計画を作成すること」に答えを出すようプログラムを作成してもらいたい。

32

中間評価

【評価委員会のコメント】

（1）評価できる点、推進すべき点

- 多職種介入の方法・資材の収集がほぼ完了し、多職種連携プログラムの改訂に繋げていくよう進めていることは評価 できる。
- 前研究を更に発展させ、多職種連携のための標準的な教育プログラムを開発・普及させる目標に向かって着実に成果 を挙げている。
- CKDの管理において多職種連携が効果的であることを示したのは評価できる。具体的な連携の方法を明らかにして、これを広げることが重要である
- 他職種連携による療養指導のエビデンス。

（2）疑問点、改善すべき点、その他助言等

- 多職種連携の効果に施設間差がみられることについて、今後どのように解決していけるかが問題である。また、CKD のステージと運動の程度についても検討していただきたい。
- 多職種連携のエビデンス構築において追加因子も含めての解析では、結果を出すために症例数の増加の必要性も考慮 されるが、可能だろうか。
- 病院などのスタッフのが常駐している施設では多職種連携は可能であるが、個人医院なども多職種連携の輪の中に入れるようにすることも工夫されたい。
- 地域格差の是正についての提言。

33

ロードマップ

	2023年度				2024年度				2025年度			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
多職種連携のエビデンス構築と実態把握	追加解析の実施 残る課題の抽出			追加解析の取りまとめ 必要に応じ二次研究の実施			二次研究結果の解析		課題への反映			
教育プログラムの作成	教育資材の収集		教育プログラムの検討、開発				標準化プログラム完成		標準化プログラムの普及			
マニュアルの普及・有効活用の推進、ガイドライン改訂と連携		マニュアルの普及、評価					腎臓病療養指導士ガイド等への反映					
ホームページ等による成果の公表	ホームページのメインテナンス、成果の公表											
課題解決のための戦略案策定	課題の抽出						課題のまとめ・評価				課題解決への提言の作成	

34

34

35

別添5

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
竹内裕紀	服薬指導・薬剤情報 腎血管性高血圧症	福井次矢、高木誠、小室一成	今日の治療指針 2025年度版	医学書院	東京	2025	618-619
竹内裕紀	臓器移植・造血幹細胞移植・輸血	編集：吉尾隆、鍋島俊隆、渡辺泰裕、早勢信正、賀川義之、大井一弥、丸山徹、篠原悦子、渡辺朋子、佐々木英久、野田幸裕、本屋敏郎、松尾和廣、高村徳人、唯野貢司	薬物治療学 改訂14版	南山堂	東京	2025	904-907

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kitai T, Maruyama S, Kuwahara K, Tamura K, Kinugawa K, Kashihara N.	Establishing Cross-Specialty Expert Consensus on the Optimal Management of Hyperkalemia in Patients With Heart Failure and Chronic Kidn	Circ J.	89(4)	470-478	2025
Kashihara N, Okada H, Suzuki Y, et al.	Efficacy and safety of patiromer for hyperkalemia: a randomized, placebo-controlled phase 3 study.	Clin Exp Nephrol.	Online ahead of print		2025
Johannes CB, Ziemiecki R, Pladevall-Vila M, et al.	Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A	Diabetes Ther.	16(2)	205-226	2025
Mondal R, Ritu RB, Kitaoka K, et al.	Oral microbiome alpha diversity and all-cause, cardiovascular, and non-cardiovascular mortality in US adults: Evidence from the NHANES	Atherosclerosis.	401	119074	2025
Pollock C, Carrero JJ, Kanda E,	Baseline Characteristics of the DISCOVER CKD Prospective Cohort.	Adv Ther.	42(3)	1393-1418	2025
Perkovic V, Barratt J, Rovin B, Kashihara N, et al.	Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.	N Engl J Med.	392(6)	531-543	2025

Ohashi M, Ishikawa Y, Arai S, et al.	Comparative analysis of kidney function prediction: traditional statistical methods vs. deep learning techniques.	Clin Exp Nephrol.	Online ahead of print.		2025
Asahi K, Konta T, Tamura K, et al.	The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 dia	J Diabetes Investig..	16(1)	108-119	2025
Konta T, Asahi K, Tamura K, et al.	The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese non-diabetic patients.	Clin Exp Nephrol.	Online ahead of print.		2024
Heerspink HJL, Perkovic V, Tuttle KR, et al.	Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial.	J Am Soc Nephrol.	35(12)	1726-1736.	2024
Shimamoto S, Nakahara T, Yamada S, Nagasu H, et al.	Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database e	Sci Rep.	28(8)	784-792	2024
Kashihara N, Kumeda Y, Higashino Y, et al.	Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-	Clin Exp Nephrol.	Online ahead of print.		2024
Umebayashi R, Matsuoka-Uchiyama N, Sugiyama H, et al.	The Change in Public Perception and Knowledge Acquisition Methods of Chronic Kidney Disease Among General Population in Okayama Prefect	Diseases.	12(11)	268	2024
Kishi S, Kadoya H, Kashihara N.	Treatment of chronic kidney disease in older populations.	Nat Rev Nephrol.	20(9)	586-602	2024
Aoki R, Nihei Y, Matsuzaki K, et al.	Gross Hematuria after the COVID-19 mRNA Vaccination: Nationwide Multicenter Prospective Cohort Study in Japan.	Kidney360.	5(9)	1322-1332	2024
Sugawara Y, Kanda E, Hamano T, et al.	Guidelines for clinical evaluation of chronic kidney disease in early stages : AMED research on regulatory science of pharmaceuticals a	Clin Exp Nephrol.	28(9)	847-865	2024
Pollock C, Carrero JJ, Kanda E,	The Lived Experience of Patients with Chronic Kidney Disease: Insights From DISCOVER CKD.	Am J Nephrol.	55(6)	618-628	2024

Fishbane S, Carrero JJ, Kumar S,	Hyperkalemia Burden and Treatment Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective Cohort.	Kidney360.	5(7)	974-986	2024
Kanaoka T, Wakui H, Yano Y, Nagasu H, et al.	J-CKD-DB investigators. Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtrat	Diabetes Obes Metab.	26(7)	2905-2914	2024
Nangaku M, Herrington WG, Goto S, et al.	Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.	Clin Exp Nephrol.	28(6)	588-595	2024
Kitaoka K, Yano Y, Nagasu H, et al.	Kidney outcomes of SGLT2 inhibitors among older patients with diabetic kidney disease in real-world clinical practice: the Japan Chroni	BMJ Open Diabetes Res Care.	12(3)	e004115	2024
Nyma Z, Kitaoka K, Yano Y, et al.	Evaluating the associations between compliance with CKD guideline component metrics and renal outcomes.	Sci Rep.	14(1)	11481	2024
Waki K, Nara M, Enomoto S, et al.	Effectiveness of DialBetesPlus, a self-management support system for diabetic kidney disease: Randomized controlled trial.	NPJ Digit Med.	7(1)	104	2024
Okada H, Ono A, Tomori K, et al.	Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients.	PLoS One	19(4)	e0302101	2024
Yusei O, Nagasu H, Nakagawa N, Terawaki S, Moriwaki T, Itano S, Kishi S, Sasaki T, Kashihara N, Otomo T.	A case series of Fabry diseases with CKD in Japan.	Clin Exp Nephrol.	28(5)	404-408	2024
柏原 直樹	NPO法人日本腎臓病協会の取り組み.	日本医師会雑誌	153(4)	393-396	2024
岡田浩一, 柏原直樹, 棗原孝成, 小林一雄.	日本のCKD対策に今,何が必要か.	日本医師会雑誌	153(4)	369-382	2024
角谷裕之, 柏原直樹.	今,なぜ,透析医療と臨床倫理なのか? AMED CKMガイド2022から日本透析医学会の提言2020を倫理的に読み解く.	臨床透析	40(10)	1261-1265	2024

柏原直樹.	高齢化社会における腎臓病診療. Management of Kidney Disease in Aging Societies: Challenges and Innovations″.	日本腎臓学会誌	66(2)	351-356	2024
Shimamoto S, Okada H, et al.	Association between proteinuria and mineral metabolism disorders in chronic kidney disease: the Japan chronic kidney disease database e	Sci Rep	14	27481	2024
Nyma Z, Okada H, et al	Evaluating the associations between compliance with CKD guideline component metrics and renal outcomes.	Sci Rep	14	11481	2024
Okada H, et al	Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients.	PLoS One	19	e0302101	2024
Kishi S, Okada H, et al	Association of serum magnesium levels with renal prognosis in patients with chronic kidney disease	Clin Exp Nephrol	28	784-792	2024
Kanaoka T, Okada H, et al	Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible	Diabetes Obes Metab	26	2905-2914	2024
Tomori K, Okada H, et al	Long-term survival of patients receiving home hemodialysis with self-punctured arteriovenous access	PLoS One	19	e0303055	2024
Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S.	Examine the optimalmultidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study.	Kidney Res Clin Pract	44	249-264	2025
阿部雅紀	CKD診療におけるチーム医療の効果	日本腎臓リハビリテーション学会誌	4	46-55	2025
阿部雅紀	透析予防のためのCKDチーム医療の効果.	腎と透析	98	167-171	2025
石川祐一	透析患者の足病変と腎臓リハビリテーション 足病変予防のための栄養療法の実践 (管理栄養士の立場から)	日本腎臓リハビリテーション学会誌. 2024	3(1)	34-40	2024

令和7年3月27日

厚生労働大臣　　殿

機関名　杏林大学

所属研究機関長　職　名　学長

氏　名　渡邊 卓

次の職員の令和６年度厚生労働科学研究費補助金の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

１．研究事業名　腎疾患政策研究事業

２．研究課題名　慢性腎疾患（CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究

３．研究者名　（所属部署・職名）医学部　腎臓・リウマチ膠原病内科学・客員教授

（氏名・フリガナ）要　伸也・カナメ　シンヤ

４．倫理審査の状況

	該当性の有無	左記で該当がある場合のみ記入（※1）		
	有　無	審査済み	審査した機関	未審査（※2）
人を対象とする生命科学・医学系研究に関する倫理指針（※3）	■　□	■	杏林大学	□
遺伝子治療等臨床研究に関する指針	□　■	□		□
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	□　■	□		□
その他、該当する倫理指針があれば記入すること（指針の名称：　　）	□　■	□		□

（※1）当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他（特記事項）

（※2）未審査に場合は、その理由を記載すること。
（※3）廃止前の「疫学研究に関する倫理指針」、「臨床研究に関する倫理指針」、「ヒトゲノム・遺伝子解析研究に関する倫理指針」、「人を対象とする医学系研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

５．厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 ■　未受講 □

６．利益相反の管理

当研究機関におけるＣＯＩの管理に関する規定の策定	有 ■　無 □（無の場合はその理由：　　）
当研究機関におけるＣＯＩ委員会設置の有無	有 ■　無 □（無の場合は委託先機関：　　）
当研究に係るＣＯＩについての報告・審査の有無	有 ■　無 □（無の場合はその理由：　　）
当研究に係るＣＯＩについての指導・管理の有無	有 □　無 ■（有の場合はその内容：　　）

令和7年　3月　14日

厚生労働大臣　殿

機関名　埼玉医科大学

所属研究機関長　職　名　学長

氏　名　竹内　勤

次の職員の令和６年度厚生労働科学研究費補助金の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

１．研究事業名　腎疾患政策研究事業

２．研究課題名　慢性腎疾患（CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究

３．研究者名　（所属部局・職名）　医学部・教授

（氏名・フリガナ）　岡田　浩一・オカダ　ヒロカズ

４．倫理審査の状況

	該当性の有無	左記で該当がある場合のみ記入（※1）		
	有　無	審査済み	審査した機関	未審査（※2）
人を対象とする生命科学・医学系研究に関する倫理指針（※3）	□　■	□		□
遺伝子治療等臨床研究に関する指針	□　■	□		□
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	□　■	□		□
その他、該当する倫理指針があれば記入すること（指針の名称：　）	□　■	□		□

（※1）当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他（特記事項）

（※2）未審査に場合は、その理由を記載すること。

（※3）廃止前の「疫学研究に関する倫理指針」、「臨床研究に関する倫理指針」、「ヒトゲノム・遺伝子解析研究に関する倫理指針」、「人を対象とする医学系研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

５．厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 ■　未受講 □

６．利益相反の管理

当研究機関におけるＣＯＩの管理に関する規定の策定	有 ■　無 □（無の場合はその理由：　）
当研究機関におけるＣＯＩ委員会設置の有無	有 ■　無 □（無の場合は委託先機関：　）
当研究に係るＣＯＩについての報告・審査の有無	有 ■　無 □（無の場合はその理由：　）
当研究に係るＣＯＩについての指導・管理の有無	有 □　無 ■（有の場合はその内容：　）

令和７年３月３１日

厚生労働大臣　　殿

機関名　　川崎医科大学

所属研究機関長　職　名　　学長

氏　名　　砂田　芳秀

次の職員の令和６年度厚生労働科学研究費の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

１．研究事業名　腎疾患政策研究事業

２．研究課題名　慢性腎臓病(CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究

３．研究者名　(所属部署・職名)　医学部・学長付特任教授

(氏名・フリガナ)　柏原　直樹・カシハラ　ナオキ

４．倫理審査の状況

	該当性の有無	左記で該当がある場合のみ記入 (※1)		
	有　無	審査済み	審査した機関	未審査 (※2)
人を対象とする生命科学・医学系研究に関する倫理指針 (※3)	□　■	□		□
遺伝子治療等臨床研究に関する指針	□　■	□		□
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	□　■	□		□
その他、該当する倫理指針があれば記入すること (指針の名称：　　)	□　■	□		□

(※1) 当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他（特記事項）

(※2) 未審査に場合は、その理由を記載すること。

(※3) 廃止前の「疫学研究に関する倫理指針」、「臨床研究に関する倫理指針」、「ヒトゲノム・遺伝子解析研究に関する倫理指針」、「人を対象とする医学系研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

５．厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 ■　　未受講 □

６．利益相反の管理

当研究機関におけるＣＯＩの管理に関する規定の策定	有 ■　無 □(無の場合はその理由：　　)
当研究機関におけるＣＯＩ委員会設置の有無	有 ■　無 □(無の場合は委託先機関：　　)
当研究に係るＣＯＩについての報告・審査の有無	有 ■　無 □(無の場合はその理由：　　)
当研究に係るＣＯＩについての指導・管理の有無	有 □　無 ■ (有の場合はその内容：　　)

(留意事項)　・該当する□にチェックを入れること。
・分担研究者の所属する機関の長も作成すること。

令和 7 年 1 月 14 日

厚生労働大臣 殿

機関名 国立大学法人大阪大学

所属研究機関長 職 名 大学院医学系研究科長

氏 名 熊ノ郷 淳

次の職員の令和６年度厚生労働科学研究費の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

１．研究事業名 腎疾患政策研究事業

２．研究課題名 慢性腎臓病（CKD）患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究

３．研究者名 （所属部署・職名） 大学院医学系研究科・教授

（氏名・フリガナ） 猪阪 善隆・イサカ ヨシタカ

４．倫理審査の状況

	該当性の有無		左記で該当がある場合のみ記入（※1）		
	有	無	審査済み	審査した機関	未審査（※2）
人を対象とする生命科学・医学系研究に関する倫理指針（※3）	■	□	■	大阪大学医学部附属病院	□
遺伝子治療等臨床研究に関する指針	□	■	□		□
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	□	■	□		□
その他、該当する倫理指針があれば記入すること（指針の名称： ）	□	■	□		□

（※1）当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他（特記事項）

（※2）未審査に場合は、その理由を記載すること。

（※3）廃止前の「疫学研究に関する倫理指針」、「臨床研究に関する倫理指針」、「ヒトゲノム・遺伝子解析研究に関する倫理指針」、「人を対象とする医学系研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

５．厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 ■ 未受講 □

６．利益相反の管理

当研究機関におけるＣＯＩの管理に関する規定の策定	有 ■ 無 □（無の場合はその理由： ）
当研究機関におけるＣＯＩ委員会設置の有無	有 ■ 無 □（無の場合は委託先機関： ）
当研究に係るＣＯＩについての報告・審査の有無	有 ■ 無 □（無の場合はその理由： ）
当研究に係るＣＯＩについての指導・管理の有無	有 □ 無 ■（有の場合はその内容： ）

（留意事項） ・該当する□にチェックを入れること。

・分担研究者の所属する機関の長も作成すること。

令和 7年 3月 17日

厚生労働大臣
~~（国立医薬品食品衛生研究所長）~~ 殿
~~（国立保健医療科学院長）~~

機関名　国立大学法人島根大学

所属研究機関長　職　名　学長

氏　名　大谷　浩

次の職員の令和６年度厚生労働科学研究費の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

１．研究事業名　腎疾患政策研究事業

２．研究課題名　慢性腎臓病(CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究

３．研究者名　（所属部署・職名）　医学部・教授

（氏名・フリガナ）　金﨑　啓造　・カナサキ　ケイゾウ

４．倫理審査の状況

	該当性の有無	左記で該当がある場合のみ記入（※1）		
	有　無	審査済み	審査した機関	未審査（※2）
人を対象とする生命科学・医学系研究に関する倫理指針（※3）	□　■	□		□
遺伝子治療等臨床研究に関する指針	□　■	□		□
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	□　■	□		□
その他、該当する倫理指針があれば記入すること（指針の名称：　）	□　■	□		□

（※1）当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他（特記事項）

（※2）未審査に場合は、その理由を記載すること。
（※3）廃止前の「疫学研究に関する倫理指針」、「臨床研究に関する倫理指針」、「ヒトゲノム・遺伝子解析研究に関する倫理指針」、「人を対象とする医学系研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

５．厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 ■　未受講 □

６．利益相反の管理

当研究機関におけるＣＯＩの管理に関する規定の策定	有 ■　無 □（無の場合はその理由：　）
当研究機関におけるＣＯＩ委員会設置の有無	有 ■　無 □（無の場合は委託先機関：　）
当研究に係るＣＯＩについての報告・審査の有無	有 ■　無 □（無の場合はその理由：　）
当研究に係るＣＯＩについての指導・管理の有無	有 □　無 ■（有の場合はその内容：　）

（留意事項）　・該当する□にチェックを入れること。
・分担研究者の所属する機関の長も作成すること。

令和 7 年 4 月 22 日

厚生労働大臣　殿

機関名　日本大学医学部

所属研究機関長　職　名　医学部長

氏　名　木下浩作

次の職員の令和６年度厚生労働科学研究費補助金の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

１．研究事業名　腎疾患政策研究事業

２．研究課題名　慢性腎疾患（CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究

３．研究者名　（所属部署・職名）　内科学系腎臓高血圧内分泌内科学分野・教授

（氏名・フリガナ）　阿部 雅紀　（アベ マサノリ）

４．倫理審査の状況

	該当性の有無	左記で該当がある場合のみ記入（※1）		
	有　無	審査済み　審査した機関		未審査（※2）
人を対象とする生命科学・医学系研究に関する倫理指針（※3）	■　□	■	日本大学医学部附属板橋病院	□
遺伝子治療等臨床研究に関する指針	□　■	□		□
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	□　■	□		□
その他、該当する倫理指針があれば記入すること（指針の名称：　）	□　■	□		□

（※1）当該研究者が当該研究を実施するに当たり遵守すべき倫理指関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他（特記事項）

（※2）未審査に場合は、その理由を記載すること。

（※3）廃止前の「疫学研究に関する倫理指針」、「臨床研究に関する倫理指針」、「ヒトゲノム・遺伝子解析研究に関する倫理指針」、「人を対象とする医学系研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

５．厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 ■　未受講 □

６．利益相反の管理

当研究機関におけるＣＯＩの管理に関する規定の策定	有 ■　無 □（無の場合はその理由：　）
当研究機関におけるＣＯＩ委員会設置の有無	有 ■　無 □（無の場合は委託先機関：　）
当研究に係るＣＯＩについての報告・審査の有無	有 ■　無 □（無の場合はその理由：　）
当研究に係るＣＯＩについての指導・管理の有無	有 ■　無 □（有の場合はその内容：　）

2025年 4月24日

厚生労働大臣　　殿

機関名　医療法人社団クレド
さとうクリニック

所属研究機関長　職　名　理事長

氏　名　佐藤　純彦

次の職員の令和６年度厚生労働科学研究費補助金の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

１．研究事業名　腎疾患政策研究事業

２．研究課題名　慢性腎疾患（CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究

３．研究者名　（所属部署・職名）　総括部長兼学術部主任

（氏名・フリガナ）　内田　明子（ウチダ　アキコ）

４．倫理審査の状況

	該当性の有無	左記で該当がある場合のみ記入（※1）		
	有　無	審査済み	審査した機関	未審査（※2）
人を対象とする生命科学・医学系研究に関する倫理指針（※3）	□　■	□		□
遺伝子治療等臨床研究に関する指針	□　■	□		□
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	□　■	□		□
その他、該当する倫理指針があれば記入すること（指針の名称：　　）	□　■	□		□

（※1）当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他（特記事項）

（※2）未審査に場合は、その理由を記載すること。

（※3）廃止前の「疫学研究に関する倫理指針」、「臨床研究に関する倫理指針」、「ヒトゲノム・遺伝子解析研究に関する倫理指針」、「人を対象とする医学系研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

５．厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 ■　未受講 □

６．利益相反の管理

当研究機関におけるＣＯＩの管理に関する規定の策定	有 ■　無 □（無の場合はその理由：　　）
当研究機関におけるＣＯＩ委員会設置の有無	有 ■　無 □（無の場合は委託先機関：　　）
当研究に係るＣＯＩについての報告・審査の有無	有 ■　無 □（無の場合はその理由：　　）
当研究に係るＣＯＩについての指導・管理の有無	有 □　無 ■（有の場合はその内容：　　）

（留意事項）　・該当する□にチェックを入れること。
・分担研究者の所属する機関の長も作成すること。

2025年　3月31日

厚生労働大臣　　殿

機関名　　茨城キリスト教大学

所属研究機関長　職　名　　学長

氏　名　東海林　宏司

次の職員の令和６年度厚生労働科学研究費補助金の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

１．研究事業名　腎疾患政策研究事業

２．研究課題名　慢性腎疾患（CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究

３．研究者名　（所属部署・職名）　生活科学部食物健康科学科　教授

（氏名・フリガナ）　石川　祐一　（イシカワ　ユウイチ）

４．倫理審査の状況

	該当性の有無	左記で該当がある場合のみ記入（※1）		
	有　無	審査済み	審査した機関	未審査（※2）
人を対象とする生命科学・医学系研究に関する倫理指針（※3）	□　■	□		□
遺伝子治療等臨床研究に関する指針	□　■	□		□
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	□　■	□		□
その他、該当する倫理指針があれば記入すること（指針の名称：　　）	□　■	□		□

（※1）当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他（特記事項）

（※2）未審査に場合は、その理由を記載すること。

（※3）廃止前の「疫学研究に関する倫理指針」、「臨床研究に関する倫理指針」、「ヒトゲノム・遺伝子解析研究に関する倫理指針」、「人を対象とする医学系研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

５．厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 ■　未受講 □

６．利益相反の管理

当研究機関におけるＣＯＩの管理に関する規定の策定	有 ■　無 □（無の場合はその理由：　　）
当研究機関におけるＣＯＩ委員会設置の有無	有 ■　無 □（無の場合は委託先機関：　　）
当研究に係るＣＯＩについての報告・審査の有無	有 ■　無 □（無の場合はその理由：　　）
当研究に係るＣＯＩについての指導・管理の有無	有 □　無 ■（有の場合はその内容：　　）

（留意事項）　・該当する□にチェックを入れること。
・分担研究者の所属する機関の長も作成すること。

令和 7 年 3 月 31 日

厚生労働大臣

機関名　東京医科大学

所属研究機関長　職　名　学長

氏　名　宮澤　啓介

次の職員の令和６年度厚生労働科学研究費の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

１．研究事業名　腎疾患政策研究事業

２．研究課題名　慢性腎臓病(CKD)患者に特有の健康課題に適合した多職種連携による生活・食事指導等の実証研究

３．研究者名　（所属部署・職名）　薬剤部・薬剤部長

（氏名・フリガナ）　竹内　裕紀（タケウチ　ヒロノリ）

４．倫理審査の状況

	該当性の有無	左記で該当がある場合のみ記入（※1）		
	有　無	審査済み	審査した機関	未審査（※2）
人を対象とする生命科学・医学系研究に関する倫理指針（※3）	□　■	□		□
遺伝子治療等臨床研究に関する指針	□　■	□		□
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	□　■	□		□
その他、該当する倫理指針があれば記入すること（指針の名称：　）	□　■	□		□

（※1）当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他（特記事項）

（※2）未審査に場合は、その理由を記載すること。
（※3）廃止前の「疫学研究に関する倫理指針」、「臨床研究に関する倫理指針」、「ヒトゲノム・遺伝子解析研究に関する倫理指針」、「人を対象とする医学系研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

５．厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 ■　未受講 □

６．利益相反の管理

当研究機関におけるＣＯＩの管理に関する規定の策定	有 ■　無 □（無の場合はその理由：　）
当研究機関におけるＣＯＩ委員会設置の有無	有 ■　無 □（無の場合は委託先機関：　）
当研究に係るＣＯＩについての報告・審査の有無	有 ■　無 □（無の場合はその理由：　）
当研究に係るＣＯＩについての指導・管理の有無	有 □　無 ■（有の場合はその内容：　）